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Abstract 
 
The Structure and Activation of Soluble Guanylate Cyclase 
 
 
by 
 
Benjamin G. Horst 
 
Doctor of Philosophy in Chemistry 
 
University of California, Berkeley 
 
Professor Michael A. Marletta, Chair 
 
 
 
The biochemical signaling pathways that involve gaseous primary signaling molecules 
have only been characterized in the last three decades, due to the small diversity of diatomic gases 
and the lack of other known physiological functions of these gases (apart from O2 as the terminal 
electron acceptor in oxidative phosphorylation). In general, certain events must take place for any 
process to be considered biochemical signaling: the primary signaling molecule must be 
synthesized and excreted from the generator cell or be present or absent in the environment, that 
signaling molecule must come in contact with its specific receptor molecule within the receiving 
cell, and the receptor molecule must transduce the primary singling molecule into a secondary 
signal which activates downstream signaling pathways. Only a pathway that is comprised of signal 
generation, the primary signal, and signal reception constitutes a complete biochemical signaling 
pathway. In spite of the relatively recent discovery, gaseous signaling molecules control critical 
signaling pathways in many aspects of organismal physiology. 
 
In the 1980s, two different lines of research serendipitously came together to describe the 
first gaseous biochemical signaling pathway. The first was pharmacologists’ observation that 
vasculature that had the endothelium removed would constrict, and thus there must be an 
Endothelium Derived Relaxation Factor (EDRF) that maintained appropriate vasculature tone. 
Curiously, EDRF had the exact same chemical properties as nitric oxide (NO), however there was 
no known biotic source of this toxic gas. The second line of research centered on the observation 
that excreted nitrates spiked in concentration when sickness was incurred, even when nitrate intake 
remained the same. This led to the discovery that macrophages synthesize the cytotoxic agent NO 
to attack invading pathogens, and thus a biotic source of NO had been discovered. The EDRF and 
NO were shown to be one and the same, and this coupled with the fact that soluble guanylate 
cyclase had been known to be stimulated by NO since the 1970s provided the receptor of the first 
gaseous biochemical signaling pathway. 
 
 The enzyme responsible for the generation of NO is nitric oxide synthase (NOS) (EC 
1.14.13.39). NOS catalyzes the 5-electron oxidation of arginine to citrulline and NO. There are 
three different isoforms of NOS in Homo sapiens, inducible NOS (iNOS), endothelial NOS 
2 
 
(eNOS), and neuronal (nNOS). Nitric oxide synthases are activated by calcium-bound calmodulin 
(Ca2+-CaM). iNOS has a high affinity for Ca2+-CaM, and thus is regulated at the transcriptional 
level in macrophages where it synthesizes NO at sites of infection or inflammation. eNOS and 
nNOS have lower affinity for Ca2+-CaM and are constitutively expressed, which allows calcium 
gradients in neurons and endothelial cells to control the activation of these isoforms. For example, 
when endothelial cells hyperpolarize due to high blood pressure, intracellular concentrations of 
Ca2+ increase up to ten-fold which in turn increases Ca2+-CaM concentration and thus activates 
eNOS. 
 
Activated eNOS generates NO at nanomolar concentrations, which diffuses to nearby 
smooth muscle cells that express the mammalian NO receptor, soluble guanylate cyclase (sGC) 
(EC 4.6.1.2). sGC is a heterodimeric hemeoprotein which can sense NO at nanomolar 
concentrations. When NO binds to sGC, the enzyme increases its catalytic activity of cyclizing 5′-
guanosine triphosphate (GTP) to 3′,5′-cyclic guanosine monophosphate (cGMP). The molecular 
mechanisms by which NO activates sGC are not completely understood. In particular, it is clear 
from experiments both in vitro and in cells that one equivalent of NO does not activate sGC to its 
maximal activity but only to a low activity state. Excess NO must be present in order to completely 
stimulate the enzyme. If that excess NO is removed either with a buffer exchange or a chemical 
trap, the enzyme returns to a low activity state. The increase in cellular concentration of cGMP 
activates a variety of downstream signaling proteins, including cGMP-dependent protein kinases, 
cGMP-regulated ion channels, and phosphodiesterases that mediate the downstream cell signaling 
cascade. The resultant phenotype of these cellular signaling molecules is the relaxation of the 
smooth muscle cells, the dilation of the vasculature, and the decrease of overall blood pressure. 
Thus, any malfunctions of this pathway can result in too high of blood pressure and increased risk 
of cardiovascular diseases. 
 
The NOS-NO-sGC-cGMP signaling pathway has been the target for stimulating therapeutics to 
treat forms of high blood pressure. A screen of small molecules that induce platelet aggregation 
found that the chemically synthesized benzylindazole YC-1 was able to stimulate sGC in a heme-
dependent manner. Significant efforts in medicinal chemistry in the following two decades yielded 
riociguat, the first FDA-approved sGC stimulator that is used to treat certain forms of pulmonary 
hypertension. However, the specific binding site of YC-1 derived compounds on sGC and the 
reason for the specificity of these types of molecules against the soluble form of guanylate cyclases 
has not been elucidated. Additionally, atypical soluble guanylate cyclases have been described that 
sense O2 instead of NO. Thus, the possibility exists for gases other than NO and O2 to function as 
signaling molecules in eukaryotic organisms. These outstanding questions will be answered in the 
following thesis entitled: The Structure and Activation of Soluble Guanylate Cyclase. 
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CHAPTER 1 
 
 
PHYSIOLOGICAL ACTIVATION AND DEACTIVATION OF SOLUBLE 
GUANYLATE CYCLASE 
 
 
Summary 
 
Soluble guanylate cyclase (sGC) is responsible for transducing gaseous signaling molecules into 
the ubiquitous secondary signaling messenger cyclic guanosine monophosphate in eukaryotic 
organisms. Mammalian sGC is exquisitely tuned to sense low levels of nitric oxide (NO), allowing 
cells to respond to non-toxic levels of NO. Other eukaryotic sGCs respond to oxygen (O2) to 
regulate motility and behavior, while other gases await the discovery of protein-specific receptors. 
In this chapter, sGC is discussed in the context of its activation and deactivation in response to gas 
molecules. The sequence of events in the activation pathway are developed into a comprehensive 
model of in vivo sGC activation as elucidated both from studies with purified enzyme and those 
done in cells. This model is then used to discuss the deactivation of sGC, as well as the molecular 
mechanisms of pathophysiological deactivation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Portions of this chapter have been reported in a previous publication.1 
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Introduction 
 
 In the 1980s, nitric oxide (NO) was first characterized as critical to both innate immunity 
and endogenous signaling in animals.2–6 NO was the first gaseous signaling molecule synthesized 
by animals to have its biochemical signaling pathway fully described.3 Physiologically, NO 
signaling causes relaxation of vascular smooth muscle, inhibition of platelet aggregation in the 
vasculature, and modulation of various forms of neurotransmission.7,8 Beyond these well-
established functions, additional aspects of NO signaling continue to emerge, including in insect 
development and sensory systems,9 as well as in human pathologies, such as early-onset 
achalasia10 and cancer proliferation.11  
 
Soluble guanylate cyclase (sGC), a eukaryotic nitric oxide receptor, is a central component 
in NO-dependent signaling.4,12 sGC converts 5′-guanosine triphosphate (GTP) to 3′,5′-cyclic 
guanosine monophosphate (cGMP). When NO binds to sGC, enzyme activity increases several 
hundredfold, transducing the gaseous paracrine-signaling molecule to a ubiquitous secondary 
signaling molecule. The molecular details of how NO activates sGC to maximal physiological 
activity are not fully understood, though much progress has been made. 
 
Aberrations resulting in decreased function of this sGC-dependent signaling pathway have 
been linked to multiple pathologies, including cardiovascular disease, hypertension, asthma, and 
neurodegeneration.13,14 Many emergent pharmaceuticals seek to increase sGC activity in these 
diseased states. One set of examples are the sGC stimulators, initially exemplified by the 
benzylindazol compound YC-115 and culminating in Bayer’s riociguat (Adempas®), the latter was 
approved by the FDA in 2013 to treat pulmonary arterial hypertension and chronic 
thromboembolic pulmonary hypertension.16 This class of molecules has also added to our 
understanding of the NO-dependent activation mechanism of sGC, however it is still unclear how 
these molecules by themselves promote the active conformation of sGC17,18. 
 
This chapter combines structural and functional aspects of NO-dependent activation and 
deactivation of sGC to build a model of sGC activation in vivo. Stimulators and activators are 
discussed in the context of physiological activation, and interested readers are directed to other 
reviews18,19 that are dedicated to these small molecules.  
 
 
Structure of Soluble Guanylate Cyclase 
 
 Soluble guanylate cyclase is a heterodimer comprised of an α and a β subunit (Figure 1.1A). 
Multiple isoforms of these two subunits have been identified, yet sGC is most commonly expressed 
as a heterodimer composed of α1 and β1 subunits (Uniprot IDs of Homo sapiens proteins: Q02108 
and Q02153).20 Each subunit consists of four domains: a heme nitric oxide and oxygen binding 
(H-NOX) domain,21 a Per/Arnt/Sim (PAS)-like domain, a coiled-coil (CC) domain, and one 
subunit of the catalytic heterodimer (CAT). Although the H-NOX subunit structures are similar, 
only the β subunit has the capacity to bind heme. Since a high-resolution structure of full-length 
sGC has only been obtained in the last few months, in the past five years the vast majority of 
structural information has been derived from isolated domains of sGCs. Others have recently 
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reviewed the structure of sGC,22,23 and thus the discussion here will be limited to pertinent details 
and recent developments. 
 
 
Figure 1.1 – Domain and subdomain organization of sGC A) Schematic of soluble guanylate cyclase domains. The 
four domains of the α (in orange) and β (in blue) subunits are listed above: heme nitric oxide and oxygen binding 
domain (H-NOX), Per-Arnt-Sim domain (PAS), coiled-coil domain (CC), and the catalytic domain (CAT). The 
approximate numbering of the Human α1 and β1 domains is shown. The heme cofactor, shown as a red diamond, 
binds to β1 H105. 
B) Motions of heme nitric oxide and oxygen binding domains (H-NOX) upon nitric oxide binding. Overlay of the 
Shewanella oneidensis H-NOX domain in the Fe2+ (wheat, PDB ID: 4U99) and Fe2+–NO (blue, PDB ID: 4U9B) states. 
Structures have been aligned by the proximal domains (residues 95–180). Displacement of the distal domain and 
rotation of the proximal histidine are noted with arrows. 
 
 
 H-NOX domains, also known as heme nitric oxide binding (HNOB) or sensor of nitric 
oxide (SONO) domains,24 consist of an N-terminal alpha helical subdomain and a C-terminal 
subdomain composed of alpha helices and four antiparallel beta sheets. A single heme cofactor 
binds in a central cavity between the two subdomains (Figure 1.1B). The N- and C- terminal 
subdomains are termed distal and proximal, respectively, with the proximal subdomain defined by 
the presence of a heme-ligating histidine residue (termed the proximal histidine). H-NOX domains 
are also found as stand-alone proteins in prokaryotes,25 and the study of these proteins has greatly 
improved our understanding of how these domains bind gaseous ligands and then transduce 
chemical signals.26–29 These studies, as well as spectroscopic studies of sGC, showed that NO 
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initially binds to the 5-coordinate (5c) high-spin ferrous heme cofactor (5c His–Fe2+, see Figure 
1.2), which leads to a transient 6-coordinate (6c) complex (6c His–Fe2+–NO).30–32 This complex, 
driven by the strong σ trans effect NO exerts on the proximal histidine, spontaneously dissociates 
to the 5c low-spin ferrous nitrosyl complex (5c Fe2+–NO).33 In turn, cleavage of the iron–histidine 
bond results in a 90° rotation of the α-helix (αF) that contains the histidine; this conformational 
change is thought to be the initial step in propagating the NO signal.34 Some studies have examined 
the next steps in signal transduction pathway by examining other residues on the αF helix, 
however, it remains unclear exactly how these events confer full activity to the enzyme.35,36 
 
 
Figure 1.2 – The heme cofactor in sGC has an inherent sidedness as defined by the presence of the coordinating 
histidine residue (H105 in humans). The histidine binds to the ferrous iron of the heme cofactor from one side, termed 
the proximal side, as shown. The opposing side of the heme is referred to as the distal side. Upon binding of NO to 
the distal side of the heme, the strong σ trans effect induces rupture of the iron–histidyl bond, which is thought to be 
the first step in signal transduction. However, this cleavage event results in the opening of the proximal coordination 
site for an additional NO molecule to bind. To clarify the potential heme ligation states in sGC, the following naming 
convention will be used in this review: 4/5/6c (proximal ligand)–Fe2+–(distal ligand), where 4/5/6c refers to the 
coordination number of the Fe2+ center. For example, unliganded ferrous sGC with the proximal histidine bound would 
be described as 5c His–Fe2+, whereas a distal ferrous nitrosyl complex would be termed 5c Fe2+–NO. 
 
 
 The PAS and CC domains of sGC have been studied less by comparison, though their 
function in sGC signal transduction is likely important. PAS domains are versatile as they can play 
varied roles in different proteins, such as quaternary structure organization, cofactor binding, and 
signal transduction.37–39 Indeed, in sGC the PAS domains are implicated in dimerization,40 gas 
binding,41 and Hsp90-mediated heme insertion.42 Additionally, the crystal structure of the 
Manduca sexta sGC α1 PAS domain was recently solved, revealing an extra beta strand and a 
flexible helix that could be important for transducing the NO signal;43 however, the exact 
mechanism of signal transduction is still not fully understood. The first crystal structure of the β 
CC domain in sGC exhibited the coils oriented in an anti-parallel orientation.44 More recently, 
cross-linking mass spectrometry and single particle electron microscopy experiments suggest that 
the orientation of these helices are parallel in the native structure.41,45 Through the use of hydrogen 
deuterium exchange mass spectrometry, the linker region between the PAS and the CC domains 
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has been shown to undergo remarkable solvent exchange dynamics with the addition of NO, 
suggesting that conformational changes affect this linker region in an NO-dependent manner.46 
Since the PAS/CC linker region appears to be important for transducing the NO signal, additional 
studies to elucidate the molecular details of this process will be very important. 
 
 The CAT domains of sGC are members of the Class III nucleotide cyclase domain family, 
as determined by sequence analysis and secondary structural motifs.47–50 The CAT domains form 
a heterodimer: one active site and one pseudosymmetric site are formed at the interface of the α 
and β subunits. ATP is a mixed-type inhibitor of sGC and this pseudosymmetric site is proposed 
to be the site of ATP action.17,51,52 The interested reader is directed to the review by Childers et 
al.53 for more details on the structure and function of the CAT domain. 
 
 
Figure 1.3 – Reconstructed full-length representation of sGC. Using available crystal structures and single-particle 
electron microscopy data from Ref. 40, a representation of the full-length structure of sGC was constructed. The 
subunits are colored as in Figure 1.1A. Beginning with two representative EM volumes (left), the following crystal 
structures were fit into the densities: Human α1 and β1 sGC H-NOX domain homology models were derived from the 
bacterial H-NOX from Nostoc sp (PDB ID: 2O09); Human α1 and β1 PAS domain homology models were derived 
from eukaryotic PAS from C. reinhardtii (PDB ID: 4GJ4) and aligned using the Nostoc punctiforme PAS dimer (PDB 
ID: 2P04); Human α1 and β1 CC domain homology models and the human CAT structure (PDB ID: 4NI2) were 
aligned to the Mycobacterium intracellulare adenylate cyclase structure (PDB ID: 505l), for chains C and D, and 
adjusted to fit within the volumes. These crystal structures have been fitted into the densities and are shown as ribbon 
diagrams (middle). The two extreme conformations of sGC are shown and labeled as “Extended” and “Contracted” 
(see Figure 1.4). The space-filling model of both conformations is shown (right). 
6 
 
 
 
Full-length structures of sGC have been obtained only recently after twenty-five years of 
work (see Chapter 2)54, the delay likely due to conformational flexibility in the quaternary structure 
in conjunction with challenges of expressing sufficient quantities of protein. Previously, Campbell 
et al.45 successfully used single particle electron microscopy to visualize the quaternary structure 
of sGC. The H-NOX and PAS domains were clustered in a heterotetramer-like lobe at one end of 
the particle, while the CAT domains formed a tight heterodimeric lobe on the opposing end with 
the CC domain forming a bridge (Figure 1.3). These studies showed that sGC is highly flexible in 
the presence and absence of NO, independent of the pH of the stain. Recently, Vercellino et al.55 
solved the first crystal structure containing both the CC and the CAT domains of an adenylate 
cyclase from Mycobacterium intracellulare. Because these structural motifs are conserved across 
many nucleotidyl cyclases, this crystal structure can be used to improve modeling of the quaternary 
structure of sGC, as shown in Figure 1.3.  
 
There had been two hypotheses that predict how the quaternary structure of sGC changes 
upon NO activation. It was postulated that the β H-NOX domain comes in direct contact with the 
α CAT domain through space to inhibit CAT domain activity (Figure 1.4A). Alternatively, it was 
proposed that the signal transduction event occurs through the protein backbone (Figure 1.4B). 
The hypothesis that the β H-NOX domain inhibits the catalytic activity is based on individual H-
NOX domain inhibition of catalytic activity in trans, and cross-linking experiments establishing 
contacts between these two domains.41,56 Support for the signal transduction event to take place 
through the protein backbone comes from the observation of NO-independent flexibility observed 
by electron microscopy.45 While it is possible that some continuum between these two extremes is 
physiologically relevant, important new details are now available with the recently published 
strtcures (Chapter 2). 
 
 
Activation of Soluble Guanylate Cyclase 
 
The molecular steps involved in sGC activation have evolved significantly over the last 
several years. The key studies are outlined below, but here we provide an overall summary. The 
activation mechanism of sGC was initially proposed to be relatively simple, where the 5c Fe2+–
NO heme complex generated upon NO binding led to fully active enzyme. Detailed kinetic studies 
on NO binding to the heme and enzyme activity has led to a more complicated mechanism, perhaps 
in hindsight not unexpected given the pivotal role played by sGC in human physiology. There are 
two aspects to NO activation of sGC. The first involves the formation the 5c ferrous nitrosyl heme 
complex, and the most recent evidence is consistent with a distal version of this species (5c Fe2+–
NO). sGC treated with 1 equivalent of NO is activated to only ~15% of maximal activity. Addition 
of excess NO fully activates sGC and increases the rate at which the 5c Fe2+–NO heme complex 
forms from the 6c His–Fe2+–NO species. All evidence points towards a second NO binding site 
for the action of this excess NO as discussed below. 
 
NO binding to the H-NOX domain 
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Figure 1.4 – Quaternary domain organization of sGC upon NO activation. It is predicted that some spatial 
reorganization of the sGC domains occurs when NO activates the enzyme. A) Self-inhibition of the CAT domain 
through contact of the β H-NOX domain to the α CAT domain, termed the contracted conformation. Upon NO binding, 
this contact would be released allowing a conformational change into the extended conformation which in full catalytic 
activity. B) When NO is not bound, the tertiary structure holds sGC in a non-active conformation while the quaternary 
structure is flexible (not depicted). Upon NO binding, structural rearrangements occur along the protein backbone, 
which results in full catalytic activity. 
 
It is well established that the first step in sGC activation is NO binding to the 5c His–Fe2+ 
heme cofactor in the β1 H-NOX domain30–32. The resulting 6c His–Fe2+–NO complex has been 
observed by stopped-flow UV-Vis spectroscopy and electron paramagnetic resonance (EPR) 
spectroscopy with samples prepared at 4 °C or lower to slow iron–histidyl bond scission.30,57–60 
The strong σ trans effect of NO ruptures the iron–histidyl bond (k6c  k5c = 50,000 M-1s-1), 
resulting in a 5c Fe2+–NO heme complex, which exhibits a relatively long half-life in solution (koff 
for NO = 0.0006 s–1) compared to other species in sGC activation (discussed below).31,61 Even so, 
it was only recently that Herzik et al. solved a crystal structure of the 5c ferrous nitrosyl H-NOX 
domain, using the H-NOX protein from the gamma proteobacterium Shewanella oneidensis (So).34 
This study also used a stable 6c His–Mn2+–NO porphyrin complex to characterize possible 
structural changes in the H-NOX domain due to gas binding, removing the complication of iron–
histidyl bond cleavage.62 The root mean square deviation of the atoms in the 5c His–Mn2+ structure 
aligned to the 6c His–Mn2+–NO structure was 0.099 Å, indicating that the driving force behind 
iron–histidyl bond cleavage is the σ trans effect of NO rather than any structural rearrangement 
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resulting from ligand binding. These results support the hypothesis that the H-NOX 
conformational change is dependent on iron–histidyl bond cleavage.30,62 
 
 Two hypotheses have been proposed for H-NOX conformational change required to initiate 
a gas-induced activity change in a response regulator. Ma et al. solved crystal structures of the 
unliganded, NO-bound, and CO-bound H-NOX protein from Nostoc sp., and found that in this H-
NOX, both ligands formed 6c complexes. The authors proposed a heme pivoting mechanism that 
is dependent on gas binding for signal transduction. Herzik et al. compared the structures of 
Shewanella oneidensis with and without NO and described a relative motion of the N-terminal and 
C-terminal subdomains along a pair of conserved glycines, termed the “glycine hinge” (Figure 
1.1B). However, the mechanism of H-NOX induced conformational change resulting in activation 
of sGC is currently not known and await high resolution structures of full-length sGC with and 
without NO bound for clarification of these possibilities (see Chapter 2). 
 
Connecting NO binding to iron–histidyl bond cleavage 
Stone et al.57 first observed an unexpected phenomenon that indicated interaction of NO 
with sGC is not as simple as NO binding to the heme: the rate of conversion of 6c His–Fe2+–NO 
to 5c Fe2+–NO depends on the concentration of NO. This result was then expanded upon by Zhao 
et al. (Figure 1.5).30 This surprising concentration dependence implies that a second molecule of 
NO must interact with the 6c His–Fe2+–NO sGC enzyme to influence the rate of iron–histidyl bond 
dissociation. There are several proposals for this additional interaction: a second, non-heme NO 
binding site that could be covalent or non-covalent; nucleophilic addition of NO to the heme-bound 
NO; or a second NO binding to the proximal side of the heme. These proposals remain somewhat 
contested,63,64 and the molecular basis for this concentration dependence has yet to be conclusively 
demonstrated. Given that two of the proposals are difficult to test experimentally, namely 
nucleophilic addition of NO to the heme-bound NO and a hydrophobic site specific for NO, in this 
section we review the major studies that seek to determine whether this dependence on NO 
concentration of histidine dissociation is due to a second NO binding event on the proximal side  
Figure 1.5 – Nitric oxide-dependent spectral transitions in sGC. Both the formation of the 6c ferrous nitrosyl complex 
and cleavage of the iron–histidyl bond are dependent on NO concentration. A) The absorbance at 431 nm, which 
corresponds to Soret maximum the 5c ferrous-histidine complex, decreases with time as sGC interacts with the 
indicated NO concentrations (in μM). B) Dependence of the slow and the fast rates extracted from A) on NO 
concentration. Adapted from ref30.  
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of the heme. The next section of the review will be devoted to articles focused on a second non-
heme NO binding site. 
When the hypothesis that NO could bind to the proximal side of the heme was first 
proposed in 1999 by Zhao et al.,30 cleavage of the iron–histidyl bond was considered to be the only 
step necessary to fully activate sGC. NO first must bind to the distal side of the heme forming a 
transient 6c His–Fe2+–NO complex before iron-histidine bond cleavage leading to 5c Fe2+–NO 
(Figure 1.6A, species (1)  (2)  (3)). Accordingly, the re-formation of the iron–histidyl bond 
was thought to be the only step involved in sGC deactivation. When NO binds to the distal face of 
the heme (5c Fe2+–NO), the dissociation path is straightforward. By the principle of microscopic 
reversibility, NO would dissociate in the reverse path of its association (Figure 1.6A, species (3) 
 (2)  (1)). However, if NO binds to the proximal face of the heme (5c NO–Fe2+), it is not clear 
how NO would dissociate, assuming the generation of a 4-coordinate porphyrin is energetically 
unfeasible (not depicted) (Figure 1.6B, (5)  (1)). Without excess NO (or another ligand) to bind 
and reform a 6c species, the dissociation of proximal NO would not be easily reversed. 
 
Nonetheless, several studies have found NO bound in the proximal pocket of bacterial H-
NOX proteins and in the H-NOX domain of sGC. In the NO-bound crystal structure of So H-NOX 
mentioned above, electron density corresponding to the NO ligand was observed on the proximal 
side of the heme (5c NO–Fe2+). In this structure with the proximal ligation of NO, the proximal 
histidine was shifted 8.5 Å and the αF helix rotated 90° (Figure 1.1B). Proximal NO ligation was 
also observed in an earlier crystal structure of cytochrome c′ from Alcaligenes xylosoxidans. 
Although the protein structures are unrelated, this cytochrome c′, also forms a 5c NO–Fe2+ heme 
cofactor via a 6c dinitrosyl complex (6c NO–Fe2+–NO)65. However, the crystal structure of the So 
H-NOX domain provided the first crystallographic evidence that NO can bind to the proximal side 
of the heme in H-NOX domains, and thus potentially in sGC. The structure of the 5c NO–Fe2+ H-
NOX exhibited a displacement of the distal domain by 2.5 Å compared to the 5c His–Fe2+structure, 
when the two structures were aligned by the proximal domain (Figure 1.1B). A similar 
displacement was also observed in prokaryotic O2-sensing H-NOX domains, suggesting that these 
structural changes upon gas binding may be universal for the signal transduction of gases through 
H-NOX domains, including in sGC.66  
 
In 2012, Martin et al.59 found that NO could coordinate to the proximal side of the heme in 
full-length sGC. Rapid freeze quench (RFQ) EPR with isotopically labeled NO was used to discern 
which isotopes of NO bound to the heme under sequential mixing conditions. First, 5c His–
Fe2+sGC was mixed with 14NO to generate 6c His–Fe2+–14NO, then 15NO was added and the 
samples were rapidly frozen after approximately 5 seconds. Isotopically mixed 5c samples were 
measured by EPR, implying the formation of two different populations: ferrous nitrosyl heme with 
either 14NO or 15NO bound. Although this EPR experiment does not distinguish between NO 
bound to the distal or the proximal side, the experimental design was such that the NO isotope 
used in the second addition must initially bind to the proximal side. The authors were able to show 
that the ratio of 14NO:15NO bound to sGC was influenced by the concentration of 15NO used. For 
example, whereas an equimolar concentration ratio of 14NO:15NO gave sGC populations with 
43:57 (14NO:15NO) bound, ten-fold excess of 15NO led to an sGC population of 15 : 85 
(14NO:15NO). This concentration dependence indicates that on this timescale, NO–Fe2+–NO forms, 
however it is not clear how many times NO is binding to the heme so NO could be proximal or 
distal (species (3), (4), and (5) in Figure 1.6). Under these conditions on the timescale of 
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milliseconds to seconds, NO is binding to the proximal side of the heme, and the authors conclude 
that the proximal side of the heme is the site where the second NO molecule binds. 
 
 
Figure 1.6 – Nitric oxide sidedness on the heme. A depiction of the molecular steps of NO binding to and dissociation 
from the heme in sGC. A) NO binds to the distal side of the heme with an association rate of k1 to form species (2). 
Rupture of the proximal histidine iron bond with the rate of k2 yields species (3). Note that k2 is dependent on NO 
concentration, as shown in Figure 1.5. To reverse this process, the proximal histidine rebinds to the heme with a rate 
of k–2, followed by the dissociation of NO from the distal side. B) For NO to bind on the proximal side of the heme, 
the distal 5c species must form first (as in A). Another molecule of NO binds to the proximal side of the heme with a 
rate of k3 to form species (4), followed by the cleavage of the distal NO–Fe bond with a rate of k4 to yield species (5). 
The reverse of this process requires either excess NO (to undergo the microscopic reverse), or another ligand (L) to 
bind to the distal side of the heme. Figure adapted from ref67. 
 
 
Conversely, Yoo et al.31 studied the motion of the proximal histidine of sGC with NO 
present by using time-resolved absorption spectroscopy on timescales from nanoseconds to 
milliseconds, and did not see evidence of NO binding to the proximal side of the heme. Previous 
work by the authors established that laser flash photolysis of ferrous nitrosyl heme to generate the 
4c Fe2+ species resulted in 97% geminately recombined ferrous nitrosyl heme (τ = 7.5 ps).68,69 
They then examined the 3% of heme that did not geminately recombine with NO; this population 
rebound the proximal histidine to form 5c His–Fe2+(τ0 = 70 ps). Following this 5c His–Fe2+ species, 
four specific transitions were identified spanning nanosecond to millisecond timescales (Figure 
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1.7). Of these, the first two spectral changes to occur were unaffected by NO concentration: 6c 
His–Fe2+–NO formation (τ1 = 6.5 ns), and the subsequent iron–histidyl bond scission to form 5c 
Fe2+–NO (τ2 = 0.66 μs). These early events were attributed to geminate recombination of NO to 
the heme after the laser pulse has ended, and subsequent iron–histidyl bond rupture. The spectral 
changes resulting from geminate recombination of NO (τ1 and τ2) are an outcome of the 
experimental setup where the initial condition of ferrous nitrosyl sGC is followed by NO 
dissociation from the heme and are not relevant to physiological activation of sGC. Additional 
processes occur on longer timescales and are dependent on NO concentration: 6c His–Fe2+–NO 
formation (τ3) and iron–histidyl bond scission (τ4). Concentrations of 20 μM and 200 μM were 
used, bracketing the lifetimes of these processes at 50 μs ≤ τ3 ≤ 250 μs and 10 ms ≤ τ4 ≤ 43 ms, 
which are consistent with bimolecular rates measured by stopped-flow UV-Visible spectroscopy.30 
The authors conclude that these four observed kinetic transitions can be described by a model 
where NO only binds to the distal side of the heme, at least within a window of 200 ms following 
initial NO binding. 
 
 
Importantly, Yoo et al.31 observed that the slow iron–histidyl bond rupture (τ4) is NO-
dependent, consistent with results from Zhao et al.30 The transition that is dependent on NO 
concentration is strictly 6c His–Fe2+–NO to 5c Fe2+–NO. Since no spectral signature of the 6c NO–
Fe2+–NO was observed (or any higher Fe2+ coordination species as has been postulated), the 
hypothesis that the NO dependence of the iron–histidyl bond scission is caused by NO binding to 
the proximal side of the heme is not supported by this data.59 It is noteworthy that the lifetime of 
the fast iron-histidyl bond scission (τ2) is independent of NO concentration and is faster than the 
predicted timescale for protein conformational changes (1 – 50 μs), suggesting there is an 
additional, unobserved change in sGC that has different effects on the fast and slow iron–histidyl 
bond dissociation rates. However, for the reasons outlined above, this change cannot be a result of 
proximal NO binding. It has also been shown that treating sGC with excess NO then rapidly 
quenching the reaction activates sGC on sub-second time scales, as fast as 200 ms.30 When 
evaluated in the context of the time-resolved data, this suggests that bimolecular NO binding and 
iron–histidyl bond cleavage occurs prior to sGC activation, but before proximal NO formation. 
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Figure 1.7 – Kinetics of sGC transitions in the heme pocket. The fate of the 5c iron-histidine species formed after 
laser photolysis of NO is depicted. A 6 ns 532nm laser pulse, indicated by the green bar, dissociates NO. The 
proximal histidine rebinds to the heme with a time constant of 0, measured in a separate experiment. There are two 
routes through which the 5c His–Fe2+  species can proceed. In the route occurring at faster timescales (bottom), 
geminate recombination of NO occurs with a lifetime of 6.5 ns, followed by cleavage of the iron–histidyl bond with 
a life time of 0.66 μs. τ1 and τ2 do not depend on NO concentration. In the route occurring at longer timescales (top), 
NO from the solution diffuses into the heme pocket in a bimolecular process and binds to the heme with lifetimes of 
50 μs ≤ τ3 ≤ 250 μs, followed by cleavage of the iron–histidyl bond with lifetimes of 10 ms ≤ τ4 ≤ 43 ms (NO 
concentration between 20 μM and 200 μM). Both τ3 and τ4 are dependent on the NO concentration, consistent with 
the stopped-flow spectroscopy data in Figure 1.5. Figure adapted from ref31. 
 
 
On timescales shorter than a second, it appears that sGC does not form a proximal NO 
complex. However, such a complex may form under steady-state conditions. One result of this 
hypothesis would be that the 5c NO–Fe2+ species would require excess NO to access 5c Fe2+–NO 
via a 6-coordinate intermediate (Figure 1.6B, species (5)  (3)), and thus would be predicted to 
dissociate more rapidly with excess NO than with substoichiometric NO. To evaluate whether the 
proximal NO complex forms under steady-state conditions, Guo et al.67 measured the NO off-rate 
for a bacterial H-NOX from S. oneidensis under steady-state conditions with substoichiometric or 
excess NO. However, the observed off-rates were the same within experimental error and are 
inconsistent with a model where the primary species in solution is 5c NO–Fe2+. Double electron-
electron resonance electron paramagnetic resonance (DEER-EPR) spectroscopy was then used to 
measure the distance from NO to a spin label bound to a surface cysteine residue located 23 Å 
from the distal side of the heme and 28 Å from the proximal side of the heme. This experiment 
enabled the differentiation of NO bound to the proximal and distal sides of the heme. While some 
proximal NO is observed in the presence of excess NO, the major species was in all cases 5c Fe2+–
NO. In fact, when treated with excess NO and then that excess was removed, NO in that case was 
found only in the distal position. 
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Given the disparate conclusions from these studies, is it possible to reconcile these 
differences into a unified model for sGC activation? One hypothesis is that the proximal NO-bound 
species is more rigid than the distal analog, which enabled the selective crystallization of proximal-
bound NO H-NOX. Both the RFQ-EPR and DEER-EPR studies indicate that the proximal NO 
species can form with sufficient time and NO concentration, however, the primary species at 
equilibrium is the distal NO complex. If the proximal NO complex were to form, it would occur 
after the iron–histidyl bond has been broken and sGC has already been activated, given the 
timescale of these processes. Taken together, it appears that NO binding to the proximal side of 
the heme is likely not the reason for the NO dependence of iron–histidyl bond scission which, in 
turn, is necessary but not sufficient for physiological activation of sGC. 
 
NO binding to the second site of sGC for full physiological activation 
Alternative hypotheses exist to explain the NO dependence of the iron–histidyl bond 
cleavage. Specifically, several groups have postulated that a second, non-heme NO binding site 
exists elsewhere on sGC. Here, the biochemical evidence for this secondary binding site will be 
discussed. 
 
 The first biochemical evidence for a second NO binding site was characterized by Bellamy 
et al. in 2002.70 The authors measured the activation of sGC using constant or clamped NO 
concentrations (where the addition of a NO donor is in equilibrium with a NO scavenger) and 
found that the Hill coefficient of sGC to be 2.1. This suggests that there is cooperativity in the 
binding of more than one NO molecule to sGC, and the molecular steps in full activation of sGC 
involve more than NO binding to the heme. In 2004, Russwurm et al.71 measured both the UV-Vis 
spectrum and the activity of sGC in the same sample. Upon the addition of excess NO, the UV-
Visible spectrum remained unchanged, but the activity increased dramatically compared to 
substoichiometric amounts of NO. The authors found they could generate a low activity state of 
sGC by either adding a sub-stoichiometric amount of NO relative to sGC, or by removing excess, 
non-heme bound NO by a buffer exchange. These results suggested that sGC exists in two different 
activity states, depending on the concentration of NO, without any changes to the 5c ferrous-
nitrosyl heme. The proposed second site has a dissociation constant much higher than that of the 
heme cofactor (Kd < 1.2 × 10–12 M).30 The substiochiometric, low-activity state will be henceforth 
referred to as the 1-NO state, indicating that one NO is bound to sGC at the heme and the enzyme 
is in a low activity state. The occupancy of the heme by NO under these conditions is 100%.  
 
 In 2005, Cary et al.17 compared enzymatic activity to the dissociation rate of NO in sGC. 
The authors found that sGC deactivates over 150 times faster than NO dissociates from the heme  
with purified enzyme, indicating that NO dissociation does not directly cause sGC deactivation. 
These results suggest that a binary model of sGC activation and deactivation is likely incomplete. 
Corroborating Russwurm’s data, the authors isolated 1-NO sGC with low activity by using two 
different traps that bind excess, non-heme bound NO, further indicating that breaking the His-Fe2+ 
bond is not sufficient to fully activate sGC. Additionally, the authors found that YC-1, a known 
stimulator of sGC activity, fully activates the 1-NO state and has only a small effect on the activity 
of sGC when excess NO is present. Subsequent deactivation of the 1-NO sGC with YC-1 present 
occurs slowly. This result is critical to discussing the activation of sGC in cells, discussed below. 
The model proposed in this paper is a three-activity model of sGC, where sGC has basal activity 
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without NO, ~15% activity with one equivalent of NO, and 100% activity when excess NO is 
present. 
 
 In a slightly different approach, Derbyshire et al.72 used butyl isocyanate (BIC) as a ferrous 
distal heme ligand (6c His–Fe2+–BIC) to block diatomic gases from binding to the heme. With 
BIC as the distal ligand, it was found that the addition of excess NO resulted in a slight shift in the 
Soret band from 429 nm to 432 nm. This result indicates that excess NO affected the heme 
environment without replacing the BIC ligand, as ferrous nitrosyl heme would exhibit a Soret band 
at 399 nm. BIC-bound sGC was activated 5-fold over basal activity in the absence of NO, 
compared to BIC-bound sGC with excess NO was activated 89-fold over basal. Addition of 
dithionite, which reacts with all non-heme bound NO, eliminated this additional activity. Together, 
these findings strongly suggest that there is a second, non-heme NO binding site whose occupancy 
is required for full sGC activation. 
 
 Fernhoff et al.73 hypothesized that the second NO molecule interacts with a cysteine residue 
on sGC. In this study, the authors used S-methyl methanethiosulfonate (MMTS), a small molecule 
that reversibly reacts with thiols to form an S-methyl-cysteine disulfide bond. When the cysteines 
of sGC formed a disulfide bond with MMTS, the activity was ~15% of maximal activity with 
excess NO (Figure 1.8A) and is nearly identical to the activity of the 1-NO state (Figure 1.8D). 
Under these conditions, all heme was found to be in the ferrous nitrosyl state. Maximal activity 
was restored upon the addition of excess thiol to remove the MMTS label, thus returning the 
cysteine disulfides to the native thiol (R-SH) (Figure 1.8C). Excess MMTS did not affect the basal 
activity of sGC (Figure 1.8B). 
 
 The interaction of thiols and NO is not a new idea. S-nitrosation is a known chemical 
modification of proteins that has been studied for nearly two decades. However, formation of S-
nitrosothiols (RSNO) requires a one-electron oxidation of NO and is thus dependent on the 
presence of an oxidant. Conversely, sGC activation does not dependent on oxidation.73 
Additionally, the half-life of an S-nitrosothiol is on the order of hours, which is far longer than the 
timescale of sGC deactivation which occurs in seconds. Therefore, the authors proposed that NO 
interacts with an sGC cysteine as a transient S-nitrosylthiol radical anion (RSNO●–). While 
RSNO●– and RNSO differ by only one electron, that single electron dramatically changes the 
properties of the complex. The half-life of an S-nitrosylthiol radical anion could be stabilized by 
adjacent residues via electrostatic interactions. Additionally, the nucleophilic addition of a thiolate 
to NO to generate RSNO●– is freely reversible. Such an interaction is commensurate with the 
concentration of free NO in cells and provides a rapid physiologically-relevant deactivation 
mechanism of sGC. Since the critical cysteine(s) involved in this transient interaction have yet to 
be identified, the NO–cysteine interaction remains a hypothesis, albeit with compelling evidence 
to support it. 
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Figure 1.8 – Blocking of sGC cysteines prevents full enzyme activation. A) Experimental data showing that MMTS-
treated sGC will not fully activate with excess NO but will activate to a certain extent with NO and a stimulator. B) 
MMTS does not affect the basal activity level of sGC. C) Treatment of the MMTS-labeled enzyme with DTT reverses 
the inhibition. D) The activity of the MMTS-treated sGC is comparable to the activity of the 1-NO state. Figure 
reprinted from ref73. 
 
An NO–cysteine interaction could explain the NO-dependence of τ4, but not τ2, as observed 
by Yoo et al.31 Those authors described a structural change in sGC that occurs on a timescale 
between τ2 and τ3 in order to account for the vastly different time scales of iron–histidyl bond 
cleavage. However, no explanation why τ4, but not τ2, depends on NO concentration was provided. 
An interaction between NO and a cysteine is likely to occur on this timescale and induce the 
observed structural transition. This conformational change could then influence the cleavage of 
the iron–histidyl bond, thereby accounting for the NO-dependence of τ4. 
 
 Cary et al.17 showed that small molecule sGC stimulators synergize with the 1-NO state of 
the enzyme. However, discovering precisely how NO and stimulators activate sGC to maximal 
activity is of great interest and directly relevant to the therapeutic action of these molecules. 
Despite a number of studies that seek to identify or narrow down the site of stimulator binding,74–
82 the mechanism by which sGC activity is increased is still unknown.  A recent study by Wales et 
al.83 localizes the stimulator binding site between the N- and C- terminal subdomains of the β1 H-
NOX domain, clarifying the specificity of these stimulators to sGCs. Further studies focused on 
the interaction between stimulators and sGC residues will parse out the necessary steps for 
stimulator  activation and their synergy with NO. 
 
sGC activation in cells 
 sGC activation should occur on similar timescales with the same ligand dependence, 
whether measured with purified enzyme or in cells. If this is not the case, it could signify that 
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additional cofactors or binding partners are missing with studies conducted with purified enzyme. 
Measuring sGC activity directly in cells is challenging experimentally, and yet significant progress 
has been made toward this goal. Bellamy et al.84 constructed an apparatus to reliably quench rat 
cerebellar cell suspensions on millisecond timescales. No lag in the synthesis of cGMP was 
detected, even at 20 ms after addition of NO, indicating that sGC is activated on sub-millisecond 
timescales at cellular concentrations of sGC. This is in agreement with the timescale of sGC 
activation as measured with purified enzyme.30 
 
Concerning the ligation state of sGC, there is currently no accurate method to measure the 
ligation state of heme cofactors in vivo. However, the assumption that sGC in cells has NO bound 
to the β H-NOX domain is based on two different sets of experiments. The first is that free NO has 
been measured by a variety of techniques, including fluorescent probes, NO biosensors, and 
several other methods. These studies indicate that the physiological signaling concentrations of 
NO are between 100 pM to 5 nM.85–89 This is 100 to 1,000-fold higher than the dissociation 
constant for NO bound to the H-NOX domain of sGC (Kd < 1.2 × 10–12 M).30 Based on these 
values, it seems likely that the resting ligation state of sGC in cells is 5c Fe2+–NO. The second set 
of experiments examined the effect of adding a small molecule sGC stimulator to human umbilical 
vein endothelial cells.73 Without the addition of excess NO, YC-1 was able to stimulate sGC 
activity. As work with purified enzyme shows YC-1 has very little effect on 5c His–Fe2+ sGC, this 
implies there is a ligand` bound to the heme cofactor of sGC in cells.  
 
As discussed, measuring the ligation state of sGC in cells has been a formidable challenge. 
From work with purified enzyme, NO dissociates slowly from the heme, even in the presence of 
ATP and GTP.17 However, either with purified enzyme or experiments done in cells, sGC activity 
quickly decreases once NO is removed.17,71,87,89 Roy et al. measured the EC50 of sGC in rat platelets 
to be 11 ± 1 nM, with a Hill coefficient of 1.2 ± 0.1, and the authors concluded that sGC possesses 
one binding site for NO in this concentration range (approximately 1 nM to 200 nM NO).87 One 
interpretation from these data is that the one binding site measured was for the heme. However 
given that the Kd of the H-NOX domain for NO is four orders of magnitude below the EC5030 and 
the Hill coefficient for NO activating purified sGC is 2.1,70 another interpretation of these data is 
that sGC in cells already has NO at the heme and the one binding site measured is the second site 
cysteine interaction. 
 
 Using the recently developed fluorescent cGMP biosensor δ-FlincG, Batchelor et al.88 
measured sGC activation at very low concentrations of NO, in the picomolar range. They 
developed a model that accounts for both sGC activation and the phosphodiesterase activity that 
degrades the cGMP signal. An increase in activity at such a low NO concentration is unusual, but 
the authors argue that the efficiency of signal transduction (defined as the turnover of enzyme per 
molecule of NO) is highest under these conditions. These experiments demonstrate that sGC can 
respond to exquisitely low amounts of NO, much lower than previously thought. The EC50 for NO 
in these studies depended on the relative concentrations of sGC and phosphodiesterase, however 
it is likely between 1-10 nM, in agreement with other studies done in platelets and astrocytes.90,91 
Thus, studies conducted in cells are consistent with work with purified enzyme and demonstrate 
that sGC activates on sub-second timescales, the ligation state of the H-NOX is likely 5c Fe2+–
NO, and sGC can respond to low amounts of NO. 
 
17 
 
 
Activation of Atypical Soluble Guanylate Cyclases 
 
In addition to the NO signaling pathway elucidated in mammals, there are homologous 
signaling pathways in lower animals that use NO and O2 as primary signaling molecules. For 
example, specific invertebrates contain either NO-sensitive sGCs, O2-sensitive sGCs, or some 
species carry both NO and O2 sensitive sGCs. The fall army worm (Manduca sexta) expresses 
NOS and sGC within neuronal cells where the signaling pathway is thought to play critical roles 
in the development of the olfactory system. Soil-dwelling nemotodes including Caenorhabditis 
elegans have been shown to have O2-sensing sGCs that respond to environmental O2 concentration 
to adjust social and eating behaviors.92 Drosophila melanogaster possesses both NO-sensing and 
O2-sensing sGCs, however distinct spatial expression patterns segregate these sensors to distinct 
locations in larvae.93 There are also some reports of carbon monoxide (CO) acting as the 
physiological ligand for sGCs. Iron-limited cultures of Chlamydomonas reinhardtii produce 
limited amounts of chlorophyll. However, production of chlorophyll recovers upon addition of 
CO, indicating some sensing mechanism for this gas is present in the organism (see Chapter 4). 
 
 
Deactivation of Soluble Guanylate Cyclase 
 
Physiological deactivation of sGC 
 GC deactivation is rapid following the removal of free, excess NO, both in cells and with 
purified enzyme.84,94 To understand deactivation, the physiological concentrations of NO and sGC 
in cells must be considered. A recent estimate of sGC concentration in cells is 2 μM, deduced from 
cGMP formation in platelets using the kinetic parameters of isolated sGC.88 Additionally, by 
deleting one isoform of the α-subunit of heterodimeric sGC and measuring the vascular response 
in both control and knockout mice, one study found that fewer copies of sGC can still elicit a full 
physiological response.95 Thus, there is general agreement that sGC is present in excess relative to 
NO in cells. 
 
 As mentioned above, the ligation state of sGC in cells is assumed to be 5c Fe2+−NO. This 
hypothesis stands in apparent contrast to the measured intracellular abundances of sGC (~2 µM) 
and NO (~1 nM); however, it should be noted that measurements of NO in cells is likely an 
underestimation as these data come from measurements made on free NO and thus sGC-bound 
NO is not accounted for in these estimations. Thus, since the measured concentration of free NO 
is higher than the dissociation constant of NO from the sGC heme (Kd < 1.2 × 10–12 M)30, we 
assume that all sGC in cells will have NO bound. Additionally, the half-life of most human proteins 
is on the order of hours, so even if not every sGC heterodimer is bound by NO immediately post 
translation, the majority of the population will exist long enough to bind to NO.96 Consequently, 
all sGC in cells would be in the low-activity, 1-NO state (Figure 1.9, middle). When the local 
concentration of free NO increases to nanomolar concentrations, NO will interact with the second 
binding site, and a small fraction of sGC will be converted to the fully active state. The estimation 
of nanomolar concentrations as the apparent Kd of the second site is deduced from the 
concentration of NO necessary to fully activate  both purified sGC57 and sGC in cells87. In this 
model, deactivation of this fraction is straightforward: as the concentration of NO decreases below 
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1 nM within a cell, the dissociation constant for the second site will favor NO release, returning 
sGC to the 1-NO state. 
 
 sGC stimulators were initially characterized as NO-independent, heme-dependent 
modulators of sGC activity. Indeed, in cell studies, stimulators increase sGC activity in the absence 
of excess NO. However, with purified enzyme, ligand binding to the heme is required to increase 
sGC activity, although the ligand can be either NO or CO. These differences can be reconciled by 
returning to the three-activity model. In cells, where the ligation state of the heme is assumed to 
be 5c Fe2+–NO, the exogenous stimulator alone can render sGC fully active without the addition 
of additional NO. This model was further supported by cell studies where human umbilical vein 
endothelial cells (HUVECS) were pre-treated for two hours with a nitric oxide synthase inhibitor 
Nω-nitro-L-arginine methyl ester, essentially removing NO from the cells. Upon addition of YC-
1, it was found that sGC activity in cells, as measured by cGMP production, was severely 
decreased,73 suggesting that a heme ligand is also necessary to activate sGC with YC-1. 
Deactivation proceeds once the stimulator concentration decreases below stimulator’s Kd for sGC. 
 
Pathophysiological deactivation of sGC 
Low sGC activity has been implicated in several pathologies, including cardiopulmonary 
disease, hypertension, asthma, and neurodegeneration.13,97,98 In particular, several studies have 
shown that prolonged oxidative stress deactivates sGC and renders it less responsive to NO. 
Currently, two different mechanisms have been hypothesized to explain these effects. First, direct 
oxidation of cysteine thiols to S-nitrosothiols could decrease sensitivity to NO by obscuring the 
putative secondary binding site, thereby preventing a necessary conformational change or 
decreasing substrate binding.99 Second, oxidation of the ferrous heme could yield ferric- and 
subsequently apo-sGC.100 The discussion here will focus on the molecular details by which sGC 
deactivates in these pathologies. 
 
 Sayed et al.101 evaluated the extent of cysteine S-nitrosation of sGC in cells when exposed 
to excess NO. The authors treated smooth muscle cells,cells from rat aorta, and HUVECs to 
varying forms of NO, including S-nitrosocysteine, vascular endothelial growth factor, and 
acetylcholine. The authors found that sGC was S-nitrosated and desensitized to NO. While it is 
known that sGC requires reduced cysteines to function, this study was the first to show that S-
nitrosation directly leads to desensitized sGC. In a follow-up study, neonatal cardiomyocytes were 
exposed to NO to carry out the S-nitrosations in a biologically-relevant environment.102 After 
examining the enriched peptides by mass spectrometry, nine new sites of S-nitrosation on sGC 
were identified. While the majority of these sites were localized to the CAT domain, two were 
identified in the active site pocket, suggesting that decreased substrate binding may cause 
desensitization. 
 
 Heme oxidation can also affect sGC activity. A recent paper by Surmeli et al.103 provided 
the first biochemical data showing that ferric sGC loses heme more readily than ferrous sGC, 
confirming a longstanding hypothesis.104 Apo-sGC is then quickly degraded by cells.105 One study 
has sought to unify these two modes of deactivation, where ferric-nitrosyl heme of sGC may 
undergo reductive elimination to generate a ferrous heme and an S-nitrosated cysteine.106 The 
authors show that exogenous thiols prevent this S-nitrosation event from occurring with ferric-
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nitrosyl sGC, restoring sGC sensitivity to NO. However additional studies are necessary to confirm 
this hypothesis. 
 
 
 
Figure 1.9 – sGC activation and deactivation in vivo. A) A model that accounts for all available data of physiological 
sGC activation and deactivation is depicted. For ease of representation, the activity of basal sGC is depicted in the 
conformation in which the β H-NOX contacts the α sGC CAT domain. The first molecule of NO that sGC encounters 
will bind to the heme of the H-NOX domain with picomolar affinity and remains bound. Thus, the vast majority of 
sGC in cells will be in the ~15% active state (1-NO). With an increase in the NO cellular concentration, NO will 
interact with the second site, which has nanomolar affinity. The physiologically relevant sGC states are boxed. 
Although the location of the second site has not yet been located yet, it is depicted here in the PAS domains. The 
modulation between these two states accounts for the downstream effects of NO in cells, as well as the rapid activation 
and deactivation of sGC observed both with purified enzyme, in cells, and in tissues. B) Atypical sGCs that sense 
oxygen are maximally active with no ligand bound, which are then inhibited with oxygen bound. C) A new class of 
sGC homologues have been discovered that are maximally activated with CO as the ligand. 
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Conclusion 
 
 The eukaryotic nitric oxide receptor sGC plays a pivotal role in eukaryotic gas signaling 
and is essential for many physiological processes that affect human health. The biochemical 
activation and deactivation of sGC has been challenging to understand, partly because of the 
difficulty in generating large quantities of homogeneous protein, but more so due to the complexity 
of the activation mechanism of the enzyme. To date, the best supported model of sGC activation 
and deactivation is outlined in Figure 1.9. In this three-activity model, the first molecule of NO 
binds on the distal side of the heme in the H-NOX domain, resulting in a partially activated 
enzyme. As the concentration of NO increases to nanomolar levels, NO interacts with the second 
site on sGC to fully activate the enzyme. As this concentration decreases, NO dissociates from the 
second site, and returns the enzyme to partial activity. 
 
Moving forward, biochemical investigations centered on sGC should be validated on the 
full-length enzyme whenever possible to ensure catalytic competence. While truncations of sGC 
are easier to obtain, the full-length heterodimer is the only known form to exhibit the intricate 
activation sequence. Advances in structural biology techniques such as cryo-electron microscopy 
in the past few years have provided a high-resolution quaternary structure of sGC and will aid in 
answering some of the most difficult outstanding biochemical questions. Still, great care must be 
exercised in designing experiments to gain further understanding of this complex signaling 
enzyme. 
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Thesis Research 
 
The focus of this dissertation centers on the activation mechanism of mammalian, insect, 
and algal homologues of soluble guanylate cyclase. While exclusively studying the mammalian 
homologue has been the norm in the first few decades, there are certain drawbacks to this narrow 
focus. Difficulties with protein expression and protein stability in certain biophysical experiments 
has increased interest in homologues of sGC. Thus, an examination of a broader panel of sGC 
homologues has uncovered important aspects of sGC activation by NO and YC-1, as well as a new 
class of sGC homologues that are more activate by carbon monoxide (CO). 
 
Chapter 1 discusses and provides further background for the mammalian nitric oxide 
receptor soluble guanylate cyclase, and the activation and deactivation of the enzyme as related to 
a physiological setting. A detailed discussion outlines the structural aspects of sGC critical for its 
activation and the molecular steps involved in the activation of sGC. Emphasis is placed on NO 
binding to the heme and potential for the second binding site of NO. Studies are placed in context 
of the activation mechanism and studies of sGC in cells are highlighted. Finally, critical 
experiments are outlined that represent the next period of research into the mammalian NO 
receptor. 
 
Chapter 2 describes the full-length structure of an insect NO-sensitive soluble guanylate 
cyclase from Manduca sexta (Ms). The biochemical properties of Ms sGC are confirmed to be 
similar to that of mammalian sGC, namely the binding of NO and CO, the ability for the enzyme 
to be stimulated by excess NO, and the ability for YC-1 to activate the 1-NO state. Cryo-EM was 
used to solve a 5.1 Å map of the unliganded state and a 5.8 Å map of the excess NO with YC-1 
state. The unliganded state of sGC has bent coiled coil domains and the catalytic domain in a 
closed conformation that does not allow the substrate to bind. The excess NO plus YC-1 state of 
sGC has straight coiled coils, an open catalytic domain, and YC-1 bound in a central pocket formed 
by the β H-NOX and both CC domains. The extension of the activated state was also observed in 
solution by Small Angle X-Ray Scattering (SAXS). This work delineates the endpoints of the 
allosteric activation of sGC by NO and YC-1 and allows for detailed biochemical experiments to 
now be guided by structure, a long-standing goal in the field. 
 
Chapter 3 outlines the progress made towards an understanding of the second NO binding 
site of sGC. Excess NO is required to generate the maximally active form of the enzyme, however 
certain treatments of sGC with bioconjugational agents prevent excess NO from generating this 
form of the enzyme. A wider range of bioconjugational agents has been explored, yet only cysteine 
modifications disrupt the NO-stimulated activity of sGC. The reactivities of different cysteine 
reactive agents has been explored to determine the requirements to disrupt activity. Structural 
guidance from the structures discussed in Chapter 2 and future directions will be proposed to more 
accurately understand the mechanism of inhibition of sGC by these bioconjugational agents. 
 
Chapter 4 describes the characterization of a new family of sGCs that sense carbon 
monoxide (CO). Organisms are required to sense their external environment in order to adapt to 
low nutrient conditions. In low iron conditions, Chlamydomonas reinhardtii has been described to 
use CO as a signaling molecule to increase its chlorophyll production. Four of the six sGC coding 
genes were expressed in E. coli and examined biochemically. While only two of the four genes 
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had significant heme incorporation, it appears that the homodimers were binding one heme, despite 
having two binding sites. One gene, Cyg11, was activated to a larger extent by CO than by NO 
and had the smallest Kd for CO of any full-length sGC. This study classified the biochemistry the 
first CO sensor of the sGC family, opening up the potential for CO to be a signaling molecule 
similar to NO. 
 
Chapter 5 outlines experiments related to Chapter 4 but did not merit publication including 
the kon,NO of Cyg11, the growth and culturing of Chlamydomonas reinhardtii, and the 
quantification of cyg genes transcribed. Additionally, future directions for the biochemical studies 
of soluble guanylate cyclases are discussed. 
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CHAPTER 2 
 
 
ALLOSTERIC ACTIVATION OF THE NITRIC OXIDE RECEPTOR SOLUBLE 
GUANYLATE CYCLASE MAPPED BY CRYO-ELECTRON MICROSCOPY 
 
 
Summary 
 
Soluble guanylate cyclase (sGC) is the primary receptor for nitric oxide (NO) in mammalian nitric 
oxide signaling. We determined structures of full-length Manduca sexta sGC in both inactive and 
active states using cryo-electron microscopy. NO and the sGC-specific stimulator YC-1 induce a 
71° rotation of the heme-binding β H-NOX and PAS domains. Repositioning of the β H-NOX 
domain leads to a straightening of the coiled-coil domains, which, in turn, use the motion to move 
the catalytic domains into an active conformation. YC-1 binds directly between the β H-NOX 
domain and the two CC domains. The structural elongation of the particle observed in cryo-EM 
was corroborated in solution using small angle X-ray scattering (SAXS). These structures delineate 
the endpoints of the allosteric transition responsible for the major cyclic GMP-dependent 
physiological effects of NO. 
 
 
 
 
 
 
 
Portions of this chapter have been reported in a previous publication.1 
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Introduction 
 
Nitric oxide (NO) is a critical primary signaling molecule in eukaryotic organisms.2,3 Cells 
detect this diatomic gas through the NO receptor soluble guanylate cyclase (sGC), which is 
activated by NO to catalyze the cyclization of 5′-guanosine triphosphate (GTP) to 3′,5′-cyclic 
guanosine monophosphate (cGMP).4–9 The NO signaling pathway, with sGC as a central 
component, plays crucial roles in the cardiovascular and neurological systems in mammals.10–12 
Furthermore, aberrations in these signaling pathways can lead to pathologies that include various 
forms of hypertension, cardiovascular disease, and neurodegeneration.13–17 
 
sGC is a heterodimer composed of two subunits, denoted α and β, that are each composed 
of four domains: an N-terminal heme nitric oxide/oxygen (H-NOX) domain, a Per/Arnt/Sim 
(PAS)-like domain, a coiled-coil (CC) domain, and a catalytic (CAT) domain.7,8 Although each 
subunit contains an H-NOX domain, only the β H-NOX domain binds a heme cofactor, with direct 
ligation occurring through a conserved histidine residue.18 The CC domains, together with the PAS 
domains, are thought to form a structured assembly upon dimerization of sGC.19 The CAT domains 
form a wreath-like structure with the active site at the dimer interface.7,20  
 
Biochemical aspects of sGC activation by NO have been studied in great detail. Without a 
ligand bound to the β H-NOX domain, sGC has a low basal activity. A stoichiometric equivalent 
of NO relative to the sGC heterodimer results in the cleavage of the proximal histidine-iron bond 
and the formation of a distal five-coordinate ferrous nitrosyl enzyme with 15% of maximal 
activity.6,21–23 This low-activity state of sGC will be referred to here as the 1-NO state; importantly, 
the KD of the ferrous nitrosyl heme is 1.2 × 10–12 M thus in this state NO remains bound to the 
heme.24 The activity of the 1-NO state can be increased to a maximally-active state either by the 
addition of excess NO (xsNO), or by addition of small-molecule stimulators.25 The benzylindazole 
compound YC-1 was the first reported small-molecule sGC stimulator.26 It was identified in a 
screen of compounds that inhibit platelet aggregation, one of the physiological responses of sGC 
activation. The molecular mechanisms by which NO and small molecule stimulator binding leads 
to enzyme activation remain unclear, despite the fact that the sGC-targeted drug Adempas® 
discovered through a small molecule screen based on the YC-1 scaffold was approved by the FDA 
in 2013. 
 
Visualization of the molecular steps in sGC activation has been a longstanding challenge. 
Crystal structures of individual truncated domains from various homologues of sGC have been 
reported.27–30 Additionally, structures of related heterodimeric and multidomain proteins have 
provided insight into the higher order connectivity of sGC. The heterodimeric catalytic domain 
from Homo sapiens was solved in an inactive conformation.31,32 Structures of membrane-bound 
adenylate cyclases have been solved that contain catalytic domains as well as portions of or the 
entire CC domains, helping to orient the C-terminal domains of sGC.33,34 However, the precise 
quaternary structural arrangement of domains in the N-terminal portion of sGC is not known. 
Consequently, the mechanism by which NO and small-molecule stimulators couple binding 
through the protein for activation are poorly understood. 
 
In the absence of a high-resolution full-length structure, previous work has used alternative 
methods in attempts to understand interdomain interactions and how small molecules activate sGC. 
   
 
32 
 
Crosslinking experiments and negative stain electron microscopy support the hypothesis that sGC 
is a flexible dumbbell-shaped particle, in which the CC domains serve to connect the H-NOX and 
PAS domains on one end of the dumbbell to the CAT domain on the other.19,35 Hydrogen 
deuterium exchange mass spectrometry (HDX-MS) has implicated the linker region between the 
PAS domains and the CC domains as critical in the activation mechanism, as both regions change 
in H/D exchange upon NO binding to sGC.36 Truncations of sGC have suggested that the β H-
NOX domain directly inhibits the CAT domains.37 Point mutagenesis was used to identify several 
residues thought to transmit the ligand occupancy of the gas-binding H-NOX domain to the 
catalytic domains, including β D102 and β D106.38,39 None of these methods, however, afford 
sufficient resolution to discern domain organization and interdomain communication for the full-
length protein. 
 
Here, we report the first full-length structures of sGC with and without activating ligands 
using cryoelectron microscopy (cryo-EM) to 5.1 and 5.8 Å resolution, respectively. We find that 
sGC adopts two dramatically different conformations, revealing a large-scale global 
conformational change in response to NO and YC-1. Density consistent with YC-1 is observed in 
the active state map directly between the β H-NOX and both CC domains. We also show the 
functional relationship of NO binding to sGC on overall organization of sGC in solution by small 
angle X-ray scattering (SAXS). By visualizing the quaternary structural changes that activate this 
NO receptor, we can now answer the long-standing question as to how the ligand binding in the 
regulatory domains of sGC is communicated to the catalytic domains. 
 
 
Materials and Methods 
 
Key Resource Table 
Key Resources Table 
Reagent type 
(species) or 
resource 
Designation Source or 
reference 
Identifiers Additional 
information 
gene 
(Manduca 
sexta) 
 Ms sGC α1 Integrated DNA 
Technologies  
Genbank: 
AF062750 
 Uniprot: 
O77105 
gene 
(Manduca 
sexta) 
Ms sGC β1 Integrated DNA 
Technologies  
Genbank: 
AF062751 
Uniprot: 
O77106 
strain, strain 
background 
(E. coli) 
 XL1-Blue UC Berkeley 
MacroLab 
   Cloning strain 
strain, strain 
background 
(E. coli) 
DH10-Bac UC Berkeley 
MacroLab 
 Transposition 
Strain 
recombinant 
DNA reagent 
pFastBac (plasmid) Thermo Fisher  Donor Plasmid 
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recombinant 
DNA reagent 
pFastBac_Ms_α1_His6 This paper   
recombinant 
DNA reagent 
pFastBac_Ms_β1 This paper   
Sequence-
based regent 
Primers   See primer 
table in 
materials and 
methods 
cell line 
(Spodoptera 
frugiperda) 
SF9 cells UC Berkeley 
Cell Culture 
Facility 
 Expression 
Strain 
Commercial 
Assay or Kit 
Cellfectin II Thermo Fisher  Transfection 
reagent 
Transfected 
Construct 
(Manduca 
sexta) 
bMON14272_ 
Ms_α1_His6 (bacmid) 
This paper  Transfected 
construct 
Transfected 
Construct 
(Manduca 
sexta) 
bMON14272_ 
Ms_β1_His6 
This paper  Transfected 
construct 
Chemical 
compound 
DEA NONOate Cayman 
Chemical 
Item No: 
82100 
 
CAS: 372965-
00-9 
 
Chemical 
compound 
PROLI NONOate Cayman 
Chemical 
Item No: 
82145 
 
CAS: 178948-
42-0 
 
 
Commercial 
Assay or Kit 
cGMP ELISA Enzo Life 
Science 
ADI-901-
013 
 
 
 
 
Materials 
All chemicals were purchased from commercial vendors and used without further purification, 
unless otherwise noted. Primers and gBlocks were obtained from Integrated DNA Technologies 
(Coralville, IA). Gibson Master Mix was purchased from New England Biolabs (Ipswich, MA). 
PrimeSTAR Max DNA polymerase and TALON superflow resin was purchased from Takara Bio 
USA (Mountain View, CA). DNA purification kits were purchased from Qiagen (Germantown, 
MD). ExCell-420 media, sodium dithionite (Na2S2O4), DNAse I from bovine pancreas, β-
mercaptoethanol, sodium phosphate, dibasic (Na2HPO4), sodium carbonate (Na2CO3), potassium 
phosphate (K2HPO4), guanosine 5′-triphosphate sodium salt (GTP) (>95%, HPLC), and zinc 
acetate (Zn(CH3CO2)2) were purchased from Millipore Sigma (Burlington, MA). 4-(2-
aminoethyl)benzenesulfonyl fluoride hydrochloride (AEBSF) was purchased from Research 
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Products International (Mount Prospect, IL). Isopropyl β-D-1-thiogalactopyranoside (IPTG), 4-(2-
hydroxyethyl)piperazine-1-ethanesulfonic acid (HEPES), and the Pierce BCA Protein Assay Kit 
were purchased from Thermo Fisher Scientific (Waltham, MA). Benzamidine, sodium chloride 
(NaCl), magnesium chloride (MgCl2), and glycerol were purchased from VWR Life Science 
(Visalia, CA). Dithiothreitol (DTT) was purchased from Bachem (Bubendorf, Switzerland). 
Imidazole was purchased from Oakwood Chemical (West Columbia, SC). Vivaspin spin 
concentrators were purchased from Sartorius (Concord, CA). BioSpin 6 desalting columns were 
purchased from BioRad (Hercules, CA). Diethylamine NONOate (DEA NONOate), PROLI 
NONOate, diethylamintriamine NONOate (DETA NONOate), and YC-1 were purchased from 
Cayman Chemical Company (Ann Arbor, MI). Carbon monoxide (CO, >99%) gas was purchased 
from Praxair Inc. (Danbury, CT). 
 
Construction of Plasmids 
Manduca sexta sGC α1 (Uniprot: O77105) and β1(Uniprot: O77106) genes were purchased as 
gBlocks from IDT with a C-terminal 6x His tag on the α1 gene with Golden Gate cloning sites. 
The gBlocks were subcloned into a Golden Gate entry vector (gift of the Tullman-Ercek lab, 
Northwestern University). PCR was used to add regions of homology to pFastBac (Bac-to-Bac 
Baculovirus Expresion System, Thermo Fisher Scientific), and Gibson Assembly was performed 
to generate pFastBac_Ms_sGC_α1_His6 and pFastBac_Ms_sGC_β1. The genes were transposed 
into a baculovirus bacmid using DH10Bac-GFP cells. The bacmid was isolated, validated, and 
then transfected into SF9 cells (Berkeley Cell Culture Facility) to generate recombinant 
baculovirus for both genes. 
 
Name Sequence (5’  3’) Target Purpose 
oBGH
130 
GGAGATAATTAAAATGATAACCATCTCGC pFastB
ac 
Sequenci
ng 
oBGH
131 
TTTATTTGTGAAATTTGTGATGCTATTGC pFastB
ac 
Sequenci
ng 
oBGH
297 
CGATGGAGTACGAAGCGAATTTCGTATG Ms_α Sequenci
ng 
oBGH
168 
GCCTGCACGATCATCTCGGGAC Ms_β Sequenci
ng 
oBGH
195 
CTGCCAAGCTCCAGGAACACC 
ATGACGTGTCCATTCCGTCGTG 
Ms_α 
(F) 
Cloning 
oBGH
196 
CCTCGAGACTGCAGGCTCTAGA 
TTAGTGATGGTGATGGTGATG 
Ms_α 
(R) 
Cloning 
oBGH
197 
GCTCCGGGAGCGGACACC 
ATGTACGGGTTTGTGAACTATGCCC 
Ms_β 
(F) 
Cloning 
oBGH
198 
CCCCACAAAGGCTGCCAT 
TTAATGGATCTTCCTGGTGAGGAACCAG 
Ms_β 
(R) 
Cloning 
oBGH
199 
CATCACCATCACCATCACTAATCTAGAGCCTGCAGTC
TCGAGG 
pFastB
ac (F) 
Cloning 
oBGH
200 
CACGACGGAATGGACACGTCATGGTGTTCCTGGAGC
TTGGCAG 
pFastB
ac (R) 
Cloning 
oBGH
201 
CTGGTTCCTCACCAGGAAGATCCATTAAATGGCAGC
CTTTGTGGGG 
pFastB
ac (F) 
Cloning 
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oBGH
202 
GGGCATAGTTCACAAACCCGTACATGGTGTCCGCTCC
CGGAGC 
pFastB
ac (R) 
Cloning 
 
 
Protein Expression and Purification 
SF9 cells were maintained in monolayer and in suspension in ExCell-420 media at 27 °C (cells 
were shaken at 135 rpm). The recombinant baculovirus was amplified until the titer was greater 
than 1 × 108 cfu/mL. Five liters of SF9 cells were coinfected with 50 mL of amplified virus per 
liter and allowed to express for 72 hours. Cells were spun down at 4300 g for 20 minutes, snap 
frozen in liquid nitrogen, and stored at –80 °C. 
 
The following steps were performed at 4 °C. Cell pellets were thawed in ice water and resuspended 
in lysis buffer: Buffer A (50 mM Na2HPO4, pH 8.0, 200 mM NaCl, 1 mM imidazole, 1 mM 
benzamidine, 5% (v/v) glycerol, 0.22 μm filtered) supplemented with 10 mM benzamidine, 1 mM 
AEBSF, 0.5 mg/mL bovine DNAse I, and 5 mM β-mercaptoethanol. Cells were lysed in a bead 
beater (BioSpec) with 0.5 mm glass beads. The resulting cell lysate was clarified by spinning at 
4,300 g for 5 minutes, followed by spinning at 158,000 g for 2 hours (Ti45 rotor, Beckman 
Coulter). The lysate was passed through a column containing 2 mL TALON superflow at 0.5 
mL/min, and the flow-through was collected. The column was washed with 15 column volumes 
of Buffer A supplemented with 5 mM β-mercaptoethanol at 0.5 mL/min. The protein was eluted 
with 10 CV of Buffer B (50 mM Na2HPO4, pH 8.0, 200 mM NaCl, 150 mM imidazole, 1 mM 
benzamidine, 5% (v/v) glycerol, 0.22 μm filtered) supplemented with 5 mM β- mercaptoethanol. 
Fractions with yellow color were concentrated to < 2 mL using a 30,000 molecular weight cutoff 
spin concentrator, supplemented with 5 mM DTT and 5 mM EDTA, and stored overnight. Next, 
the sample was diluted to 9 mL with Buffer C (25 mM triethanolamine, 25 mM NaCl, 5 mM DTT, 
5% (v/v) glycerol, 0.22 µm filtered), and applied to a POROS HQ2 anion exchange column 
(Thermo Fisher Scientific). The column was washed with 3 CV of Buffer C, and then a gradient 
to 50% Buffer D (25 mM triethanolamine, 750 mM NaCl, 5 mM DTT, 5% (v/v) glycerol, 0.22 µm 
filtered) was established over 17 CV at 0.5 mL/min. Fractions with purified sGC were concentrated 
to 5–50 µM and stored in liquid nitrogen. A typical yield for this expression and purification 
procedure is 100 µg sGC per liter of insect cells. 
 
Intact Protein Mass Spectrometry 
Purified proteins were buffer-exchanged into 25 mM HEPES, pH 7.5, 25 mM NaCl using three 
rounds of dilution and concentrations in a Vivaspin 500 (30,000 MWCO) spin concentrator. 
Samples were filtered with a 0.22 μM spin filter (Millipore). The final sample concentration was 
approximately 5 µM. Samples were separated with an Agilent 1200 series high pressure liquid 
chromatography (HPLC) system over a ProSwift column (ThermoFisher Scientific), and 
subsequently analyzed by an Agilent 6224 time-of-flight (TOF) mass spectrometer with a 
Turbospray ion source in positive ion mode. 
 
Absorption Spectroscopy 
Samples were reduced in an anaerobic glove bag (Coy) with 5 mM Na2S2O4 for 15 minutes, and 
then desalted with a BioSpin6 column equilibrated with Buffer E (50 mM HEPES, pH 7.5, 150 
mM NaCl, 5% (v/v) glycerol, 0.22 µm filtered). CO-saturated buffer (950 μM CO) was prepared 
by sparging 3 mL of anaerobic Buffer E for 15 minutes in a Reacti-Vial (Thermo Fisher Scientific). 
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CO was added to the sample to achieve a final concentration of 425 μM. Nitric oxide was added 
to a concentration of 500 μM by addition of DEA NONOate, based on 1.5 moles of NO released 
per mole of NONOate. Protein-ligand complexes were incubated for 15 minutes at room 
temperature to establish equilibrium, and no further spectral changes were observed after this time. 
Samples were placed in a septum-sealed 1 cm pathlength quartz cuvette inside the glove bag, and 
UV–Vis spectra were recorded on a Cary 300 spectrophotometer (Agilent Technologies). 
 
Activity Assays and Quantification 
Steady-state kinetics for Ms sGC were measured by quantifying the amount of cGMP produced in 
duplicate endpoint activity assays, performed in at least biological triplicate. Samples were 
reduced in an anaerobic glove bag with 5 mM Na2S2O4 for 15 minutes, and then desalted with a 
BioSpin6 column equilibrated with Buffer E. Ms sGC with 1-NO and xsNO were prepared by first 
adding PROLI NONOate to 50 µM, based on 2 moles of NO released per mole of PROLI 
NONOate. This sample was then buffer exchanged into Buffer E through a BioSpin6 column to 
generate the 1-NO state. To generate the xsNO state, PROLI NONOate was added back to a portion 
of the 1-NO sample and allowed to equilibrate for 5 minutes. YC-1 was added from a 100x stock 
solution in DMSO to a final concentration of 150 µM (final DMSO concentration 1%). The protein 
concentration was determined using the reduced heme Soret peak at 433 nm (149,000 M–1 cm–1).40 
Protein concentration was adjusted after desalting the excess NO by comparing the A280 peaks to 
the unliganded protein. Activity assays were conducted at 25 °C and pH 7.5 in Buffer D, 
supplemented with 5 mM DTT and 5 mM MgCl2. Reactions were initiated with 2 mM GTP and 
timepoints from were quenched with 125 mM Zn(CH3CO2)2, followed by 125 mM Na2(CO3) to 
adjust to pH 7. Samples were frozen at –80 °C until quantification. Quenched assays were thawed, 
and the zinc precipitate was spun down for 10 min at 23,150 g. The reactions were diluted by one 
to three orders of magnitude, and the cGMP was quantified in duplicate using an extracellular 
cGMP Enzyme Linked Immunosorbent Assay, following the manufacturer’s instructions (Enzo 
Life Sciences). Concentrations of cGMP were determined from a standard curve, generated over 
0.16–500 pmol/mL. Initial rates were calculated from the linear phase of the time course, where 
5–10% of the GTP substrate was consumed. The experiment was repeated at least three times to 
ensure reproducibility. 
 
Cryo-EM Sample Preparation and Data Collection 
Samples were reduced in an anaerobic glove bag with 5 mM Na2S2O4 for 15 minutes, and then 
desalted with a BioSpin6 column equilibrated with Buffer F (25 mM triethanolamine, pH 7.5, 25 
mM NaCl, 5 mM DTT, 0.22 µM filtered). The inactive protein sample was diluted after thawing 
from a single frozen stock to ~2–4 µM in 1–3% trehalose. The sample (3.5 µL) was applied to 
glow discharged UltrAUfoil 2/2 200 mesh gold grids (Quantifoil) and plunge-frozen using a 
vitrobot Mark IV (Thermo Fischer). Blotting was performed under 100% humidity with zero blot 
force for 3–6 seconds. sGC was dispersed in vitreous ice which displayed clear contrast transfer 
function information (Figure A.3A). Active sample was prepared in a similar manner, but 500 µM 
NO (from DEA NONOate) and 150 µM YC-1 were added (Supplemental S4a-b).  
 
Grids were screened and imaged on a Talos Arctica (Thermal Fischer) operated at 200 kV. 
Complete imaging conditions are described in Table A.1. Micrographs were collected at 36,000X 
nominal magnification on a K3 direct electron detector (Gatan) in super-resolution counted mode 
at 0.5685 Å/pix. Serial EM was used for automated image shift data collection of 2,841 and 9,330 
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movies for the inactive and active sample, respectively. Movies were taken in 100 ms frames, 
totaling an electron dose of 60 electrons per movie.  
 
Cryo-EM Data Processing 
Inactive sGC movies were drift-corrected, gain-corrected, and binned to 1.137Å/pix in 7x5 patches 
using MotionCor2.41 Micrographs were CTF-corrected using CTFFIND4 and single particles were 
manually picked for initial 2D classification within Relion 3.0.42–44 Class averages representing 
the full length complex (Supplemental S2c) were used for template picking with Relion autopicker, 
resulting in 675,956 particles. Particles were imported into Cryosparc2 and pruned using 2D 
classification and 3D ab initio classification.45 Initial 2D classification yielded a large number of 
falsely picked background particles and particles which represented broken sGC dimers. We 
suspect the background particles are due to the size of the complex, while the broken particles 
likely stem from damage at the air-water interface (Figure A.3C). These poor class averages were 
removed from further processing steps. In total, 59,165 final particles were refined using non-
uniform refinement with default parameters (Figure A.3B). Active sGC movies were binned to 
2.274 Å/pix before template-free Laplacian picking for initial particle selection.44 Micrographs 
were manually cleaned by visual inspection and FFT quality. Initial single particles were pruned 
using iterative 2D and 3D techniques (Supplemental S4b, c), as described above for the inactive 
state. Similarly, many of the initial picked particles were background or broken in the Active 
dataset (Supplemental S3c) Blurred density at low thresholds was seen in a predicted region for 
the alpha-HNOX but did not resolve during processing and was masked away during the final 
reconstruction. Of note, both Inactive and Active datasets underwent exhaustive processing 
schemes, including Bayesian polishing, multibody refinement and focused classification, none of 
which improved the resolution or showed evidence of multiple conformations in a single dataset. 
 
Model Building 
Homology models for each domain were built using Phyre2 and correspond to the following PDB 
entries: α H-NOX (2O0C), α PAS (4GJ4), α CC (3HLS), α CAT (3UVJ), β H-NOX (2O0C), β 
PAS (4GJ4), β CC (3HLS), β CAT (2WZ1).46 Domains (with side chains removed) were rigid-
body docked into the inactive reconstruction using the fit_in_map function of Chimera.47 Clear 
density for heme in the β H-NOX domain enabled clear distinction of the two H-NOX domains. 
Linkers between the H-NOX and PAS domains are missing in the density, likely due to flexibility, 
and were left out of the model (α 238–278 and β184–206). Initial placement of the CAT dimer 
was based on a significant extension in the sequence of the α CAT C-terminus, which is visible as 
unmodeled density. Continuous density from the CAT dimer enabled assignment of the CC and 
PAS domains. The linker region between the PAS domains and the CC were manually modeled in 
COOT based on secondary structure predictions from PSIPRED.48,49 Refinement using iterative 
rounds of phenix.real_space_refine and inspection in COOT led to the final carbon back bone 
trace of the inactive state. Active state modeling was based on rigid-body fitting of domains based 
on the inactive state. Helical density was apparent throughout the structure (with the exception of 
the α H-NOX, as mentioned above). Linker regions between domains were corrected with COOT 
and phenix.real_space_refine. Final model idealization was carried out using 
phenix.model_idealization and validated using Molprobity.50 
 
Small-angle x-ray scattering in-line with size-exclusion chromatography (SEC-SAXS)  
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Samples were reduced in an anaerobic glove bag with 5 mM Na2S2O4 for 15 minutes, concentrated 
to 60 µL at 50 µM (~7.5 mg/mL), and then three rounds of dialysis were performed in Buffer G 
(50 mM KH2PO4, pH 7.4, 150 mM NaCl, 2% glycerol). The activated sample was prepared with 
500 µM NO (from DEA NONOate). The samples were sealed and run within 3 hours of being 
prepared; samples did not undergo freeze–thaw after the sample was prepared (the protein was 
freeze–thawed once after purification for initial storage). 
 
In situ sample purification was accomplished through SEC to isolate well-folded proteins from 
aggregates and other impurities immediately before exposure to synchrotron X-ray radiation using 
a custom designed flow cell. SEC-SAXS was collected at the SIBYLS beamline (bl12.3.1) at the 
Advanced Light Source at Lawrence Berkeley National Laboratory, Berkeley, California.51,52 X-
ray wavelength was set at λ = 1.127 Å and the sample-to-detector distance was 2,105 mm, as 
determined by silver behenate calibration, resulting in scattering vectors, q, ranging from 0.01 Å–
1 to 0.4 Å–1. The scattering vector is defined as q = 4πsinθ/λ, where 2θ is the scattering angle. Data 
was collected using a Dectris PILATUS3X 2M detector at 20 °C and processed as previously 
described.53,54 Briefly, a SAXS flow cell was directly coupled with an Agilent 1260 Infinity HPLC 
system using a Shodex KW-803 column. The column was equilibrated with running Buffer E with 
a flow rate of 0.5 mL/min for inactive sGC and 0.55 mL/min for activated sGC. To achieve 
activation conditions, the buffer was continuously sparged with nitrogen gas and the column was 
equilibrated for at least 2 hours to maintain an anaerobic environment. Several NONOates with 
various half-lives were added to the running buffer to achieve activation of sGC. These NONOates 
include DEA NONOate and DETA NONOate, which spontaneously release NO with half-lives of 
16 minutes and 56 hours, respectively. Each sample was run through the SEC-SAXS system and 
3-second X-ray exposures were collected continuously over the 30-minute elution. The SAXS 
frames recorded prior to the protein elution peak were used to correct all other frames. The 
corrected frames were investigated by radius of gyration Rg derived by the Guinier approximation 
I(q) = I(0) exp(–q2Rg2/3) with the limits q*Rg < 1.3 (Figure A.5B). The elution peak was mapped 
by comparing the integral of ratios to background and Rg relative to the recorded frame using the 
program SCÅTTER (Figure A.5A).  
 
The frames in the regions of least Rg variation were averaged and merged in SCÅTTER to produce 
the highest signal-to-noise SAXS curves. These merged SAXS curves were used to generate the 
Guinier plots, volumes-of-correlation (Vc), pair distribution functions, P(r), and normalized Kratky 
plots. The Guinier plot indicated an aggregation-free state of the protein (Figure A.5B). The P(r) 
function was used to determine the maximal dimension of the macromolecule (Dmax) and estimate 
inter-domain distances (Fig. 4A).55 P(r) functions were normalized based on the molecular weight 
(MW) of the assemblies, as determined by the calculated Vc.56 
 
Eluent was subsequently split (4 to 1) between the SAXS line and a multiple wavelength detector 
(UV-vis), set to 432 and 280 nm, multi-angle light scattering (MALS), and refractometer. The 
ratios of the protein (280 nm) and Soret band (432 nm) of the heme from SEC were used to evaluate 
the ligation state of Ms sGC upon NO binding (Figure A.5A). MALS experiments were performed 
using an 18-angle DAWN HELEOS II light scattering detector connected in tandem to an Optilab 
refractive index concentration detector (Wyatt Technology). System normalization and calibration 
was performed with bovine serum albumin using a 60 μL sample at 10 mg/mL in the same SEC 
running buffer and a dn/dc value of 0.185 and 0.15 mL/g for inactive and active sGC respectively. 
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The MALS data was used to compliment the MWs calculated by the SAXS analysis and, being 
furthest downstream, the MALS peaks were used to align the SAXS and UV-vis peaks along the 
x-axis (elution volume in mL/min) to compensate for fluctuations in timing and band broadening 
(Figure A.5A). UV–vis data was integrated using Agilent Chemstation software and baseline 
corrected using Origin 9.1 (Figure A.5A). MALS and differential refractive index data was 
analyzed using Wyatt Astra 7 software to monitor the homogeneity of the sample molecular 
weights across the elution peak, complementing the SEC-SAXS signal validation (Figure A.5A).  
 
Solution Structure Modeling 
The cryo-EM refined crystal structure for inactive sGC was used to build an initial atomistic 
model; all missing loops and terminal residues were added using MODELLER.57 A purpose-
designed rigid body modeling pipeline was applied to the completed structure using BILBOMD 
to systematically explore conformational space for both the inactive and activated states of sGC 
(Video 4).58 To obtain an inactive state model, the α H-NOX domain and both α terminal tails were 
moved, then all α and β domains were moved by allowing flexibility at the hinge region where the 
CCs meet the CAT domains, while holding the CAT domains fixed and still permitting flexibility 
of the terminal tails. This was then used to generate the 1-NO state model by moving the same 
regions as the inactive state in reverse order. Theoretical SAXS curves were produced by 
FOXS.59,60 Each model generated through BILBOMD as compared to the experimental SAXS 
profiles to assess the goodness of fit. Multistate model ensembles for activated sGC were 
determined using MultiFOXS.61 
 
Results 
 
Characterization and activity of full-length Manduca sexta sGC  
We selected Manduca sexta (Ms) sGC as a biochemically tractable protein which has 36% 
and 59% sequence identity when compared to the human homolog for the α and β monomers, 
respectively. A schematic of the domain organization is shown in Figure 2.1A. Additionally, the 
regulatory properties in response to NO and YC-1 mirror those of its human counterpart and YC-
1 had been shown to increase the Ms sGC 1-NO state to maximal activity.40 While full-length Ms 
sGC has only been previously reported to be expressed in E. coli, we used a baculoviral expression 
protocol to produce reliable quantities of stable, full-length protein (Figure A.1).40 UV–visible 
absorption spectra of Ms sGC without ligands (unliganded, U), with xsNO, and with carbon 
monoxide (CO) show the expected ligand-dependent shifts of the Soret and Q bands, indicating 
the β H-NOX domain is competent to bind diatomic gases (Figure 2.1B). 
 
We confirmed that Ms sGC displays catalytic activity similar to other well-characterized 
mammalian homologues, including Homo sapiens sGC. Ms sGC exhibits a low, basal activity in 
the unliganded state (71 ± 36 nmol/min/mg) and partial activation in the 1-NO state (309 ± 77 
nmol/min/mg) (Figure 2.1C, Figure A.1C), consistent with previous reports of mammalian sGCs.22 
Maximal activity could be achieved by adding excess NO to the 1-NO sample (1,988 ± 131 
nmol/min/mg), or by the addition the sGC stimulator YC-1 to the 1-NO state (1,522 ± 38 
nmol/min/mg) (Figure 2.1C, Figure A.1D, Figure A.2). Taken together, Ms sGC displays 
biochemical properties comparable to well-characterized mammalian sGCs. 
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Figure 2.1 – Domain arrangement and activation of Manduca sexta (Ms) soluble guanylyl cyclase (sGC). A) 
Schematic representation of the Ms sGC heterodimer domain architecture. sGCs contain four domains: a heme nitric 
oxide/oxygen (H-NOX) binding domain, a Per/Arnt/Sim (PAS)-like domain, a coiled-coil (CC) domain, and a 
catalytic cyclase domain (CAT). The heme binding site in β H-NOX is represented by the grey quadrilateral. B) UV–
visible absorption spectra of Ms sGC in the unliganded (U), NO-bound, and CO-bound states. The wavelength maxima 
of the Soret peaks are indicated. Inset: Q bands show increased splitting upon gas binding. C) Discontinuous cGMP 
activity assay for Ms sGC with various activation conditions: 1-NO, xsNO, and YC-1 ligands. Initial rates were taken 
from assays run at 25 °C, pH 7.5 with 2 mM Mg•GTP as the substrate (see Figure A.1D). cGMP formation was 
measured using an enzyme linked immunosorbent assay. The average initial rate is plotted, and the error bars reflect 
one standard deviation (n = 4). 
 
 
Inactive conformation of sGC exhibits bent coiled-coils  
Cryo-EM was used to solve the structure of full-length inactive Ms sGC. Two-dimensional 
classification after removing poor particles showed intact density with two lobes with connective 
density between them similar to previously reported EM envelopes obtained by negative stain 
(Figure A.3A-C).19 Three-dimensional classification and refinement yielded a single 
reconstruction with a 5.1 Å nominal resolution (Figure A.3D) that exhibited a clear dimer interface 
and distinct CCs (Figure 2.2A, Table A.1). While particles display a slight orientation preference, 
local resolution is uniform throughout the density map (Figure 2.2E,F). Additionally, the overall 
map exhibits well-defined helices and continuous density. The two lobes of the structure are 
termed the “regulatory” lobe and the “catalytic” lobe, with the CC domains acting as a bridge 
between them (Figure 2.2A). The long axis of the regulatory lobe is positioned perpendicular to 
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the catalytic lobe and is predicted to contain the H-NOX/PAS bundle, while the CAT domains are 
predicted to form the catalytic lobe.19 
 
Several features enabled conclusive assignment of the α and β subunit domains in the 
density map, despite the intermediate resolution and pseudosymmetry between the two subunits 
(Figure 2.2B). A rigid body global search of potential H-NOX positions revealed two possible 
positions for H-NOX domains within the regulatory lobe.47 The αF helix of the β H-NOX domain 
(Figure A.1E) binds a heme cofactor while the α H-NOX does not. Only the position closest to the 
catalytic lobe contains density for the heme cofactor (Figure 2.2C), hence this was assigned to the 
β subunit. The two CAT domains could be differentiated because the α CAT domain contains a C-
terminal extension (residues 661–699) which is absent in the β CAT domain. Only one of the 
domains in the catalytic lobe contains extra C-terminal density and thus the CAT domains could 
be assigned unambiguously (Figure A.3F). Connective density from the CAT domains enabled 
clear differentiation of the two CC and PAS domains (Figure 2.2D, green). As a result, the α PAS 
is assigned as the top domain, while β is the bottom domain (Figure 2.2B). Homology models for 
Ms sGC domains were combined representing residues α 51-250, 279-699 and β1-183, 205-597 to 
create a full-length model (Described in Methods). 
 
The CC domains are in a parallel orientation, and both domains have a clear bend, distinct 
from a previously determined CC X-ray structure.29 A linker extends from the C-terminus of the 
PAS domains and forms a rigid loop connecting the bent helix to the H-NOX/PAS domains (Figure 
2.2D, light and dark green). The CC density bends sharply at residues α A422 and β L343. This 
bent region forms a buried helix, and along with the C-terminal PAS linker, creates an interaction 
nexus between the H-NOX, PAS, and CC domains (Figure 2.2D, highlighted in light and dark 
purple). The bent N-terminal portion of the CC domains (α 403–415 and β 333–345), is highly 
conserved across sGC homologues (Figure A.3I). 
 
The CAT dimer displays a wreath-like fold with the monomers related by a twofold axis, 
typical for class III nucleotide cyclase domains.20,62 The CAT domains align well with a previous 
structure of an inactive guanylate cyclase (Cα RMSD of 1.3 Å to PDB ID: 4NI2), displaying an 
inaccessible nucleotide-binding pocket that would require a significant rearrangement for 
activation (Figure A.3H). In the absence of a substrate-bound structure of a guanylate cyclase, we 
compared our model to a substrate-bound adenylate cyclase. The alignment of the α chain of an 
active adenylate cyclase structure (PDB ID: 1CJK, gray) with the α CAT domain of our inactive 
Ms sGC structure reveals that the Cα of β N538 from the β CAT domain is within 2 Å of the bound 
nucleotide analog in the adenylate cyclase structure (Figure 2.2E). This state is thus in a closed 
conformation that is sterically incompatible with nucleotide binding, explaining the lack of 
guanylate cyclase activity. 
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Figure 2.2 – Inactive Ms sGC forms a bent coiled-coil structure. A) Views of cryo-EM density for the inactive state, 
colored by subunit (α - orange, β - blue). Dimensions of the complex are shown in black. The two lobes of the 
enzyme are denoted “regulatory” and “catalytic”. B) Molecular model of Ms sGC with domains labeled and colored 
as in Figure 2.1A. The heme is colored gray. C) Two views of the β H-NOX domain with heme shown in gray and 
H105 in red D) View of the bent coiled-coil (purple) and PAS linker (green) shown in shades for the α (dark) and β 
(light) dimer. Close up shows connective density between the PAS and CC domains (threshold 12σ). The sequences 
of the bent CC domains are shown below. E) View of the inactive catalytic dimer fit into density (α - orange, β - 
blue). Close up shows aligned active adenylyl cyclase (α CAT domain) and nucleotide in gray (PDB: 1CJK) 
compared with the inactive sGC model. The distance between the substrate analogue and nearest backbone Cα (β 
N538) is shown. 
 
 
Activated sGC extends the regulatory lobe from catalytic core 
To elucidate conformational changes associated with sGC activation, a structure of sGC 
bound to NO and the small molecule stimulator YC-1 was determined. We elected to supplement 
the xsNO Ms sGC with YC-1 to generate the most stable activated conformation. Particles of active 
Ms sGC were well-dispersed in vitreous ice (Figure A.4A,4B). Cleaned two-dimensional class 
averages exhibit a two-lobed density that is distinct from the inactive structure (Figure 2.3C). The 
final 3D reconstruction of the active state at 5.8 Å resolution displays clear density for the CCs, β 
H-NOX, and α helices throughout the structure (Figure 2.3A, Figure A.4D-F). Only diffuse density 
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was present for the α H-NOX, likely due to increased flexibility of this domain and it was thus 
omitted in the model (Figure 2.3B). 
 
The orientation of the domains in the regulatory lobe is maintained from the inactive state 
to the active state, and the β H-NOX position is readily identified via the bound heme cofactor 
density (Figure 2.3C). A triangular-shaped lobe of unassigned density is present in the active state 
map but not in the inactive state map (Figure 2.3C, arrow). This density is located directly between 
the β H-NOX domain and the α and β CC domains, adjacent to either the A or B pyrrole of the 
heme (opposite of the propionate chains). The volume likely corresponds to YC-1 (304.3 Da) and 
with the current resolution two orientations of this small molecule are possible (Figure 2.3C). 
Residues within 5 Å of the density include α CC 422-427 (AQDGLR), and β V39, F77, C78, Y112, 
and Q349. 
 
Although the density for the β H-NOX and PAS domains is similar between the inactive 
and active states, the overall shape of the molecule is more linear (Figure 2.3B). Continuous, linear 
helices from α L406–L457 and β A333–Y386 are seen in the active state (Figure 2.3D, highlighted 
in purple). This conformation is more aligned with predicted CC length and is more similar to the 
previously published crystal structures in terms of the range of residues seen in an unbent coiled-
coil 29,34 
 
The CAT heterodimer in the active state still forms a wreath-like geometry, but with the 
two monomers moved apart from one another roughly perpendicular to the CC domain axis (Figure 
2.3E). An alignment of the α chain of an active adenylate cyclase structure (PDB ID: 1CJK, gray) 
with the α CAT domain of our active Ms sGC structure shows the Cα of β N538 is now greater 
than 4 Å from the bound nucleotide analog, providing sufficient space for the nucleotide to bind 
in the active site. The Ms sGC CAT domain thus adopts an open conformation with the apparent 
capacity to bind substrate. 
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Figure 2.3 – Active Ms sGC forms an elongated structure. A) Views of cryo-EM density for the active state, colored 
by subunit (α - orange, β - blue). Dimensions of the complex are shown in black. B) Molecular model of Ms sGC 
colored as in Figure 2.1A. The heme is colored gray. The α H-NOX domain is not shown due to lack of density. C) 
View of the β H-NOX domain with heme shown in gray and β H105 in red. Two fits for the stimulator, YC-1, are 
shown in purple D) Model of the extended coiled-coil region (purple), highlighting the PAS linker region (green) 
shown in shades for the α (dark) and β (light) dime. The sequences of the bent CC region are shown below. E) View 
of active catalytic dimer (α - orange, β - blue) shown fit into the reconstruction density. Close up shows aligned active 
adenylate cyclase structure (PDB: 1CJK) with bound nucleotide (gray). The distance between the substrate analogue 
and Cα of the β N538 is shown. 
 
 
Allosteric conformational rearrangement of sGC  
Binding of NO to β H-NOX initiates the signal transduction event, thus interfaces were 
examined between the inactive and active states. A significant rearrangement of the quaternary 
structure of Ms sGC occurs upon activation with the regulatory domain rotating 71° and the 
catalytic domain rotating 40° (Figure 2.4A). In both inactive and active states, the β H-NOX 
domain is the closest domain of the regulatory lobe to the CAT domains (Figure 2.4A); however, 
in neither model does the β H-NOX domain come into direct contact with the CAT domains. In 
the inactive state, the Cα of β I47 is 12 Å away from the Cα of β H399 (Figure 2.4A, gray), too far 
for direct contact. The closest Cα-Cα distance of residues between the β H-NOX domain and the 
CAT domains in the active state is between β M33 and α W468 at 21Å (Figure 2.4A, black), 
remaining too far for direct contact between the β H-NOX and the CAT dimer. Therefore, allosteric 
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communication is transmitted through changes in CC positioning, not through direct H-NOX:CAT 
interactions. 
 
Interaction surfaces, defined by a ≤ 10 Å Cα to Cα distance63, occur between the β H-NOX 
and the PAS or CC region in both inactive and active states (Figure 2.4B,4C). In the inactive state, 
the αE, αF, and β2 secondary structural elements of the β H-NOX (82-126, green) form an 
extensive interface with the β PAS (270-275, red) and the α PAS-CC linker (400-419, blue) regions 
(Figure 2.4B, Figure A.1E). Overall, these interfaces are maintained in the active state (Figure 
2.4C), in spite of the straightening by the CC domains. Activation of sGC induces the formation 
of an interface between β CC (355-367) and β H-NOX (33-41) (Figure 2.4C, purple). These 
residues on the β H-NOX comprise a loop located between helix αB and αC in the β H-NOX 
domain which was extended away from the CC in the inactive state. The large conformational 
change of the H-NOX/PAS bundle is necessary for the formation of the new interface in the active 
site, and thus this interaction could be critical for stabilizing the active sGC conformation. 
 
In the active structure the CCs undergo a significant conformational change and rotation 
relative to the CAT dimer (Figure 2.4D). The active state CC domains are completely extended 
(56 Å and 63 Å for α and β respectively in the inactive state, to 74 Å for both CC domains the 
active state), as the bend present in the inactive state moves away from the CAT domains to be in 
line with the C-terminal portion of both CC domains. The CC conformational change upon 
activation twists the CC interface such that the β CC helix rotates relative to the α CC by 72 degrees 
(Figure 2.4D). The dramatic rearrangements of the H-NOX/PAS bundle leads to unbending of the 
CC domains, a change in their orientations as they project from the regulatory lobe, and finally to 
opening of the nucleotide binding pocket (Figure 2.4E). Alignment to the α CAT domain shows a 
clear rotation of the β CAT domain away from α CAT domain by 40° (Figure 2.4E, left). This 
rotation entails the pinching together of the base of the CC domains (Figure 2.4E, middle). In 
combination, these motions open the GTP binding pocket by moving the β CAT active site helix 
(535-545) away from the α CAT domain and into an active conformation. 
 
SAXS shows a distribution of inactive and active states in solution 
Small angle X-ray scattering (SAXS) was used to interrogate conformational changes with 
and without NO in solution. Experiments with sGC stimulators were not included as the limited 
solubility of YC-1 is precludes the collection of scattering data. Size exclusion chromatography 
(SEC)-SAXS and SEC-multi angle light scattering (MALS) chromatograms show a symmetrical 
peak for both samples with little variation in radius of gyration (Rg) and estimated MW across the 
peaks, indicating sample homogeneity (Figure A.5A). 
 
The UV-visible absorption of the Soret band of the heme and of the protein itself were used 
to evaluate the ligation state of Ms sGC in the SAXS experiment. The ratios of Soret band to 
protein peak in the full UV-visible absorption spectra are 0.85, 0.35, and 0.20 in the unliganded, 
1-NO, and xsNO states, respectively (Figure 2.1B, Figure A.5A). The ratios of these two peaks in 
the SEC-SAXS experiments were 0.77 with NO and 0.32 without NO (Figure A.5A). The 432/280 
ratio in the SAXS sample without NO is less than in the full UV-Visible spectra, indicating that 
the sample had a slightly lower heme incorporation. The ratio for the SAXS sample with NO was 
lower than that expected for 1-NO, but much larger than predicted for the xsNO ratio, indicating 
that the SAXS samples were in the unliganded and 1-NO state during elution, respectively. 
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Figure 2.4 – Conformational rearrangements of Ms sGC upon activation. A) Overlay of the inactive (transparent, 
gray) and active (α - orange, β – blue) shown in two views. Rotation of the regulatory domain and CAT dimer are 
shown with arrows and label with degree of rotation. Distances between the β Η-ΝΟΧ domain and CAT dimer are 
labeled for inactive (gray) and active (black). B) Close up view of the inactive interfaces between the β HNOX (green), 
β PAS (red), and α CC (blue). C) Close up view of the active interfaces colored as in Figure 2.4B with the β H-NOX:β 
CC interface in purple. D) Overlay of the inactive (transparent) and active (colored) CC domains when aligned to the 
active α CC domain. Dimensions of the CC and rotation are labeled in color for the inactive and black for the active. 
E) Three views of aligned inactive (transparent) and active (colored) CAT dimers are shown. Direction of rotation 
(curved arrows) and pinching (arrows) are shown. 
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The Rg for the unliganded and 1-NO state were 43.1 ± 0.4 and 43.8 ± 0.2 Å, respectively, 
representing an elongation of the structure (Figure A.5A, Table A.2). Additionally, the Pair-
distance function (P(r)), which shows a composite of the inter-atomic distances, displays a distinct 
shift between the unliganded and 1-NO states in the region from ~70 to ~100 Å. This corresponds 
to an extension of the regulatory lobe from catalytic lobe (Figure 2.5A). Shifts in the secondary 
peaks of the Kratky plots (Figure A.5B) further suggest separation of the regulatory and catalytic 
lobes upon activation. 
 
 
Figure 2.5 – SAXS analysis of the activation of sGC. A) Normalized P(r) for the unliganded (black) and 1-NO 
(gray) states of sGC are shown together with corresponding models of the inactive and partially extended 
conformations of sGC (N-terminal and C-terminal tails are omitted for clarity). The area of each P(r) is normalized 
relative to the SAXS-determined molecular weights (Table A.2). B) Experimental (black and gray) and theoretical 
(blue and red) SAXS profiles for the solution state models in the panel a. SAXS fits are shown together with the fit 
residuals in the below graph. 
 
Using the inactive model obtained from cryo-EM as an initial Cα model, a rigid-body 
modeling pipeline was developed to systematically explore conformational space (see Materials 
and Methods).58 A minimal ensemble search was performed over thousands of sGC conformations 
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and corresponding scattering curves were calculated and compared to the experimental data. The 
result of this minimal ensemble search confirmed the presence of a single sGC conformation while 
in an inactive state (Figure 2.5B, Figure A.5C), which overlays with the inactive structure with an 
RMSD of 2.0 Å. The 1-NO state was best modeled as an ensemble of two states, with the majority 
(72%) of the sample consistent with the inactive model (Figure 2.5B). However, the remainder of 
the sample (28%) is consistent with a more elongated conformation, one that is in between the 
inactive and active state obtained by cryo-EM. The Cα RMSD of the partially active SAXS model 
and the active state cryo-EM model is 13.5 Å. This analysis shows that sGC adopts a mixture of 
inactive and active conformations in the 1-NO state, suggesting that NO binding at the heme 
establishes an equilibrium between these two conformational extremes (Figure A.5C). 
 
 
Discussion 
The structures of the inactive and active states of full-length sGC provide detailed insight into the 
molecular mechanism of activation of Ms sGC. The most unexpected feature of the inactive state 
of the enzyme are the bends in the CC domains. Straightening of the bent CCs is the clearest 
structural link between the regulatory and catalytic lobes during activation. Previous HDX-MS 
data showed a differential exchange pattern for the CC domains, where the N-terminal portion of 
the α CC and the C-terminal portion of the β CC increase in H/D exchange upon NO binding, 
while the C-terminal portion of the α CC and the N-terminal portion of the β CC decrease in H/D 
exchange (Figure A.4G)36. The changes seen in HDX in the CCs near the bend are thus consistent 
with the large-scale rearrangements of the CCs that we have now observed in the cryo-EM. 
Furthermore, the bent portion of the CC domain is highly conserved among sGC homologues, 
consistent with its centrality to allosteric communication. 
 
The C-terminal portions of the CC domains undergo a 72° twist and contain a motif known 
as the signaling helix (or S-helix)64. Similar to sGC, proteins with this motif contain both receptor 
and output domains that are connected by dimeric coiled-coils. The inactive and active sGC 
structures are the first full-length enzyme with a S-helix motif to be characterized. This motif 
aligns with C-terminal part of the CC domain, part of the 72° twist described above (Figure A.3J). 
It is possible that the twisting motion of these domains is a more general mechanism of activation 
for proteins with S-helices. 
 
In transitioning between the inactive and active states, the H-NOX/PAS bundle rotates 71° 
in order for β H-NOX residues 33-41 to form an interface with residues β 355-367 of the β CC 
domain (Figure 2.4C, purple). The αH helix of the β H-NOX domain contains the proximal 
histidine that binds to the heme cofactor.18 Crystal structures of bacterial H-NOX domains with 
and without NO show a rotation in the αF helix of the β H-NOX. However, in our full-length 
structures, the αF of the β H-NOX retains its interface with the β PAS and the α CC domain in 
both states (Figure 2.4B,4C). More strikingly, binding of YC-1 at a site bridging the β H-NOX and 
CC domain highlights how stabilization of this contact drives CC unbending (Figure 2.3C). This 
interface corroborates specific point mutations known to decrease activity of the full-length 
protein; specifically, single point mutants of β I41E in the β H-NOX domain retain basal activity 
but are only minimally activate with excess NO, implying that these sGC variants are catalytically 
competent but not as sensitive to stimulation as the wildtype enzyme.39,65 The structural finding 
that residue Ile41 of the β H-NOX form contacts with the unbent β CC that are specific for the 
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active conformation explains these phenotypes. Destabilizing these contacts by mutating Ile41 thus 
blocks this interface and prevents sGC from reaching the active conformation. While this paper 
was under review, a cryo-EM map of activated H. sapiens sGC was reported, where the activation 
was achieved by using xsNO.66 This xsNO map and the xsNO + YC-1 map reported here overlay 
well, except for the proposed density for YC-1. This lends support to our assignment of the YC-1 
binding site at the β H-NOX- β CC interface. These insights suggest that the β H-NOX- β CC 
contact may be the most critical allosteric switch in the regulatory lobe of sGC. 
 
While conformational changes are readily observed by comparing the two cryo-EM 
structures, the SAXS implies that the 1-NO state can sample similar conformations (Figure 2.5A). 
Although only a fraction of the population exhibits an extension, inspection of the Soret to protein 
UV-visible absorption indicates that the protein is in the 1-NO state. These data support the 
hypothesis that when the first NO binds to the heme of the β H-NOX, sGC adopts an equilibrium 
between the inactive and a partially extended conformation, with a Keq = [active]/[inactive] = 
[0.72]/[0.28] = 0.39. This is corroborated by the activity data from the 1-NO state, which exhibits 
15% of the maximal activity. The conformational heterogeneity observed in SAXS analysis could 
represent the physiological state of sGC at basal cellular conditions. 
 
In the absence of increased NO concentrations, sGC stimulators can maximally activate 
cGMP production and are now used to treat forms of pulmonary hypertension.67,68 YC-1 was 
present in the sample used to generate the active state reconstruction of Ms sGC, and extra density 
is seen near the new β H-NOX : β CC interface (Figure 2.3C). Distinct changes in both resonance 
Raman and electron paramagnetic resonance spectroscopy signatures for heme ligands have been 
detected with both YC-1 and BAY 41-2272 supporting this proposed binding site.69 Previously, a 
stimulator binding site was proposed between helices αA and αD in the β H-NOX domain based 
on cross linking and NMR data.70 However, there is no density for YC-1 present in the active state 
reconstruction between αA and αD helices. We note that our study used YC-1 compared to IWP-
854, IWP-051 and BAY 41-2272 previously used, which could explain the difference in binding 
sites. Visualization of YC-1 bound to sGC is an important development as a proof of concept that 
small molecule sGC stimulators can now be characterized structurally. 
 
Adenylyl cyclases (AC) catalyze a similar reaction mechanism as sGC. Mammalian 
membrane-associated ACs contain two catalytic domains which form the intrapolypeptide 
equivalent of a heterodimer. The catalytic domains in active mammalian AC heterodimer rotate 
by 7° with respect to an inactive homodimeric counterpart bound to two molecules of 
forskolin62,71,72. We observe a rotation of the sGC CAT domains about the same axis, although the 
magnitude is larger for sGC, at 40°. A full-length membrane bound AC (AC-9) was recently solved 
in the active nucleotide bound state.34 The CC domains between the full-length active sGC and 
AC9 structures overlay well, consistent with a common active geometry for GCs and ACs. The 
AC9 has a very different angle between the CC and CAT domains. The rotation of the sGC 
regulatory lobe is sterically incompatible with the presence of a membrane, thus by their different 
natures as soluble and membrane-associated enzymes, sGC and ACs must differ in the detailed 
modes of allosteric communication. 
 
To date a detailed understanding of sGC activation has been hampered by the lack of full-
length structures. The inactive and active structures in tandem with established studies lead to 
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formation of new hypotheses for the activation of sGC. First, activity assays with sGC truncations 
suggested that direct interaction of the β H-NOX domain and the CAT dimer was responsible for 
sGC inhibition.37 However, the structural data shows no direct interaction between the β H-NOX 
and the CAT domain in either conformation. Instead, the formation of the new β H-NOX/β CC 
interface in the active state stimulates the active CAT conformation. Activation leads to a global 
conformational rearrangement of the heterodimer, elongating the structure; however, only a single 
equivalent of NO is required to cleave the bond between the heme Fe center and the ligating 
histidine residue. Maximal activation of sGC involves either the binding of a second NO molecule 
to a non-heme site on sGC or a small molecule stimulator stabilizing the active state.73,74 
 
Figure 2.6 depicts the proposed physiological activation sequence of sGC, where 
unliganded sGC adopts a more compact conformation with bent CC domains. Upon NO binding 
to the heme, an equilibrium of conformational states is established, with the partially elongated 
state affording about 15% of the maximal activity. Given the very tight association between NO 
and the heme, this represents the basal cellular activity. Finally, in the presence of either an 
increase in NO concentration or sGC stimulating molecules, the completely extended, fully active 
state is reached and sGC reaches maximal catalytic activity. Using these structures as a starting 
point, new avenues of exploration can now be undertaken, to elucidate the molecular mechanisms 
of excess NO activation. Critical residues for interdomain interactions along with the proposed 
stimulator binding site can be characterized in more detail. Having resolved the two structural 
states of an important therapeutic target, the structures of sGC will influence rational design of 
improved drugs for diseases associated with NO signaling impairment. 
 
Figure 2.6 – Model for conformational rearrangement upon sGC activation. Schematic of the sGC activation pathway. 
sGC adopts a bent CC conformation after formation of the holoenzyme. Upon the addition of NO an equilibrium exists 
between the inactive and partially extended states, conferring partial activation of sGC. When excess NO enters the 
cell or the addition of a stimulator compound, the equilibrium shifts to the active state, allowing for an open CAT 
dimer conformation and maximal activity. 
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CHAPTER 3 
 
 
USING BIOCONJUGATIONAL CHEMISTRY TO CHARACTERIZE THE THREE-
STEP ACTIVATION PATHWAY OF SOLUBLE GUANYLATE CYCLASE 
 
 
Summary 
 
The mammalian nitric oxide (NO) receptor, soluble guanylate cyclase (sGC) displays a unique 
activation profile in response to NO . Sub-stoichiometric amounts of NO relative to sGC result in 
a linear activation profile up to approximately 15% of maximal activity that is reached at one 
equivalent NO relative to sGC. The addition of excess NO increases the catalytic activity to 100% 
and removal of the excess NO returns the activity to 15% of maximal observed at one equivalent 
of NO. This biochemical behavior indicates that there are two distinct binding modes for NO on 
sGC: one to the heme cofactor and a second hypothesized to involve a specific cysteine residue. 
This chapter explores in detail the effect of addition of small bioconjugational agents on sGC 
activation. Methane methylthiosulfonate (MMTS) and N-ethyl maleimide (NEM), two cysteine 
reactive molecules, prevent excess NO from activating sGC from the 1-NO state to the maximally 
active state, while different lysine-labeling chemicals do not. However, the differential reactivity 
of these and other cysteine-reactive reagents influence the final activation profile of sGC. 
Structural work from Chapter 2 will be incorporated into the data here and future work will be 
proposed to more conclusively understand the effect of these bioconjugational agents on the 
activation of sGC and to further delineate the three-step activation process. 
 
Research from parts of this chapter were performed by Carl C. Ward, Miriam Hood, Kimberly A. 
Houghton, and are thus indicated. This work is currently unpublished. 
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Introduction 
 
Nitric oxide (NO) is a critical primary signaling molecule in cardiovascular and neuronal 
signaling.1 The mammalian NO receptor, soluble guanylate cyclase (sGC), activates upon binding 
of NO to cyclize 5′-guanosine triphosphate (GTP) to 3′,5′-cyclic guanosine monophosphate 
(cGMP).2–4 sGC can transduce the NO signal into cGMP when NO is in the picomolar to 
nanomolar concentration range, however the specific details of the activation of sGC by NO 
involve unique characteristics.5 
 
 sGC first binds NO through a heme B cofactor in the β H-NOX domain with a Kd < 1.2 × 
10–12 M.6 This interaction is specific for NO and essentially irreversible in a physiological setting; 
while carbon monoxide (CO) does bind relatively weakly to sGC, cellular CO concentrations are 
not high enough to maintain this interaction.7 Biochemical quantification of sGC with only one 
equivalent of NO bound to sGC yield an enzyme that has only reached 15% of its maximal 
activity.8,9 Full activity can be reached with the addition of excess NO and removal of this excess 
NO, either through a buffer exchange or a NO-specific trap returns the enzyme back to the 15% 
activity state.9 NO remains bound to the heme after the removal of the excess NO. Previous work 
has studied the effect of different ligands bound to the heme of sGC in the absence and presence 
of excess NO. Derbyshire et al found that even with a non-native ligand bound to the heme (butyl 
isocyanate), excess NO still increases the activity of sGC.10 These observations, both in vitro and 
in cells, have led to the hypothesis of a second NO binding site and the development of the three-
state model for sGC activation: newly-translated sGC without any NO has low activity, sGC with 
NO only bound to the heme is only 15% active, while sGC with high nanomolar concentrations of 
NO has 100% activity.11,12  
 
 Discussion in Chapter 1 outlined previous work in the lab (Fernhoff et al.) that presented a 
hypothesis for the second site of NO on sGC and forms the basis for the experiments performed in 
this chapter.13 The authors found that they could block the activation effect of excess NO on sGC 
by the treatment of sGC with S-methyl methanethiosulfonate (MMTS). Treatment of a MMTS-
sGC sample with excess thiol (DTT) partially returned the activation by excess NO. This effect is 
independent of the presence or absence of oxygen, indicating that there was no redox process 
occurring. Fernhoff and colleagues concluded that the NO second site is a cysteine(s) on sGC, and 
that a direct attack of the thiolate onto NO to form a transient but stabilized radical anion was the 
basis for the second site interaction between NO and sGC. However, Chapter 2 demonstrated that 
sGC undergoes a large conformational change upon activation by excess NO. If MMTS 
modification of a cysteine residue is somehow preventing that conformational change from 
occurring, the same activation profile could exist. These hypotheses are not mutually exclusive; it 
is possible that MMTS is capping the second site cysteine at the same time it is preventing a large-
scale conformational change. 
 
 Work in this chapter broadens the range of techniques as well as expands the experimental 
conditions used to probe this behavior of sGC. Homologues of sGC from lower organisms have 
been shown to possess the same three-step activation profile that mammalian sGC has.14 Potential 
second site cysteines were narrowed by aligning Manduca sexta and Rattus norvegicus sGC and 
focusing only on conserved cysteines. Multiple types of protein mass spectrometry were brought 
to bear on this phenomenon, including a modification of activity-based protein profiling. Finally, 
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a screen of different bioconjugation agents solidified the role of cysteines as being important for 
activation for sGC. The work presented here, in combination with the work of Chapter 2, leads 
into substantial future directions that will continue to unravel the activation mechanisms of sGC. 
 
Materials and Methods 
 
Materials 
All chemicals were purchased from commercial vendors and used without further purification, 
unless otherwise noted. Primers were obtained from Integrated DNA Technologies (Coralville, 
IA). PrimeSTAR Max DNA polymerase and TALON superflow resin was purchased from Takara 
Bio USA (Mountain View, CA). DNA purification kits were purchased from Qiagen 
(Germantown, MD). ExCell-420 media, sodium dithionite (Na2S2O4), DNAse I from bovine 
pancreas, β-mercaptoethanol, sodium phosphate, dibasic (Na2HPO4), sodium carbonate (Na2CO3), 
potassium phosphate (K2HPO4), guanosine 5′-triphosphate sodium salt (GTP) (>95%, HPLC), 
zinc acetate (Zn(CH3CO2)2), methyl methanethiosulfonate (MMTS, 97%), Iodoacetic Acid (IAC), 
Iodoacetamide (IAM), and N-ethyl maleimide (NEM) were purchased from Millipore Sigma 
(Burlington, MA). 4-(2-aminoethyl)benzenesulfonyl fluoride hydrochloride (AEBSF) was 
purchased from Research Products International (Mount Prospect, IL). Isopropyl β-D-1-
thiogalactopyranoside (IPTG), 4-(2-hydroxyethyl)piperazine-1-ethanesulfonic acid (HEPES), 
Slida-A-Lyzer mini dialysis devices (10,000 MWCO), and Sulfo N-hydroxysuccinimide acetate 
(s-NHS-Ac) were purchased from Thermo Fisher Scientific (Waltham, MA). Benzamidine, 
sodium chloride (NaCl), magnesium chloride (MgCl2), and glycerol were purchased from VWR 
Life Science (Visalia, CA). Dithiothreitol (DTT) was purchased from Bachem (Bubendorf, 
Switzerland). Imidazole was purchased from Oakwood Chemical (West Columbia, SC). Vivaspin 
spin concentrators were purchased from Sartorius (Concord, CA). BioSpin 6 desalting columns 
were purchased from BioRad (Hercules, CA). Diethylamine NONOate (DEA NONOate), PROLI 
NONOate, S-nitrosoglutathione (GSNO), and YC-1 were purchased from Cayman Chemical 
Company (Ann Arbor, MI). Carbon monoxide (CO, >99%) gas was purchased from Praxair Inc. 
(Danbury, CT). Isatoic anhydride (IsaAnh) was a generous gift from Matthew Francis’s lab. 
 
Construction of Plasmids 
Rattus norvegicus (Rn) sGC α1 (Uniprot: P19686) and β1(Uniprot: P20595) genes were cloned 
into pFastBac to generate pFasBac_Rn_α1_His6  and pFastBac_Rn_β1 previously.15 Manduca 
sexta (Ms) sGC α1 (Uniprot: O77105) and β1(Uniprot: O77106) genes were cloned into pFastBac 
to generate pFastBac_Ms_sGC_α1_His6 and pFastBac_Ms_sGC_β1 (Chapter 2). For mutants of 
Rn sGC, two- or three-piece Gibson Assembly fragments were amplified from 
pFasBac_Rn_α1_His6  or pFastBac_Rn_β1, and then ligated together with Gibson Assembly. The 
genes were transposed into a baculovirus bacmid using DH10Bac-GFP cells. The bacmid was 
isolated, validated for gene transposition by amplification and sequencing (UC Berkeley DNA 
Sequencing Facility), and then transfected into SF9 cells (Gibco) to generate recombinant 
baculovirus for both genes.  
 
Protein Expression and Purification 
The following steps were used to express and purify both Rn and Ms sGC. SF9 cells were 
maintained in monolayer and in suspension in ExCell-420 media at 27 °C (cells were shaken at 
135 rpm). The recombinant baculovirus was amplified until the titer was greater than 1 × 108 
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cfu/mL. Five liters of SF9 cells were coinfected with 50 mL of amplified virus per liter and allowed 
to express for 72 hours. Cells were spun down at 4300 g for 20 minutes, snap frozen in liquid 
nitrogen, and stored at –80 °C. 
 
Two different purification procedures were followed, one for enriched lysate assays and one for 
sGC purified to homogeneity: 
 
The following steps to enrich sGC lysate were performed at 4 °C. Cell pellets from a 50 mL SF9 
cell expression were thawed in ice water and resuspended in 1 mL of lysis buffer: Buffer A (50 
mM Na2HPO4, pH 8.0, 200 mM NaCl, 1 mM imidazole, 1 mM benzamidine, 5% (v/v) glycerol, 
0.22 μm filtered) supplemented with 10 mM benzamidine, 1 mM AEBSF, 0.5 mg/mL bovine 
DNAse I, and 5 mM β-mercaptoethanol. Cells were lysed by sonication with a microtip adapter at 
power level 1.5 for the following program: 15 seconds on followed by 15 seconds off for a total 
process time of 30 seconds. Cell debris was spun down in a 2 mL microcentrifuge tube for 1 hr, 
21,130 g. To the clarified lysate, 50 µL of TALON superflow beads pre-equilibrated with Buffer 
A supplemented with 5 mM β-mercaptoethanol were added. The beads and clarified lysate mixture 
was allowed to rock for 30 min. The beads were pelleted with a gentle spin in the microcentrifuge, 
1 minute, 1,000 g, and the supernatant was saved. The beads were washed twice with 500 μL of 
Buffer A supplemented with 5 mM β-mercaptoethanol. sGC was eluted off the beads with 100 μL 
Buffer B (50 mM Na2HPO4, pH 8.0, 200 mM NaCl, 150 mM imidazole, 1 mM benzamidine, 5% 
(v/v) glycerol, 0.22 μm filtered) supplemented with 5 mM β- mercaptoethanol. Enriched lysate 
was snap frozen in liquid nitrogen and stored at –80 °C. 
 
The following steps to purify sGC to homogeneity were performed at 4 °C. Cell pellets from a 5 
L SF9 cell expression were thawed in ice water and resuspended in lysis buffer. Cells were lysed 
in a bead beater (BioSpec) with 0.5 mm glass beads. The resulting cell lysate was clarified by 
spinning at 4,300 g for 5 minutes, followed by spinning at 158,000 g (42,000 RPM) for 2 hours 
(Ti45 rotor, Beckman Coulter). The lysate was passed through a column containing 2 mL TALON 
superflow at 0.5 mL/min, and the flow-through was collected. The column was washed with 15 
column volumes of Buffer A supplemented with 5 mM β-mercaptoethanol at 0.5 mL/min. The 
protein was eluted with 10 CV of Buffer B. Fractions with yellow color were concentrated to < 2 
mL using a 30,000 MWCO cutoff spin concentrator, supplemented with 5 mM DTT and 5 mM 
EDTA, and stored overnight. The next day, the sample was diluted to 9 mL with Buffer C (25 mM 
triethanolamine, 25 mM NaCl, 5 mM DTT, 5% (v/v) glycerol, 0.22 µm filtered), and applied to a 
POROS HQ2 anion exchange column (Thermo Fisher Scientific). The column was washed with 3 
CV of Buffer C, and then a gradient to 50% Buffer D (25 mM triethanolamine, 750 mM NaCl, 5 
mM DTT, 5% (v/v) glycerol, 0.22 µm filtered) was established over 17 CV at 0.5 mL/min. 
Fractions with purified sGC were concentrated to 5–50 µM and stored in liquid nitrogen. A typical 
yield for this expression and purification procedure is 100-150 µg sGC per liter of insect cells. 
 
Sample Preparation and Labeling for Mass Spectrometry and Activity Assays 
Sample preparation was similar for both mass spectrometry and activity assays (differences noted 
in later sections). Samples were reduced in an anaerobic glove bag with 5 mM Na2S2O4 for 15 
minutes, and then desalted with a BioSpin6 column equilibrated with either Buffer E (50 mM 
HEPES, pH 7.5, 150 mM NaCl, 5% (v/v) glycerol, 0.22 µm filtered) for labeling, activity assays, 
and intact protein mass spectrometry, or Buffer F (50 mM Na2HPO4, pH 8.0, 200 mM NaCl, 5% 
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(v/v) glycerol, 0.22 µm filtered) for ABPP experiments. For samples that were to be labeled with 
cysteine alkylating agents, excess DTT was removed from the sample in a variety of ways: five 
dilutions with Buffer E and concentrations with a Vivaspin 500 (30,000 MWCO) spin filter, or 
two 30-minute rounds of dialysis of the reduced sGC against Buffer E with a sample to dialysate 
ratio of 1:10,00. It has been found that the dialysis method retained the highest amount of sGC. 
sGC with 1-NO and xsNO were prepared by first adding PROLI NONOate to 50 µM, based on 2 
moles of NO released per mole of PROLI NONOate. This sample was then buffer exchanged into 
Buffer E through a BioSpin6 column to generate the 1-NO state. To generate the xsNO state, 
PROLI NONOate was added back to a portion of the 1-NO sample and allowed to equilibrate for 
5 minutes. The protein concentration was determined using the reduced heme Soret peak at 433 
nm (148,000 M–1 cm–1).14 YC-1 was added from a 100x stock solution in DMSO to a final 
concentration of 150 µM (final DMSO concentration 1%). When called for, MMTS, IAC, IAM, 
s-NHS-Ac, and IsaAnh were diluted from 100x stocks into reduced sGC samples for final 
concentrations between 10 and 200 µM, depending on the specific experiment. Samples were 
allowed to label for 30 minutes to 1 hour. 
 
Activity Assays and Quantification 
Maximum activity for Rn and Ms sGC were measured by quantifying the amount of cGMP 
produced in duplicate endpoint activity assays. Activity assays were conducted at 25 °C and pH 
7.5 in Buffer E, supplemented with 5 mM DTT and 5 mM MgCl2 for experiments without labeling 
agents and only 5 mM MgCl2 for experiments with labeling agents. Reactions were initiated with 
1.5 mM GTP and timepoints were removed from the reaction mixture and quenched with 125 mM 
Zn(CH3CO2)2, followed by 125 mM Na2(CO3) to adjust the pH to 7. Samples were frozen at –80 
°C until quantification. Quenched assays were thawed, and the zinc precipitate was spun down for 
10 min at 23,150 g. The reactions were diluted by one to three orders of magnitude, and the cGMP 
was quantified in duplicate using an extracellular cGMP Enzyme Linked Immunosorbent Assay, 
following the manufacturer’s instructions (Enzo Life Sciences). Concentrations of cGMP were 
determined from a standard curve, generated over 0.16–500 pmol/mL. Initial rates were calculated 
from the linear phase of the time course, where 5–10% of the GTP substrate was consumed. 
 
Intact Protein Mass Spectrometry 
Purified proteins were treated as outlined in the above Sample Preparation section. Prior to intact 
protein mass spectrometry, samples were buffer-exchanged into 25 mM HEPES, pH 7.5, 25 mM 
NaCl using three rounds of dilution and concentrations in a Vivaspin 500 (30,000 MWCO) spin 
concentrator. Samples were filtered with a 0.22 μM spin filter (Millipore). The final sample 
concentration was approximately 1 µM. Samples of 2 µL were injected onto and separated over a 
ProSwift column (ThermoFisher Scientific) with an Agilent 1200 series high pressure liquid 
chromatography (HPLC) system, and subsequently analyzed by an Agilent 6224 time-of-flight 
(TOF) mass spectrometer with a Turbospray ion source in positive ion mode. 
 
Sample Preparation for Activity Based Protein Profiling Workflow 
Purified proteins were treated as outlined in the above Sample Preparation section, and diluted into 
Buffer F. Protein was concentrated to a final concentration of 2 µM and then samples were 
transferred to C. Ward for further preparation similar to previously published protocols.16 Briefly, 
samples were incubated with 100 µM of alkylating agent at room temperature for one hour. 
Samples were then acetone precipitated, resuspended in methanol, and combined according to 
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experimental design. Samples were digested with trypsin overnight at 4 °C and further prepared 
for mass spectral analysis. 
 
 
Results and Discussion 
 
Given the hypothesis of cysteine involvement in second NO binding site of sGC and the 
challenge of screening large numbers of sGC variants, sequence alignments and mass spectrometry 
were employed in attempts to narrow down the potential critical cysteine residue regulating the 
activity between the 1-NO and excess NO state. Attempts made to express Ms sGC in E. coli as 
has been reported previously were unsuccessful, and thus these alternate approaches were 
explored.14 
 
Narrowing the Cysteine List via Sequence Alignments 
In the first approach, sequence alignments were used to examine the number of conserved 
cysteines between three sGC homologues known to possess a three-state activation profile. Results 
presented in Chapter 2 illustrated that Ms sGC (in addition to Hs and Rn sGC) possess three 
different states of activity (U, 1-NO, and xsNO) and retains the ability for YC-1 to activate the 1- 
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Figure 3.1 – Multiple sequence alignments of Hs and Ms sGC. The α1 and β1 genes are aligned separately. All 
cysteines of Hs sGC are boxed by black rectangles. Only 16 of these residues are conserved between Hs and Ms sGC 
sequences. 
 
 
NO state to maximal activity. As Hs and Rn sGC 89.4% and 98.9% identical for the α1 and β1 
sequences respectively, only the Hs sGC sequence will be used for comparison with Ms sGC (the 
same cysteines are conserved when Rn sGC is used for alignments). Figure 3.1 depicts the multiple 
sequence alignment between the sequences of Hs and Ms sGC α1 and β1 sequences. Black boxes 
indicate sites where Hs sGC contains a cysteine residue. Of the 37 cysteine residues present in the 
Hs sGC sequence, only 16 of those residues are conserved between Hs and Ms sGC, indicating the 
importance cysteine residues at those positions. 
 
 It was further reasoned that a second site cysteine would be involved either stabilizing or 
interrupting a conformational change of sGC between the U, 1-NO, and excess NO states. Thus, 
this list of 16 cysteine residues was further narrowed to include cysteines whose peptides showed 
increases or decreases in exchange rates based on Hydrogen Deuterium Exchange Mass 
Spectrometry (HDX-MS).17 Figure 3.2A shows the Ms sGC heterodimer showing those 16 
conserved cysteines in purple with ribbons colored according to the differences in deuterium 
exchange rates as measured by HDX-MS between the excess NO state and the unliganded state, 
with larger exchange rates in the excess NO state colored more red. Cysteines αC532 and βC248 
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were selected based on their location adjacent to or within peptides on sGC that had decreased 
exchange when comparing the unliganded and excess NO state. These residues were mutated 
conservatively to serine, expressed in SF9 cells, and purified to homogeneity. 
By mutating the proposed second site cysteine to a serine residue, the interaction between 
NO and the critical cysteine would not be able to form and stabilize the active state, thus rendering 
the protein insensitive to excess NO. Additionally, treatment of sGC with MMTS should not have 
any effect on activity because the key cysteine has been removed. Figure 3.2B shows the activation 
profile for WT, αC532, and βC248 variants of Rn sGC under eight different conditions. All three 
proteins retain the ability to be activated by xsNO and stimulated by YC-1 in the 1-NO state. 
Additionally, none of the variants were stimulated under any conditions with MMTS present. 
These assays indicate that neither αC532 nor βC248 are solely responsible for the second NO 
binding site and other cysteines present in sGC are being modified by MMTS to prevent the 
stimulation by excess NO. 
Figure 3.2 – HDX-MS targeted selection of conserved cysteines A) HDX-MS data overlaid on the inactive structure 
of Ms sGC (HDX-MS from ref 17, Ms sGC structure from Chapter 2). Cysteines are colored purple. B) End point 
activity assays of Rn sGC and indicated variants with different small molecule stimulators and inhibitors. Contrary to 
previously published data, YC-1 did not rescue Rn sGC.13 
64 
 
To screen a larger set of these cysteine residues that were conserved between Hs and Ms 
sGC, 14 of the remaining 16 cysteine residues were mutated to serines and the lysate of SF9 cells 
was enriched to screen for inhibition of activation. The two cysteines that were not screened were 
αC3 (because the N-terminus of alpha is known to be processed in some homologues and is thus 
not conserved in all mature proteins) and β541C (as this cysteine helps guanylate cyclases 
discriminate between GTP and ATP as substrates). As a result of performing the assays in enriched 
lysate, the 1-NO state could not be interrogated in this set of experiments. Instead, excess NO with 
MMTS, excess NO, and excess NO with YC-1 were examined. Wildtype sGC is predicted to have 
low activity with excess NO and MMTS, high activity with excess NO, and high activity with 
excess NO with YC-1. The activation profile of a variant with a second site cysteine mutated to a 
serine should only vary in the excess NO condition, where it would now be predicted to be low 
activity. As seen in Figure 3.3A, the enriched lysate assay has a much lower dynamic range than 
protein purified to homogeneity, however the wildtype enzyme does show activation by excess 
NO and excess NO with YC-1 over excess NO with MMTS. A few variants screened show 
decreased activation with excess NO, namely αC653S and βC78S. The βC78S had been purified 
previously and shows decreased heme incorporation.18 Thus, the αC653S variant was expressed 
and purified to homogeneity. Figure 3.3B displays the activation profile of WT and αC653S Rn 
sGC, which both clearly show sensitivity to excess NO. That excess NO activates αC653S Rn sGC 
shows that, similar to αC532 and βC248 selected form HDXMS analysis, αC653 by itself does not 
constitute the second NO binding site. 
 
Increasing the number of sequences under examination can illuminate trends overlooked 
by comparing only two sequences. A BLAST search of the Rn β H-NOX domain (residues 1-191) 
returns 2,186 sGC sequences that are represented in Figure 3.4A as a sequence similarity network 
(made with the Enzyme Function Initiative’s EFI-EST tool).19 SSNs can be thought of as visual 
representations of a phylogenetic trees. The user selects an alignment score that is equivalent to a 
BLAST expectation value to set a threshold value for how similar two sequences (nodes) must be 
for an edge to be drawn between them. The alignment score can be manually increased until 
proteins with similar functions are contained within the same clusters. Here, an alignment score of 
130 efficiently separates mammalian and insect α subunits and β subunits from O2-sensitive sGCs 
and other sGCs from algae and choanoflagellates. Extraction of the sequences within the clusters 
that contain Rn, Hs, and Ms sGC α1 (orange) and β1 (blue) sequence yield a larger set of proteins 
that are predicted to share the same function. Sixty α1 and 215 β1 sequences were extracted and 
aligned separately with Clustal Omega. A portion of the β1 alignments are displayed in Figure 
3.4B as a WebLogo, in which the height of the amino acid letters indicates the fraction of 
sequences in the alignment that have that residue in that position.20 Cysteines boxed in red are 
conserved in Hs, Rn, and Ms, however they are not strictly conserved with greater than 5% of the 
expanded sequence alignment. In total, five cysteines are not strictly conserved in this analysis, 
bringing the final count of strictly conserved cysteines down to 11: αC191, αC282, αC493, αC516, 
αC532, αC594, βC78, βC122, βC323, βC434, and βC541 (active site GTP-selective residue). If 
the second NO binding site is a cysteine residue, it is likely to be contained within this set of 
cysteines. 
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Figure 3.3 – Full screen of targeted cysteines using a lysate assay. A) An enriched lysate screen of Rn sGC WT and 
selected variants. Each variant was treated with excess NO and then split into three fractions: MMTS to simulate 1-
NO activity, nothing further to simulate excess NO, and YC-1 to simulate full activity. B) The most promising mutant 
that was not known to interrupt protein function was selected to characterize in more detail. Rn αC635S has a similar 
activation profile to Rn sGC WT. 
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Figure 3.4 – Expansion of sequences considered using bioinformatics. A) Sequence Similarity Network generated 
from a BLAST of the Rn sGC β H-NOX domain with an alignment score of 130. Sequences were only included in the 
SSN if they were between 500 and 900 amino acids in length. The α-like sequences are colored in orange and the β-
like sequences are colored in blue (boxed). O2 sensitive sGCs, choanoflagellate sGCs, and algae sGCs are indicated 
(see Chapter 4 and 5). The blue cluster that extend off of the boxed β cluster are atypical sGCs and were not included 
in the subsequent analysis. B) WebLogo generated based on the sequences extracted from the β-like sequences. Red 
boxes indicated the cysteine is conserved in both Rn and Ms sGC, black boxes indicated the cysteine is present only 
in Hs sGC. βC214 and βC248 are conserved between Hs sGC and Ms sGC, however within the 215 sequences 
extracted from the SSN these cysteines are not strictly conserved. 
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Narrowing the Cysteine List via Proteomics 
The second approach that was used in attempts to narrow down the location of the second 
site cysteine was a modified Activity Based Protein Profiling (ABPP) approach. Briefly, ABPP 
relies on the differential reactivity of amino acids in order to extract peptides that contain hyper-
reactive residues. For example, this approach has worked well to identify reactive cysteines in 
cysteine proteases within a proteome. This is because as the ratio of two different probes is varied, 
the hyper-reactive cysteines in the active site of cysteine proteases are insensitive to probe 
concentration, whereas non-reactive cysteines are probe concentration dependent. This work was 
done in collaboration with C. Ward from the Nomura Lab at UC Berkeley. Figure 3.5A shows a 
schematic of one potential design of the experiment as it relates to sGC. We hypothesized that the 
second site cysteine would have to be quite reactive to sense NO at such low concentrations and 
form the radical anion NO adduct. By varying the ratio of deuterated to non-deuterated NEM, the 
most reactive cysteines could be extracted. Figure 3.5B depicts the area ratios from different 
peptides. We would expect the most reactive cysteines to be clustered together with a low log ratio, 
however the data was not clear in this regard. Unexpectantly, cysteine reactivity was variable 
across different runs. Because of this and technical difficulties surrounding amount of protein to 
generate a good signal, this experimental approach was not pursued further. 
 
An alternate hypothesis that was also explored using the same sequencing mass 
spectrometry techniques is that once the second site cysteine interacts with NO it would not interact 
with alkylating agents, in other words using NO as a blocking agent. In this experimental set up, 
the prediction is that there would be one cysteine where the ratio of labeling in the U state would 
be much higher than labeling in the excess NO state. Two different probes, N-(5-hexyn-1-
yl)acetamide (IAyne) and 1-(5-Hexyn-1-yl)-1H-pyrrole-2,5-dione (Maleimide-yne) were used to 
explore slightly different reactivities and steric effects. The data from this set of experiments is 
shown in Figure 3.5C and does not indicate a single cysteine that has a higher area ratio in the 
unliganded state than the excess NO state. In contrast, the data show that all cysteines sequenced 
are labeled more in the excess NO state. This result makes sense in light of the data presented in 
Chapter 2, where excess NO gives rise to a large conformational change of sGC to potentially 
expose more cysteines to alkylating agents. However, these data do not help to prioritize a specific 
set of cysteines that potentially comprise the second NO binding site. 
 
Activity Assays with Bioconjugational Agents and YC-1 
At this point, alternate hypotheses were explored for the observation of MMTS-induced 
inhibition of the excess NO state of sGC. It was hypothesized that if excess NO and YC-1 were 
indeed stimulating sGC through different mechanisms, then sGC treated with excess NO, MMTS, 
and YC-1 would show an increase in activity, as has been seen before.13 Figure 3.6 shows the 
activation profile of both Rn and Ms sGC in the 1-NO and excess NO states with and without YC-
1. In the conditions assayed here, YC-1 does not rescue sGC activity when MMTS is present in 
either the 1-NO or excess NO state.These data indicate that either the conditions where YC-1 
rescues a MMTS-treated sample of sGC are very specific, MMTS is preventing a conformational 
change, or perhaps excess NO and YC-1 are acting through the same mechanism to activate sGC. 
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Figure 3.5 – Activity Based Protein Profiling approaches to narrow cysteine list. A) Overall scheme of Activity Based 
Protein Profiling approach to look for reactive cysteines in sGC. In this example two sGC cysteines are shown, one 
that is reactive and the other that is not. If equal molar ratios of heavy and light NEM are added to two samples of 
sGC in substoichiometric amounts compared to the number of sGC cysteines, only the reactive cysteines should be 
labeled, and they should be labeled in the equivalent ratios. If unreactive cysteines are labeled, they should also be 
labeled in equivalent ratios (top). However, if an excess of the light NEM is used, reactive cysteines should still be 
labeled equivalently while unreactive cysteines should have a larger area corresponding to reaction with light NEM 
(bottom). B) The graph shows the observed peptides ordered such that the peptides with the smallest area ratio on the 
left, indicating more reactive cysteines and larger area on the right. This trend does not hold if organized by cysteine 
number (e.g. the cysteines that are most reactive with equimolar alkylating agents do not appear to be most reactive 
in the case with the excess alkylating agents). C) The graph shows the results of the second strategy in which NO 
imagined to be used as a block for the second site cysteine. The y axis depicts the area of modified peptides in the 
mass spectrum chromatogram modified in the unliganded state divided by the area of modified peptides in the mass 
spectrum in the excess NO state. We would predict that the second site cysteine would have an area ratio of much 
greater than one, however in general we saw that more cysteines were reacting with both alkylating agents in the 
excess NO state. This is most likely attributed to the larger conformational change that occurs between the unliganded 
state compared to the excess NO state which potentially allows for more cysteines to be modified. 
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Figure 3.6 – sGC activity with MMTS and YC-1. Activity data for both Rn and Ms sGC depicting the effect of small 
molecule stimulators and inhibitors on activity. In contrast to previously published data, YC-1 does not stimulate 
MMTS-treated Rn or Ms sGC.13 It is possible that under some conditions, YC-1 is able to stimulate a MMTS-treated 
sGC but it is not true for the conditions assayed here. 
 
Perhaps MMTS was not modifying the second site cysteine, but in fact was preventing the 
conformational change that allowed sGC to activate. This hypothesis would be supported if 
modifying agents that targeted other amino acids also inhibited activation of sGC by excess NO. 
To explore the hypothesis that MMTS was inhibiting a conformational change, different 
bioconjugational agents that modify both cysteine and lysine residues were used to modify sGC. 
The bioconjugation reactions used in this section as well as the mass change for the modified 
amino acid are depicted in Figure 3.7A. Preliminary activity assays with MMTS, NEM, s-NHS-
Ac, and IsaAnh indicated that the inhibition of excess NO-stimulated activity was indeed 
constricted to cysteine modifying agents (Figure 3.7B). This assay indicates that perhaps the 
modification of other residues does not prevent excess NO-stimulated activity, but it is still 
possible that a cysteine in a critical position that is modified by MMTS and NEM is preventing a 
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crucial conformational change. An alternate explanation for the differential activity is that different 
stoichiometries and reactivities of the modifying agents to amino acids results in a different 
average number of amino acids labeled per heterodimer of sGC. 
 
To quantify on average how many modifications are found on sGC after treatment with 
different bioconjugational agents, an assay was performed to measure both intact protein mass 
spectra and endpoint activity in parallel. The final concentration of Rn sGC in these labeling 
reactions was 1 µM, so based on the number of cysteines and lysines in the proteins gives final 
concentrations of 34 µM cysteine and 78 µM lysine. Figure 3.8A displays a deconvoluted mass 
spectrum that shows the mass changes for sGC subjected to the indicated final concentration of 
labeling agent, with the largest observed change noted in number of molecules per subunit. 
Interestingly, the average mass change for sGC treated with MMTS was much larger than 
expected, perhaps indicating that the MMTS reagent was more concentrated than calculated. All 
other agents modified sGC in a range that was closer to the expected average number of molecules 
per subunit. Figure 3.8B shows the results of the activity assay performed in parallel. MMTS 
inhibited sGC in both excess NO and excess NO with YC-1, however neither IAM nor IAC showed 
this same inhibition despite both agents modifying sGC. Both IAM and IAC react slower than 
MMTS and NEM, perhaps indicating either not enough time was allowed for the labeling reactions 
to progress to completion. Thus, titrations of all bioconjugational agents must be performed to see 
if the inhibition of sGC activity occurs at the same number or different number of residues 
modified per subunit. A first titration of sGC activity with MMTS is shown in Figure 3.8C, where 
maximal inhibition occurs between 50 and 100 µM MMTS for 2 µM sGC. 
 
To explore the possibility of using the differential reactivities of MMTS and IAM to our 
advantage, two rotations students in the Marletta lab M. Hood and K. Houghton attempted to label 
sGC first with IAM followed by MMTS and compared the activation of excess NO with a sample 
that was reacted with IAM followed by IAM and MMTS followed by MMTS. Figure 3.9 shows 
that it is possible to label sGC first with IAM followed more IAM and still retain NO-stimulated 
sGC activity, however addition of MMTS under any conditions prevents the NO-stimulated 
activity. This line of research is similar to what was attempted with the ABPP where we imagined 
NO functioning as a blocking agent, however IAM forms a covalent bond to the cysteine. These 
double addition type experiments hold great promise for the elucidation of critical cysteines in 
sGC. 
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Figure 3.7 – Expansion of small molecule bioconjugational agents used on sGC. A) The reactions of small molecule 
bioconjugational agents used in this chapter is shown, along with the mass change of the amino acid they modify 
(right). B) Activity data of Rn sGC in the 1-NO and excess NO state. Both cysteine labeling agents abrogated excess 
NO-stimulated activity of Rn sGC, while labeling with lysine labeling agents did not have this same effect. 
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Figure 3.8 – A tandem mass spectrometry activity assay for sGC activation. A) Deconvoluted intact mass 
spectrometry of sGC with labeling conditions noted on the left. The masses of the varied modification states are noted, 
and the accompanying number of modifications is shown for the highest observed peak. B) Activity data with the 
same samples of protein that were examined by mass spectrometry. MMTS decreased excess NO-stimulated activity, 
however IAM and IAC did not in this assay. C) A titration of MMTS with 2 µM Ms sGC showing that MMTS between 
50 and 100 µM brings the NO-stimulated activity back down to the unliganded activity state (noted by the low activity 
point at 0 µM MMTS). 
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Figure 3.9 – Order of addition sGC activity assays. Endpoint activity data of Ms sGC showing that the reactivity of 
bioconjugational agent has an effect on NO-stimulated activity. In all three cases, the final concentration of alkylating 
agent was 100 µM, added 50 µM at a time with the first addition at 0 minutes and the second addition at 30 min. The 
IAM|MMTS sample had 50 µM of IAM added at 0 minutes, and 50 µM of MMTS added at 30 minutes. 
 
 
Conclusions 
 
 A critical aspect of understanding molecular level function of signal transduction pathways 
involves locating the binding site of ligand(s) and elucidating how the signal is transduced from 
that location through the protein. Only then can detailed mechanistic understanding be applied to 
the root causes of disease states and ultimately develop therapeutics. The three different activation 
states of sGC are a fascinating biochemical phenomenon as the activation between 1-NO and 
excess NO is quite large, yet it is short lived and highly dependent on NO concentration. In this 
chapter, different sGC homologues and new evidence were applied to this problem to further our 
understanding of the three-state activation of sGC. 
 
 This investigation began with the hypothesis that the second site of NO binding is a 
cysteine residue. While new hypotheses were tested by examining conserved cysteines of other 
sGCs that have been biochemically confirmed to also possess a three-state activation profile, as 
well as other sGC homologues that cluster together in sequence space, none of the selected 
cysteines examined by themselves represented the sole second NO binding site. Advances in mass 
spectrometric techniques led to new experiments that tested both the reactivity of sGC cysteines 
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and the ability for NO to block the second site cysteine. However, this question turned out to be 
more complex than other questions answered with these techniques and no target cysteines 
emerged from this line of inquiry. Upon returning to biochemical activity assays, different 
hypotheses were explored to make sense of the set of results collected thus far. 
 
 Contrary to results previously published13, YC-1 did not rescue MMTS treated sGC in this 
analysis. Upon expansion of the bioconjugational agents used, different cysteine labeling agents 
affected the ability of sGC to be stimulated by excess NO in vastly different ways. Both MMTS 
and NEM inhibited the ability for sGC to be stimulated, while IAM and IAC had little effect. These 
results highlight the critical nature of labeling conditions for sGC activity, specifically average 
number of sGC amino acids labeled, time of reaction, temperature of reaction, and which specific 
residues were modified. A variety of experiments can now be attempted to understand this three-
state activation profile that is unique to sGC (described in Chapter 5). 
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CHAPTER 4 
 
 
CHARACTERIZATION OF A CARBON MONOXIDE ACTIVATED SOLUBLE 
GUANYLATE CYCLAE FROM CHLAMYDOMONAS REINHARDTII 
 
 
Summary 
 
Signaling pathways that involve diatomic gases in photosynthetic organisms are not well 
understood. Exposure to nitric oxide or carbon monoxide is known to elicit certain responses in 
some photosynthetic organisms. For example, Chlamydomonas reinhardtii grown in low-iron 
media responds to exogenous carbon monoxide by increasing cell growth and intracellular 
chlorophyll levels. Here, we characterize Cyg11, a gas-responsive soluble guanylate cyclase from 
the eukaryotic green alga Chlamydomonas reinhardtii that converts GTP to cGMP. Cyg11 
transcription is upregulated when C. reinhardtii is grown in iron-limited media, suggesting its 
importance in nutrient-limited environments. Cyg11 is purified as a homodimer and is activated 
by nitric oxide (2.5-fold over basal activity) and carbon monoxide (6.3 fold) The heme binding 
stoichiometry of Cyg11 was found to be one heme per homodimer, an unexpected result based on 
the sequence and oligomerization state of the enzyme. Gas binding properties, the kinetics of gas 
binding, and the ligand-modulated activity of Cyg11 are consistent with CO as the relevant 
physiological ligand.  
 
 
 
 
 
 
 
 
 
 
Portions of this chapter have been reported in a previous publication.1 
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Introduction 
 
Unicellular organisms must both sense and communicate with the outside world. Many of these 
communications occur through specific chemical interactions with selective receptor and signal 
transduction proteins, allowing the organisms to survive and proliferate in constantly-changing 
environments.2,3 The origins of these interactions can be within or between species and are 
mediated through small molecules or even peptides;4–10 however, signaling events can also be 
tuned to the surrounding environmental conditions.11–13 In fact, the ability to rapidly sense 
environmental conditions is critically important for organisms to adapt to changes in temperature, 
pH, and availability of micronutrients. Understanding how unicellular organisms detect these 
external signals can provide insight into organism adaptation and the molecular mechanisms of 
signaling cascades. In turn, these systems can be used as a model to disentangle the more complex 
signaling systems in multicellular organisms.  
 
Chlamydomonas reinhardtii, a eukaryotic unicellular green alga, is a well-suited model organism 
for the study of micronutrient sensing.14 C. reinhardtii is known to respond to the changing 
availability of environmental micronutrients, such as copper, iron, and zinc. These environmental 
changes induce C. reinhardtii to degrade organelle-specific proteins, modulating both its 
transcriptome and proteome to maintain homeostasis.15 For example, the nutritional copper sensing 
system of C. reinhardtii is particularly well understood. In low copper environments, both copper 
response proteins and a specific transcription factor, Copper Response Regulator 1 (CRR1), 
modulate the copper-dependent transcription of genes to preserve critical copper proteins.16–18 
This, and other examples, demonstrates the versatility of C. reinhardtii in determining the 
molecular mechanisms of signal transduction pathways.19–21 
 
Diatomic gaseous signaling molecules present a unique challenge for aerobic organisms, as typical 
signaling gases these tend to be lower in concentration compared to oxygen (O2). However, 
sensing systems that involve gaseous signaling molecules have been described in C. reinhardtii. 
The first such example demonstrates that nitrogen assimilation represses the transcription of nitrate 
reductase through a signaling system that potentially involves endogenously produced nitric oxide 
(NO).22–24 Additionally, studies have linked exogenous carbon monoxide (CO) levels to the 
transcription of heme oxygenase and ferredoxin in low iron environments.25,26 Furthermore, 
addition of CO to iron-depleted cells increases both the cell count and intracellular concentration 
of chlorophyll. These studies have implicated CO as a gaseous signaling molecule in C. reinhardtii 
in environments with low iron content. 
 
The C. reinhardtii genome encodes six proteins homologous to single subunits of gas sensing 
soluble guanylate cyclases (sGCs) found in higher eukaryotes. In higher eukaryotes, sGCs are 
involved in many critical paracrine signaling processes, including vasodilation, platelet 
aggregation, and neurotransmission.27–30 Higher eukaryotic sGCs are heterodimeric with each 
subunit consisting of four domains: an N-terminal Heme Nitric oxide/Oxygen (H-NOX) binding 
domain, a Per/Arnt/Sim (PAS)-like domain, a coiled-coil (CC) domain, and a catalytic cyclase 
domain (CAT). Typically, only one subunit of the heterodimer (usually denoted β) has the 
necessary residues to bind the heme cofactor. Based on the placement of the active site at the 
interface of the two subunit’s catalytic domains and on sequence alignments of critical active site 
residues, most higher eukaryotic sGCs are necessarily heterodimeric and form one active site and 
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one pseudosymmetric site within their catalytic domain dimer.31 sGCs catalyze the cyclization of 
5′-guanosine triphosphate (GTP) to 3′,5′-cyclic guanosine monophosphate (cGMP). Enzyme 
activity is modulated by the presence of NO or O2 at the heme binding site in the H-NOX domain 
of the β subunit.32,33 cGMP in turn activates cGMP-dependent kinases, cGMP-gated ion channels, 
and other proteins initiating a diverse set of physiological responses. One Cr sGC, Cyg56, has 
been implicated in the repression of nitrate reductase signaling pathway by ammonium.22 While 
the function of these proteins is well characterized in higher eukaryotes, the biochemical functions 
of the other sGCs in C. reinhardtii are largely unknown.  
 
Reported here is a biochemical characterization of Cyg11 (Phytozome: Cre07.g320700.t1.1, 
UniProt A0A2K3DJ13), the first sGC with a higher maximum velocity of cGMP formation when 
CO is bound compared to when NO is bound. Additionally, Cyg11 was found to have a fast NO 
off-rate for a ferrous heme protein and a lower KD for CO than any previously characterized sGC. 
These results suggest that Cyg11 plays a different role in signaling compared to sGCs in higher 
eukaryotes. Indeed, the results reported here provide support for CO as a signaling molecule in C. 
reinhardtii through the receptor Cyg11. 
 
Materials and Methods 
 
Materials 
All chemicals were purchased from commercial vendors and used without further purification 
unless otherwise noted. Primers were obtained from Integrated DNA Technologies (Coralville, 
IA). Gibson Master Mix was purchased from New England Biolabs (Ipswich, MA). PrimeSTAR 
Max DNA polymerase and His60 Ni Superflow resin was purchased from Takara Bio USA 
(Mountain View, CA). DNA purification kits were purchased from Qiagen (Germantown, MD). 
Terrific Broth media powder, ampicillin, and 4-(2-aminoethyl)benzenesulfonyl fluoride 
hydrochloride (AEBSF) were purchased from Research Products International (Mount Prospect, 
IL). Hemin chloride, sodium dithionite (Na2S2O4), DNAse I from bovine pancreas, β-
mercaptoethanol, H2NaPO4, NaCH3CO2, Mg(CH3CO2)2, and guanosine 5′-triphosphate sodium 
salt (GTP) (>95%, HPLC) were purchased from Millipore Sigma (Burlington, MA). Isopropyl β-
D-1-thiogalactopyranoside (IPTG), 4-(2-Hydroxyethyl)piperazine-1-ethanesulfonic acid 
(HEPES), Pierce BCA Protein Assay Kit, ammonium acetate (NH4CH3CO2), and acetonitrile 
(CH3CN, HPLC grade) were purchased from Thermo Fisher Scientific (Waltham, MA). 
Benzamidine, lysozyme from chicken egg white, and sodium chloride (NaCl) were purchased from 
VWR Life Science (Visalia, CA). Dithiothreitol (DTT) was purchased from Bachem (Bubendorf, 
Switzerland). Imidazole was purchased from Oakwood Chemical (West Columbia, SC). Vivaspin 
spin concentrators were purchased from Sartorius (Concord, CA). PD-10 desalting columns were 
purchased from GE Healthcare (Pittsburgh, PA). DEA NONOate was purchased from Cayman 
Chemical Company (Ann Arbor, MI). Nitric oxide (NO, >99.5%) gas and carbon monoxide (CO, 
>99%) gas were purchased from Praxair Inc. (Danbury, CT). NO gas was bubbled through 10 M 
NaOH to remove higher oxides prior to use. 
 
Construction of Expression Plasmids 
The Core cDNA library of Chlamydomonas reinhardtii was purchased from the Chlamydomonas 
Resource Center (University of Minnesota). Primers were designed against the 3′ and 5′ UTR of 
Cyg11 (transcript name: Cre07.g320700.t1.1) Fwd: 5′-      
80 
 
GGATCCATCGATGCTTAGGAGGTC GCCATGCAGTTCATTCTTAGT -3′, Rev: 5′-
CTGCTCATGTTTGACAGCTTATCATCG CGTGTCCGCGAGCAATGGTAA -3′. The 
underlined regions of the primers anneal to 3′ and 5′ UTR of Cyg11. The purified PCR product 
was subcloned into a linearized pCW vector with Gibson Master Mix, and the product was verified 
by DNA sequencing (UC Berkeley DNA Sequencing Facility). The Cyg11 predicted protein 
sequence was aligned to the β-subunit protein sequence of Rattus norvegicus (Rn) sGC (Uniprot: 
Q02153-1) using Clustal Omega (EMBL-EBI). The crystal structure of the Homo sapiens catalytic 
domain (99% identical to Rn, PDB ID: 4NI2) was used to identify the last ordered residue, and 
thus the N-terminal 615 amino acids were subcloned from the full-length Cyg11 gene. The final 
expression plasmid (pCW_Cyg11615_His6) includes a hexahistidine tag at the C-terminal of the 
protein, as the N-terminus of H-NOX domains are buried in the heme binding pocket and cannot 
be extended. The full peptide sequence is included in Figure B.1.  
 
Protein Expression and Purification 
pCW_Cyg11615_His6 was transformed into RP523(DE3) E. coli cells34,35 and multiple colonies 
were tested for protein expression. After overnight growth in Terrific Broth (Research Products 
International) in the presence of 100 μg/mL ampicillin, 20 μg/mL hemin chloride (Millipore) (from 
a 10 mg/mL stock dissolved in DMSO), and 0.2% glucose, the cells were subcultured 1:100 into 
1L and grown at 37 °C. A glycerol stock was created for each overnight culture. Once the cell 
density reached OD600 = 0.6, the culture temperature was lowered to 18 °C and protein expression 
was induced with 0.5 mM IPTG and grown for 16 hours. Expression levels were determined by 
pelleting approximately 108 cells pre- and post-induction, lysing with BugBuster (Millipore), 
running the cell lysate on a sodium dodecyl sulfate polyacrylamide (SDS-PAGE) gel, and 
performing a western blot to probe for His-tagged proteins using a mouse anti-His6 Ab followed 
by a goat anti-mouse HRP conjugate Ab (Life Technologies). After the confirmation of an RP523 
clone with high expression of Cyg11, overnight cultures were inoculated directly from the glycerol 
stock into liquid culture. Expression cultures (1 L) were spun down at 4300 g for 20 minutes, snap 
frozen in liquid nitrogen, and stored at –80 °C. 
 
All following steps were performed at 4 °C. Cell pellets were thawed in ice water and resuspended 
in Lysis Buffer: Buffer A (50 mM Na2HPO4, pH 8.0, 200 mM NaCl, 1 mM imidazole, 5% (v/v) 
glycerol, 0.22 μm filtered) supplemented with 10 mM benzamidine, 1 mM AEBSF, 0.5 mg/mL 
lysozyme, 0.5 mg/mL Bovine DNAse I. Cells were lysed using a high-pressure homogenizer 
(Avestin Emulsiflex-C5). The resulting cell lysate was clarified by spinning at 27,000 g (Sorvall, 
SS-34 rotor) for 30 minutes, then gently rocked with 4 mL His60 resin, pre-equilibrated with 
Buffer A, for 30 minutes. The beads were applied to a column and washed with 10 CV of Buffer 
A. The column was washed with buffers with increasing concentrations of imidazole, and finally 
the protein was eluted with 5 CV of Buffer B (50 mM Na2HPO4, pH 8.0, 200 mM NaCl, 400 mM 
imidazole, 5% (v/v) glycerol, 0.22 μm filtered). The elution fractions were supplemented with 5 
mM β-mercaptoethanol, concentrated to 5 mL using a 30,000 molecular weight cutoff spin 
concentrator, and passed over a 26/60 Superdex S200 pg size exclusion column (GE Healthcare) 
equilibrated with Buffer C (50 mM TEA, pH 7.5, 150 mM NaCl, 5 mM DTT, 5% glycerol, 0.22 
μm filtered). Fractions that possessed a 430 nm/280 nm absorbance ratio greater than or equal to 
1 (typically 1.2) were pooled, snap frozen in liquid nitrogen, and stored at –80 °C. 
 
Analytical Size-Exclusion Chromatography 
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The following protein standards (0.2 mg/mL) were dissolved in Buffer C: lysozyme (14.3 kDa), 
deoxyribonuclease I (31 kDa), bovine serum albumin (66.5 kDa), alcohol dehydrogenase (150 
kDa), and thyroglobulin (500 kDa). These standards and Cyg11 at 0.5 mg/mL were run over a 
Superdex 200 Increase 10/300 GL column (GE Healthcare) using Buffer C at a flow rate of 0.5 
mL/min. The elution times were normalized to the void volume and plotted versus the log of the 
molecular weight to generate a standard curve. 
 
Intact Protein Mass Spectrometry 
Purified proteins were buffer-exchanged into 25 mM HEPES, pH 7.5, 25 mM NaCl buffer by three 
dilution and concentrations in a Vivaspin 500 (30,000 MWCO) spin concentrator (Sartorius). 
Samples were filtered by passing them through a 0.22 μM spin filter (Millipore). The final sample 
concentration was approximately 5 µM. Samples were separated with an Agilent 1200 series high 
pressure liquid chromatography (HPLC) system over a ProSwift column (ThermoFisher 
Scientific), and subsequently analyzed by an Agilent 6224 time-of-flight (TOF) mass spectrometer 
with a Turbospray ion source in positive ion mode. 
 
Size-Exclusion Chromatography Multi-Angle Light Scattering (SEC-MALS) 
Samples were injected onto a Superdex 200 10/300 SEC column (GE Healthcare) equilibrated 
with Buffer C at 0.5 mL/min. Elution peaks were detected with an in-line DAWN HELIOS II light 
scattering detector and an Optilab rEX refractive index detector (Wyatt Technologies). All steps 
were performed at room temperature. Data acquisition and processing were performed using 
Wyatt’s ASTRA software program. 
 
Native Nanoelectrospray Mass Spectrometry 
Samples were prepared anaerobically in a glove bag (Coy) in an atmosphere of 98% Ar, 2% H. 
The sample was reduced with 5 mM Na2S2O4 for fifteen minutes. Next, protein was buffer 
exchanged into 50 mM Na2CH3CO2, pH 6.8, 2 mM DTT by diluting and concentrating the protein 
twenty times in a Vivaspin 500 (30,000 MWCO) spin concentrator (Sartorious) at 4 °C. The final 
protein concentration was 6 μM. The protein was removed from the anaerobic chamber and native 
nanoelectrospray ionization mass spectrometry (nanoESI-MS) was conducted on a Synapt G2-
Si mass spectrometer equipped with a nanoESI source (Waters, Milford, MA) in positive ion 
mode. Mass spectrometry data acquisition and processing were performed using MassLynx 
software, version 4.1 (Waters). 
 
Absorption Spectroscopy 
Samples were reduced in an anaerobic glove bag (Coy) with 5 mM Na2S2O4 for fifteen minutes, 
and then desalted with a PD-10 Minitrap desalting column (GE). CO-saturated buffer (950 μM 
CO) was prepared by sparging 3 mL of anaerobic Buffer D (50 mM HEPES, pH 7.5, 150 mM 
NaCl, 5% (v/v) glycerol, 0.22 μm filtered) for 15 minutes in a Reacti-Vial (Thermo Fisher 
Scientific). CO was added to the sample at a final concentration of 425 μM. Nitric oxide was added 
to a concentration of 500 μM by addition of DEA NONOate (Cayman Chemical Company) 
considering 1.5 moles of NO released for each mole of NONOate. Protein-gas complexes were 
incubated for 15 minutes at room temperature to establish equilibrium, and no further spectral 
changes were observed after this time. Samples were placed in a septum-sealed 1 cm pathlength 
quartz cuvette inside the glove bag, and UV–Vis spectra were recorded on a Cary 300 
spectrophotometer (Agilent Technologies). 
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Heme Reconstitution 
Samples were reduced in an anaerobic glove bag (Coy) with 5 mM DTT, and then 2 equivalents 
to homodimer of hemin chloride in 100% DMSO (Millipore Sigma) was added (final DMSO 
concentration was 1%). No difference in reconstitution was observed when samples were 
incubated for 15 minutes at 25 °C or 16 hours at 4 °C. Reconstituted samples were desalted over 
PD-10 Minitrap desalting column (GE), and absorbance spectra were recorded as above. 
 
Activity Assays and Quantification 
Steady-state kinetics for Cyg11 were measured by quantifying the amount of cGMP produced in 
endpoint activity assays. Protein-gas complexes were prepared as described for absorption 
spectroscopy. For all steady-state kinetic assays, the final protein concentration was approximately 
1 μM, as quantified by Nanodrop A280 measurement (molecular weight of Cyg11 homodimer is 
139,429 Da, extinction coefficient calculated using ExPasy ProtParam to be 52,830 M-1cm-1 
assuming all cysteines are reduced). Activity assays were conducted at 25 °C and pH 7.5 in Buffer 
D supplemented with 5 mM DTT and Mg(CH3COO2)2 greater than or equal to twice the substrate 
concentration. Reactions were initiated with GTP and timepoints were quenched into 1% formic 
acid. Reactions were analyzed by reverse-phase HPLC to quantify the amount of cGMP formed. 
Samples (88 μL) were injected onto a pre-equilibrated Eclipse Plus C18 column, 3.5 μm particle 
size (4.6 x 100 mm) (Agilent). The HPLC system used two buffers (Buffer E: 20 mM ammonium 
acetate, 0.1% v/v formic acid; Buffer F: 99.9% acetonitrile, 0.1% formic acid) and was run at 1 
mL/min to pre-equilibrate with 2% Buffer F. After sample injection, the following gradient was 
run at 1 mL/min to separate substrate from product: 2% Buffer F for minutes 0–6, 2–25% Buffer 
F for minutes 6–7.5, 25–100% Buffer F for minutes 7.5–8.5, 100% Buffer F for minutes 8.5–9, 
100–2% Buffer F from minutes 9–9.25, and 2% Buffer F for minutes 9.25–13.5. The peaks of GTP 
(1.7 min) and cGMP (4.2 min) were monitored at 254 nm. Concentrations of cGMP were 
determined from a standard curve, generated over 6–200 µM. Initial rates were calculated from 
the linear phase of the time course during which 5–10% of the GTP substrate was consumed. 
 
Gas Binding Kinetics 
Gas dissociation rates (koff) were determined for CO-bound and NO-bound Cyg11. The protein 
was reduced anaerobically and desalted as before and either diluted in CO-saturated buffer or DEA 
NONOate was added to give an initial concentration of 5 μM protein complex. The trap solution 
for CO dissociation rates was prepared by sparging NO(g) into Buffer H (50 mM HEPES, pH 7.5, 
150 mM NaCl, 0.22 μm filtered) for 15 minutes in a Reacti-Vial. The trap solution for NO 
dissociation rates was prepared by adding Na2S2O4 to Buffer H and sparging with CO(g) for 15 
minutes in a Reacti-vial. Samples were transferred in gas-tight syringes to a HiTech KinetAsyst 
(TgK Scientific) stopped-flow system. Reactions were initiated by mixing an equal volume of 
Cyg11–CO with NO(g) saturated buffer trap, or Cyg11–NO with CO/dithionite buffer trap at 20 
°C. The concentration of the NO(g) (95–950 μM) and dithionite (10–100 mM) was varied to ensure 
that the rate was independent of trap concentration. 
 
CO association rates (kon) were determined for ferrous Cyg11. Samples (approximately 5 μM) 
were transferred in gas-tight syringes into the stopped-flow system that was made anaerobic by 
incubating the sample-handling unit with 10 mM Na2S2O4 for 30 minutes. Dilutions of CO-
saturated buffer were made on the sample handling unit in gas-tight syringes by diluting CO-
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saturated buffer with anaerobic Buffer H via a three-way valve. Reactions were initiated by mixing 
equal volumes of protein solution and CO-saturated buffer at 20 °C for a final protein concentration 
of 2.5 μM. 
 
 
Results and Discussion 
Identification and sequence analysis of C. reinhardtii sGCs 
Sequence alignments of all six annotated sGC homologues from Chlamydomonas reinhardtii (Cr) 
were compared to the mammalian sGC from Rattus norvegicus (Rn) (Figure 4.1).22 All Cr sGCs 
have four predicted domains similar to mammalian sGC. A schematic of the domain organization 
is shown for both Cyg11 and Rn sGC α1β1 in Figure 4.1A. All Cr sGCs are predicted to contain a 
long C-terminal domain with no homology to any known protein domain. It is not known what 
function these C-terminal domains have in Cr sGCs, or if these domains are present in the mature 
proteins in vivo. 
Figure 4.1 – Domain arrangement of Cr sGCs. As homologues to mammalian sGC, Cr sGCs are composed of four 
consecutive domains: a Heme Nitric Oxide/Oxygen binding domain (H-NOX), a Per/Arnt/Sim domain (PAS), a 
coiled-coil domain (CC), and finally the catalytic domain (CAT). A) A cartoon schematic of the domain organization 
and approximate domain regions of both Cyg11 and Rn α1β1 sGC. The letter H represents possible heme binding sites 
in each Cyg11 subunit. B) Sequence alignments of the H-NOX domain of Cr Cyg11 and Rn sGC. All Cr sGC H-NOX 
domains have a proximal histidine, and the YxSxR motif necessary to bind a heme cofactor (see Figure B.1 for other 
Cr sGC sequences) C) Sequence alignments of Cr Cyg11 and Rn sGC CAT domains. Whereas the heterodimeric 
structure of Rn sGC is required to generate a competent active site, Cr sGC CAT domains contain all the residues 
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necessary for catalysis, rendering them catically-active homodimers. Key residues: * – metal binding, Δ – guanine 
binding, ▲ – triphosphate binding, # – ribose binding. 
 
Rn sGC is a heterodimer composed of an α1 and a β1 subunit. Only the β1 H-NOX domain contains 
the YxSxR motif, which binds the propionate groups of the heme cofactor and a histidine residue 
to act as the proximal ligand to the iron. Cr sGCs showed more homology to the heme-binding Rn 
β1 sGC than Rn α1 (average of 36% versus 28% identity), including all residues mentioned above 
to bind heme in the H-NOX domain (Figure 4.1B, Figure B.1B). As all Cr sGC H-NOX domains 
have the heme-binding motif, it is not possible to distinguish between gas-sensing homodimers 
versus heterodimers as is the case for the Rn sGC. 
 
Interestingly, in contrast to the Rn α1β1 sGC that must form a heterodimer to compose one complete 
active site and one pseudosymmetric site, Cr sGC CAT domains contain all necessary residues to 
form two competent active sites. As such, the Cr sGCs are predicted to form both active 
homodimers and active heterodimers (Figure 4.1C, Figure B.1B). Similar to sequence analysis of 
the H-NOX domain, these findings do not aid in distinguishing which oligomers are formed in 
vivo, so transcriptomics was used to narrow down the possibilities. 
 
Analysis of Trancriptomics Data 
Available transcriptomic data for Cr sGCs was obtained from Phytozome (Version 12) in order to 
help discern the oligomerization state of Cr sGCs.36 All six predicted homologues of mammalian 
sGC from C. reinhardtii are transcribed at low, but detectable levels (Figure B.2). Co-
transcriptional analyses across all studies indicated that no two Cr sGCs are predicted to be 
transcribed together greater than 85% of the time. While transcriptomic data does not guarantee 
protein expression as would be confirmed by proteomic data, the fact that none of the six sGCs are 
predicted to co-transcribed supports the hypothesis that Cr sGCs form homodimers. It is 
uncommon for higher eukaryotic sGCs to form homodimers natively, however this greatly 
facilitates heterologous expression and further characterization for C. reinhardtii sGCs. 
 
Since transcriptomics data for varying gas conditions are not available, conditions that may be 
important in gaseous signaling were analyzed. Under iron-deficient conditions, exogenous CO has 
been shown to increase cell growth, increase cellular chlorophyll concentrations, and upregulate 
genes involved in iron metabolism.25,26 Consequently, the transcripts for C. reinhardtii genes with 
varying levels of iron were analyzed (either replete, deficient, or limited).37 The transcript levels 
of two Cr sGCs (cyg11 and cyg15) increase as iron levels decrease, indicating that both genes are 
upregulated in low iron environments. Furthermore, the absolute number of cyg11 transcripts 
increases when C. reinhardtii is grown photosynthetically, potentially indicating the importance 
of this gene in a native environment. Since Cyg11 is transcribed at higher levels under normal 
physiological conditions, this enzyme was selected for further study to determine if it may be 
involved in CO-mediated recovery from iron deficiency.25,26 
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Initial Characterization of Cyg11 
Cyg11 was expressed heterologously in E. coli 
RP523(DE3), a heme-permeable strain, to ensure 
excess heme is present during protein expression.34 
Cyg11 was purified by immobilized metal affinity 
chromatography followed by size-exclusion 
chromatography (Figure B.3,B.4). The protein was 
isolated with the heme in the five-coordinate ferrous 
state. To confirm Cyg11 formed homodimers, size 
exclusion chromatography multiangle light 
scattering (SEC-MALS) experiments were 
performed with the instrument calibrated to a BSA 
standard. As shown in Figure 2A, Cyg11 eluted in a 
single peak (Vr = 11.3 mL) with a calculated 
molecular weight of 142 kDa, which is nearly 
double the expected molecular weight (69.7 kDa, 
Figure B.5). This result clearly shows that Cyg11 
forms homodimers. 
 
The Cyg11 homodimer has two H-NOX domains; 
thus, the expectation was that each homodimer 
would bind two heme cofactors. The heme 
stoichiometry was measured using two assays 
performed in tandem: a pyridine hemochromogen 
assay to measure heme concentration and a 
bicinchoninic acid (BCA) assay to measure protein 
concentration.38 The results of this tandem assay 
indicated that there was approximately one heme 
cofactor per dimer of Cyg11 (Figure 4.2B). Native 
mass spectrometry of the purified Cyg11 showed 
one homogeneous protein population with regards 
to heme occupancy (Figure 4.2C, inset). The 
deconvoluted mass spectrum of Cyg11 revealed a 
single mass of 140,314 ± 53 Da. This mass confirms 
that Cyg11 does not contain two heme cofactors, as 
a dimer with two hemes would have a mass of 
140,660 Da (Figure 4.2C). A homodimer with one 
heme is 140,044 Da, within range of the measured 
mass plus bound cations from the buffer. Attempts 
to reconstitute Cyg11 with exogenous hemin 
 
Figure 4.2 – Oligomeric state and heme occupancy of Cyg11 A) Size-exclusion multi-angle light scattering trace 
shows Cyg11 eluting in one main peak with a molecular weight around 142 kDa, about twice the monomer weight of 
70 kDa. B) A pyridine hemochromogen assay, coupled with a bicinchoninic acid (BCA) assay, suggests that Cyg11 
has only one heme per dimer, using myoglobin with one heme as a reference. C) Raw (inset), and deconvoluted native 
nano-electrospray mass spectrometry confirms the dimeric state of Cyg11 with only one heme cofactor bound to the 
purified enzyme (a dimer with two heme cofactors is 140,660 Da). 
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slightly increased the ratio of the Soret band to protein absorbance at 280 nm but did not increase 
the content to two heme cofactors per dimer (Figure B.6). Both the tandem assay and mass 
spectrometry indicate that Cyg11 contains one heme per homodimer, an unexpected result for a 
homodimer with two potentially functional heme binding domains. It is not known when heme 
loading occurs in the maturation of Cyg11. This final occupancy could be the result of homodimer 
formation that creates one functional heme binding site or loss of one heme upon dimerization. 
 
Diatomic Gas Binding to Cyg11 
All known sGCs are activated with diatomic gases. Thus, to assess which ligands the Cyg11 H-
NOX domain binds, UV-visible absorption spectroscopy was used to determine ligand-dependent 
shifts in spectra of the heme cofactor. Cyg11 purifies in the ferrous state, with a λmax of the Soret 
band centered at 431 nm, consistent with a 5-coordinate ferrous heme as isolated. Cyg11 readily 
binds both NO and CO, resulting in blue shifts to 399 nm (5-coordinate complex) and 424 nm (6-
coordinate complex), respectively (Figure 4.3). The α/β bands also show the expected increased 
splitting upon the addition of these diatomic gases (Figure 4.3, inset). Upon exposure of Cyg11 to 
atmospheric oxygen, no change in the Soret band was observed (Figure B.7). That Cyg11 does not 
bind oxygen is consistent with the sequence of its H-NOX domain, which lacks the critical 
hydrogen bonding residues required for O2 binding.39 Taken together, the ligand-dependent 
absorption spectra for Cyg11 is similar to that of both mammalian sGCs and Shewanella 
oneidensis (So) H-NOX, which indicates that Cyg11 likely senses either NO or CO in vivo (Table 
B.1).40,41 
 
 
 
 
Figure 4.3 – UV–visible absorption spectra of Cyg11 The UV–visible absorption spectra of Cyg11 with various 
gaseous ligands. The Soret band of Cyg11 is sensitive to the identity of the axial ligand, blue-shifting for CO and more 
so for NO. Inset: The α/β exhibit increased splitting as the diatomic gases bind to the heme. 
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Kinetics of cGMP Formation by Cyg11 
To discern the effects of ligand binding on enzyme activity, the steady-state kinetics of Cyg11 
were measured with three different ligation states: unliganded, NO-bound, and CO-bound (Figure 
4.4). Cyg11 displays a basal activity of 213 ± 42 nmol min–1 mg–1 at 2 mM GTP, which is higher 
than previously characterized sGC activities in the unliganded state42. Upon NO binding, the 
activity increases to 405 ± 62 nmol min–1 mg–1. However, CO binding results in an increase to 914 
± 132 nmol min–1 mg–1. Activity assays with Cyg11 reconstituted with hemin showed no difference 
when compared to Cyg11 not reconstituted with hemin (Figure B.8). While adding CO to 
previously characterized sGCs increases activity over basal, this is the first example of an sGC in 
which the CO-bound enzyme has a higher activity than the NO-bound enzyme. 
 
A Michaelis-Menten curve was constructed for 
all three ligation states (Figure B.9) from 1-32 
mM GTP. Product inhibition was observed 
before enzyme saturation is achieved, 
precluding the precise assignment of kinetic 
parameters. Estimates for kcat/KM were made by 
fitting the data up to and including 16 mM GTP 
to Equation 1: 
 
𝑉𝑉
𝐸𝐸
=  𝑘𝑘𝑐𝑐𝑐𝑐𝑐𝑐𝐾𝐾𝑀𝑀  × [𝑆𝑆]𝐾𝐾𝑀𝑀
�1+
[𝑆𝑆]
𝐾𝐾𝑀𝑀
�
 (1) 
 
thereby placing greater significance on lower 
GTP concentrations. A summary of the results 
is provided in Table 4.1. CO-bound Cyg11 is 
significantly more active than the other species. 
In all cases, KM,GTP is estimated to be above 
physiological GTP concentrations (0.9–1.5 
mM)43,44; this signifies the activity of Cyg11 
will vary greatly with small changes in GTP 
concentration.  
 
 
 
 
 
 
 
 
 
 
Figure 4.4 – Activity assay of Cyg11 with different ligation states A) Initial rates were taken from a discontinuous 
enzyme assay run at 25 °C and pH 7.5, and cGMP was measured using an HPLC assay. Two representative trials are 
shown. B) The initial rates are plotted from an assay with 2 mM GTP as the substrate. The average is plotted with the 
standard deviation as error bars from 5 independent experiments.  
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Table 4.1 – Cyg11 steady-state kinetic parameters 
Ligation State Vmax/KM (nmol/(min*mg))/mM 
Unliganded 63.8 ± 6.20 
NO 162.8 ± 39.70 
CO 406.2 ± 64.96 
 
 
Gas Binding Kinetics 
The on- and off-rates of gas ligands provide insight into how long the signal is transduced. To 
garner a comprehensive view of the gas binding kinetics for Cyg11, CO and NO gas dissociation 
rates were measured using stopped-flow UV-vis spectroscopy. 
 
The dissociation rate of CO from Cyg11 was measured by rapidly mixing of Cyg11–CO with 
NO(g)-saturated buffer. This leads to the decrease of the Soret peak at 424 nm and the increase of 
the 5-coordinate ferrous nitrosyl peak at 399 nm (Figure 4.5A). The absorbance values of the 
difference spectrum were extracted (Figure 4.5A, inset) and fit to a monoexponential decay process 
with a rate constant k = 6.04 ± 0.22 s–1, which is consistent with the CO dissociation rate of other 
H-NOX domains (Figure 4.5B, Table 2). 
 
The converse experiment was also conducted, in which the rate of dissociation of NO from Cyg11 
was measured by mixing Cyg11–NO with CO-saturated buffer containing a NO trap (30 mM 
Na2S2O4). The Soret band maximum at 400 nm for the NO complex rapidly shifts to 424 nm with 
the formation of the CO adduct (Figure 4.5C). The NO dissociation rate did not depend on the 
concentration of Na2S2O4 in the trap solution (10–100 mM). Dissociation rates were calculated 
using the change in absorbance at 424 nm (Figure 4.5D). The data were fit to both a one- (red) and 
a two-component (blue) exponential function. The NO dissociation process is best described with 
a double exponential function with rate constants of k1 = 0.13 ± 0.02 s–1 (67%) and k2 = 0.019 ± 
0.04 s–1 (33%). Biphasic NO dissociation is typical for H-NOX domains and has been attributed 
to two electronically similar “open” and “closed” states of the protein.45–49 Typically, the slow 
component dominates, and thus complete dissociation takes several hours to occur.45 However, as 
seen in Figure 4.5D, this process is complete within 5 minutes for Cyg11, and the dominant 
component of the rate constant is three orders of magnitude greater than the dominant component 
of rate constants other characterized H-NOX domains (Table 2). This indicates that NO dissociates 
far faster from Cyg11 compared to other sGCs. 
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Figure 4.5 – Dissociation rates of CO and NO from Cyg11. The dissociation rates of CO and NO were measured 
using stopped-flow UV-visible absorption spectroscopy. A) Representative absorption spectrum for the dissociation 
of CO using excess NO as the trapping agent (inset: difference spectrum). Spectra were recorded every 0.003 seconds, 
and every fourth spectrum is shown for clarity. B) The change in absorbance at 424 nm was plotted as a function of 
time and fit to a monoexponential function. The residuals are shown above the plot. C) Representative absorption 
spectrum for the dissociation of NO using CO and Na2S2O4 as a trapping agent (inset: difference spectrum). The 
concentration of Na2S2O4 did not alter the dissociation rate. The spectra were recorded every 1.5 seconds, and every 
fourth spectrum is shown for clarity. D) The change in absorbance at 424 nm was plotted as a function of time, fitting 
the data to both a single (red) and double (blue) exponential function. The residuals are shown above the plot, 
indicating that a biexponential function best captures the experimental data.  
 
CO association rates were measured by mixing equal volumes of unliganded Cyg11 with CO-
saturated buffer. The change in absorbance was measured at 424 nm as a function of time, and the 
difference spectrum was fit to a single exponential function to obtain an observed rate constant, 
kobs (Figure 4.6A and 6B). These experiments were repeated with varied CO concentrations (12-
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95 µM) under pseudo-first order reaction 
conditions to measure the bimolecular rate 
constant for CO association. The observed CO 
association rates were then plotted as a 
function of CO concentration (Figure 4.6C) to 
give a rate constant of kon,CO = 2.37 ± 0.21 × 
106 M–1 s–1, which is three orders of magnitude 
greater than previously characterized full-
length sGCs (Table 2). In conjunction with the 
CO dissociation rates measured above, 
dissociation constant for CO for Cyg11 can 
then be calculated to be KD, CO = 2.5 × 10–6 ± 
0.24 × 10–6 M. This value is approximately the 
same as for So H-NOX (KD, CO = 1 × 10–6)48 
and two orders of magnitude smaller than the 
dissociation constant for the Rn sGC (KD, CO = 
2.6 × 10–4 M).50 As was seen for activation 
parameters, gas binding kinetics for Cyg11 
deviate from previously-characterized sGCs. 
 
The ability to discriminate between 
diatomic gases is a hallmark of gas-sensing 
proteins and H-NOX domains. NO-sensing H-
NOX proteins use the femtomolar KD of NO 
for ferrous heme and a hydrophobic gas-
binding pocket to impart specificity. 
Conversely, O2-sensing H-NOX proteins 
possess a hydrogen-bonding motif in the gas-
binding pocket that stabilizes the heme O2 
adduct. Cyg11 has a KD for CO that suggests it 
may be the physiological ligand. 
 
 
Figure 4.6 – Cyg11 CO association rate. The 
association rate of CO to Cyg11 was measured using 
stopped-flow spectroscopy. A) Representative 
absorption spectrum for the association of CO to 
unliganded Cyg11 (inset: difference spectrum). Spectra 
were recorded every 0.003 seconds; every fourth 
spectrum is shown for clarity. B) The change in 
absorbance at 424 nm was plotted as a function of time. 
The data was fit to a single exponential decay and the 
residuals are shown above the plot. C) The CO 
concentration was varied in the trapping solution and 
the observed rates are plotted against the concentrations 
to give the association rate. The error bars represent the 
standard deviation of at least three measurements. 
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The dissociation rate constant for CO is in line with other H-NOX domains; however, the on-rate 
for CO is significantly faster than any other sGC or bacterial H-NOX protein. Accordingly, Cyg11 
has the tightest affinity for CO of characterized full length sGCs. Furthermore, the kinetics of NO 
dissociation are significantly faster than typical sGCs, as the dominant rate constant for Cyg11 is 
three orders of magnitude faster than previously reported sGCs. While the KD of NO is predicted 
to be much smaller than that of CO, we hypothesize that Cyg11 is transcribed and expressed under 
conditions when C. reinhardtii is not exposed to NO, thus eliminating competition for the heme 
binding pocket. Taken together, these results support the hypothesis that Cyg11 is acting as a 
putative CO sensing protein in C. reinhardtii. 
 
Table 4.2 –Dissociation and Association Rates of CO and NO 
aAll measured and reported standard deviations are depicted in parentheses. bTW – This work. 
Conclusion 
All signaling systems require receptors to transduce a primary signal to secondary signals that 
interact with downstream proteins to elicit a response. Although a number of physiological 
responses to gas molecules have been described for plants and other photosynthetic 
organisms,22,25,26,51–53 the biochemical characterization of gas receptors in these systems is in its 
infancy.54 In this study, the eukaryotic alga Chlamydomonas reinhardtii is used as a model to 
understand gaseous signaling in response to micronutrient changes. This organism is adept at 
adapting to various micronutrient conditions in its environment; therefore, the organism must have 
discriminating sensing mechanisms to determine the concentrations of analytes in the surrounding 
areas and effectively respond to these stimuli. 
 
The soluble guanylate cyclase Cyg11 from Chlamydomonas reinhardtii has some unique features 
compared to higher eukaryotic sGCs. First, it has some unusual and unexpected biochemical 
properties. It is active as a homodimer, so unique in the sGC family in that regard. Further, it has 
two H-NOX domains each competent to bind heme, and yet only one heme is found in the 
homodimer. Although consistent with one heme in higher eukaryote sGCs, this was an unexpected 
result. Second, the majority of those previously characterized sGCs demonstrate a decided 
preference for NO as both a ligand and activator of activity. The only exceptions to this are sGCs 
from D. melanogaster, whose activity is influenced by O2 heme binding. As opposed to all other 
characterized sGCs, Cyg11 has a higher activity with CO rather than NO. Moreover, the enzyme 
binds CO tighter and has a faster NO off-rate than any previously reported sGC. In combination 
with transcriptomics data, the high affinity of Cyg11 for CO and the higher activity of Cyg11 with 
CO bound could indicate that it is a CO-sensing enzyme that C. reinhardtii uses to amplify the 
signal of low-iron.  
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From these results, we hypothesize that this enzyme is a putative CO sensor and may be involved 
in the CO-dependent recovery pathway that is activated under iron-deficient growth conditions. 
Furthermore, it is possible that Cyg11 is sensing CO is formed endogenously by the enzyme heme 
oxygenase-1 when heme is degraded from other non-essential enzymes. Since this is the first sGC 
homologue showing a preference for CO, cGMP produced by Cyg11 may be implicated as a 
secondary signaling molecule that enables C. reinhardtii to adapt to iron-deficient conditions.  
  
93 
 
References 
 
(1)  Horst, B. G.; Stewart, E. M.; Nazarian, A. A.; Marletta, M. A. Characterization of a 
Carbon Monoxide-Activated Soluble Guanylate Cyclase from Chlamydomonas 
Reinhardtii. Biochemistry 2019, 58 (17), 2250–2259. 
(2)  Libert, S.; Pletcher, S. D. Modulation of Longevity by Environmental Sensing. Cell 2007, 
131 (7), 1231–1234. 
(3)  Ryan, R. P.; Dow, J. M. Diffusible Signals and Interspecies Communication in Bacteria. 
Microbiology 2008, 154 (7), 1845–1858. 
(4)  Greenberg, E. P.; Fuqua, W. C.; Winans, S. C. Quorum Sensing in Bacteria : The LuxR-
LuxI Family of Cell Density-Responsive Transcriptional Regulatorst. J. Bacteriol. 1994, 
176 (2), 269–275. 
(5)  Papenfort, K.; Bassler, B. L. Quorum Sensing Signal-Response Systems in Gram-
Negative Bacteria. Nat. Rev. Microbiol. 2016, 14 (9), 576–588. 
(6)  Homer, C. M.; Summers, D. K.; Goranov, A. I.; Clarke, S. C.; Wiesner, D. L.; Diedrich, J. 
K.; Moresco, J. J.; Toffaletti, D.; Upadhya, R.; Caradonna, I.; et al. Intracellular Action of 
a Secreted Peptide Required for Fungal Virulence. Cell Host Microbe 2016, 19 (6), 849–
864. 
(7)  Egland, P. G.; Palmer, R. J.; Kolenbrander, P. E. Interspecies Communication in 
Streptococcus Gordonii-Veillonella Atypica Biofilms: Signaling in Flow Conditions 
Requires Juxtaposition. Proc. Natl. Acad. Sci. 2004, 101 (48), 16917–16922. 
(8)  McNab, R.; Lamont, R. J. Microbial Dinner-Party Conversations: The Role of LuxS in 
Interspecies Communication. J. Med. Microbiol. 2003, 52 (7), 541–545. 
(9)  Xu, X.; He, Q.; Chen, C.; Zhang, C. Differential Communications between Fungi and 
Host Plants Revealed by Secretome Analysis of Phylogenetically Related Endophytic and 
Pathogenic Fungi. PLoS One 2016, 11 (9), e0163368. 
(10)  Weber, H. Fatty Acid-Derived Signals in Plants. Trends Plant Sci. 2002, 7 (5), 217–224. 
(11)  Porter, S. L.; Wadhams, G. H.; Armitage, J. P. Signal Processing in Complex Chemotaxis 
Pathways. Nat. Rev. Microbiol. 2011, 9 (3), 153–165. 
(12)  Gudipaty, S. A.; Larsen, A. S.; Rensing, C.; Mcevoy, M. M. Regulation of Cu(I)/Ag(I) 
Efflux Genes in Escherichia Coli by the Sensor Kinase CusS. FEMS Microbiol. Lett. 
2012, 330 (1), 30–37. 
(13)  Potrykus, J.; Ballou, E. R.; Childers, D. S.; Brown, A. J. P. Conflicting Interests in the 
Pathogen-Host Tug of War: Fungal Micronutrient Scavenging Versus Mammalian 
Nutritional Immunity. PLoS Pathog. 2014, 10 (3), 2–5. 
(14)  Merchant, S. S. The Elements of Plant Micronutrients. Plant Physiol. 2010, 154 (2), 512–
515. 
(15)  Merchant, S. S.; Allen, M. D.; Kropat, J.; Moseley, J. L.; Long, J. C.; Tottey, S.; Terauchi, 
A. M. Between a Rock and a Hard Place: Trace Element Nutrition in Chlamydomonas. 
Biochim. Biophys. Acta 2006, 1763 (7), 578–594. 
(16)  Quinn, J. M. Two Copper-Responsive Elements Associated with the Chlamydomonas 
Cyc6 Gene Function as Targets for Transcriptional Activators. Plant Cell Online 1995, 7 
(5), 623–638. 
(17)  Kropat, J.; Tottey, S.; Birkenbihl, R. P.; Depege, N.; Huijser, P.; Merchant, S. A Regulator 
of Nutritional Copper Signaling in Chlamydomonas Is an SBP Domain Protein That 
Recognizes the GTAC Core of Copper Response Element. Proc. Natl. Acad. Sci. 2005, 
94 
 
102 (51), 18730–18735. 
(18)  Sommer, F.; Kropat, J.; Malasarn, D.; Grossoehme, N. E.; Chen, X.; Giedroc, D. P.; 
Merchant, S. S. The CRR1 Nutritional Copper Sensor in Chlamydomonas Contains Two 
Distinct Metal-Responsive Domains. Plant Cell 2010, 22 (12), 4098–4113. 
(19)  Quarmby, L. M.; Yueh, Y. G.; Cheshire, J. L.; Keller, L. R.; Snell, W. J.; Crain, R. C. 
Inositol Phospholipid Metabolism May Trigger Flagellar Excision in Chlamydomonas 
Reinhardtii. J. Cell Biol. 1992, 116 (3), 737–744. 
(20)  Krouk, G.; Crawford, N. M.; Coruzzi, G. M.; Tsay, Y. Nitrate Signaling : Adaptation to 
Fluctuating Environments. Curr. Opin. Plant Biol. 2010, 13 (3), 266–273. 
(21)  Duanmu, D.; Lagarias, J. C.; Merchant, S. S.; Yang, W.; Rockwell, N. C.; Martin, S. S.; 
Niyogi, K. K.; Dent, R. M.; Grossman, A. R.; Gallaher, S.; et al. Retrograde Bilin 
Signaling Enables Chlamydomonas Greening and Phototrophic Survival. Proc. Natl. 
Acad. Sci. 2013, 110 (9), 3621–3626. 
(22)  de Montaigu, A.; Sanz-Luque, E.; Galván, A.; Fernández, E. A Soluble Guanylate Cyclase 
Mediates Negative Signaling by Ammonium on Expression of Nitrate Reductase in 
Chlamydomonas. Plant Cell 2010, 22 (5), 1532–1548. 
(23)  Sanz-Luque, E.; Ocaña-Calahorro, F.; Llamas, A.; Galvan, A.; Fernandez, E. Nitric Oxide 
Controls Nitrate and Ammonium Assimilation in Chlamydomonas Reinhardtii. J. Exp. 
Bot. 2013, 64 (11), 3373–3383. 
(24)  Sanz-Luque, E.; Ocaña-Calahorro, F.; Galván, A.; Fernández, E.; de Montaigu, A. 
Characterization of a Mutant Deficient for Ammonium and Nitric Oxide Signalling in the 
Model System Chlamydomonas Reinhardtii. PLoS One 2016, 11 (5), e0155128. 
(25)  Kong, W. W.; Zhang, L. P.; Guo, K.; Liu, Z. P.; Yang, Z. M. Carbon Monoxide Improves 
Adaptation of Arabidopsis to Iron Deficiency. Plant Biotechnol. J. 2010, 8 (1), 88–99. 
(26)  Liping, Z.; Hongbo, S.; Xiaohua, L.; Zhaopu, L. Gene Regulation of Iron-Deficiency 
Responses Is Associated with Carbon Monoxide and Heme Oxydase 1 in Chlamydomonas 
Reinhardtii. PLoS One 2013, 8 (1), e0053835. 
(27)  Stone, J. R.; Marletta, M. A. Spectral and Kinetic Studies on the Activation of Soluble 
Guanylate Cyclase by Nitric Oxide. Biochemistry 1996, 35 (4), 1093–1099. 
(28)  Zhao, Y.; Brandish, P.; Ballou, D.; Marletta, M. A. A Molecular Basis for Nitric Oxide 
Sensing by Soluble Guanylate Cyclase. Proc. Natl. Acad. Sci. U. S. A. 1999, 96 (26), 
14753–14758. 
(29)  Cary, S. P. L.; Winger, J. A.; Marletta, M. A. Tonic and Acute Nitric Oxide Signaling 
through Soluble Guanylate Cyclase Is Mediated by Nonheme Nitric Oxide, ATP, and 
GTP. Proc. Natl. Acad. Sci. 2005, 102 (37), 13064–13069. 
(30)  Horst, B. G.; Marletta, M. A. Physiological Activation and Deactivation of Soluble 
Guanylate Cyclase. Nitric Oxide 2018, 77, 65–74. 
(31)  Derbyshire, E. R.; Marletta, M. A. Structure and Regulation of Soluble Guanylate 
Cyclase. Annu. Rev. Biochem. 2012, 81 (1), 533–559. 
(32)  Buechler, W. A.; Nakane, M.; Murad, F. Expression of Soluble Guanylate Cyclase 
Activity Requires Both Enzyme Subunits. Biochem. Biophys. Res. Commun. 1991, 174 
(1), 351–357. 
(33)  Gray, J. M.; Karow, D. S.; Lu, H.; Chang, A. J.; Chang, J. S.; Ellis, R. E.; Marletta, M. A.; 
Bargmann, C. I. Oxygen Sensation and Social Feeding Mediated by a C. Elegans 
Guanylate Cyclase Homologue. Nature 2004, 430 (6997), 317–322. 
(34)  Winter, M. B.; Woodward, J. J.; Marletta, M. A. An Escherichia Coli Expression-Based 
95 
 
Approach for Porphyrin Substitution in Heme Proteins; 2013; Vol. 987. 
(35)  Herzik, M. A.; Jonnalagadda, R.; Kuriyan, J.; Marletta, M. A. Structural Insights into the 
Role of Iron–Histidine Bond Cleavage in Nitric Oxide-Induced Activation of H-NOX Gas 
Sensor Proteins. Proc. Natl. Acad. Sci. 2014, 111 (40), E4156–E4164. 
(36)  Goodstein, D. M.; Shu, S.; Howson, R.; Neupane, R.; Hayes, R. D.; Fazo, J.; Mitros, T.; 
Dirks, W.; Hellsten, U.; Putnam, N.; et al. Phytozome: A Comparative Platform for Green 
Plant Genomics. Nucleic Acids Res. 2012, 40, D1178–D1186. 
(37)  Urzica, E. I.; Casero, D.; Yamasaki, H.; Hsieh, S. I.; Adler, L. N.; Karpowicz, S. J.; 
Blaby-Haas, C. E.; Clarke, S. G.; Loo, J. A.; Pellegrini, M.; et al. Systems and Trans-
System Level Analysis Identifies Conserved Iron Deficiency Responses in the Plant 
Lineage. Plant Cell 2012, 24 (10), 3921–3948. 
(38)  Barr, I.; Guo, F. Pyridine Hemochromagen Assay for Determinig the Concentration of 
Heme Purified Protein Solutions. Bio-Protocol 2015, 5 (18), e1594. 
(39)  Hespen, C. W.; Bruegger, J. J.; Phillips-Piro, C. M.; Marletta, M. A. Structural and 
Functional Evidence Indicates Selective Oxygen Signaling in Caldanaerobacter 
Subterraneus H-NOX. ACS Chem. Biol. 2016, 11 (8), 2337–2346. 
(40)  Stone, J. R.; Marletta, M. A. Soluble Guanylate Cyclase from Bovine Lung: Activation 
with Nitric Oxide and Carbon Monoxide and Spectral Characterization of the Ferrous and 
Ferric States. Biochemistry 1994, 33 (18), 5636–5640. 
(41)  Price, M. S.; Chao, L. Y.; Marletta, M. A. Shewanella Oneidensis MR-1 H-NOX 
Regulation of a Histidine Kinase By. Biochemistry 2007, 46 (48), 13677–13683. 
(42)  Fernhoff, N. B.; Derbyshire, E. R.; Marletta, M. A. A Nitric Oxide/Cysteine Interaction 
Mediates the Activation of Soluble Guanylate Cyclase. Proc. Natl. Acad. Sci. 2009, 106 
(51), 21602–21607. 
(43)  Karl, D. M. Occurrence and Ecological Significance of GTP in the Ocean and in 
Microbial Cells. Appl. Environ. Microbiol. 1978, 36 (2), 349–355. 
(44)  Traut, T. W. Physiological Concentrations of Purines and Pyrimidines. Mol. Cell. 
Biochem. 1994, 140 (1), 1–22. 
(45)  Winger, J. A.; Derbyshire, E. R.; Marletta, M. A. Dissociation of Nitric Oxide from 
Soluble Guanylate Cyclase and Heme-Nitric Oxide/Oxygen Binding Domain Constructs. 
J. Biol. Chem. 2007, 282 (2), 897–907. 
(46)  Derbyshire, E. R.; Gunn, A.; Ibrahim, M.; Spiro, T. G.; Britt, R. D.; Marletta, M. A. 
Characterization of Two Different Five-Coordinate Soluble Guanylate Cyclase. 
Biochemistry 2008, 47 (12), 3892–3899. 
(47)  Gunn, A.; Derbyshire, E. R.; Marletta, M. A.; Britt, R. D. Conformationally Distinct Five-
Coordinate Heme − NO Complexes of Soluble Guanylate Cyclase Elucidated by 
Multifrequency Electron Paramagnetic Resonance (EPR). Biochemistry 2012, 51 (42), 
8384–8390. 
(48)  Guo, Y.; Suess, D. L. M.; Herzik, M. A.; Iavarone, A. T.; Britt, R. D.; Marletta, M. A. 
Regulation of Nitric Oxide Signaling by Formation of a Distal Receptor–Ligand Complex. 
Nat. Chem. Biol. 2017, 13 (12), 1216–1221. 
(49)  Hespen, C. W.; Bruegger, J. J.; Guo, Y.; Marletta, M. A. Native Alanine Substitution in 
the Glycine Hinge Modulates Conformational Flexibility of Heme Nitric Oxide/Oxygen 
(H-NOX) Sensing Proteins. ACS Chem. Biol. 2018, 13, 1631–1639. 
(50)  Martin, E.; Berka, V.; Bogatenkova, E.; Murad, F.; Tsai, A. L. Ligand Selectivity of 
Soluble Guanylyl Cyclase: Effect of the Hydrogen-Bonding Tyrosine in the Distal Heme 
96 
 
Pocket on Binding of Oxygen, Nitric Oxide, and Carbon Monoxide. J. Biol. Chem. 2006, 
281 (38), 27836–27845. 
(51)  He, Y.; Tang, R.-H.; Hao, Y.; Stevens, R. D.; Cook, C. W.; Ahn, S. M.; Jing, L.; Yang, Z.; 
Chen, L.; Guo, F.; et al. Nitric Oxide Represses the Arabidopsis Floral Transition. Science 
(80-. ). 2004, 305 (5692), 1968–1971. 
(52)  Salmi, M. L.; Morris, K. E.; Roux, S. J.; Porterfield, D. M. Nitric Oxide and CGMP 
Signaling in Calcium-Dependent Development of Cell Polarity in Ceratopteris Richardii. 
Plant Physiol. 2007, 144 (1), 94–104. 
(53)  Wei, L.; Derrien, B.; Gautier, A.; Houille-Vernes, L.; Boulouis, A.; Saint-Marcoux, D.; 
Malnoë, A.; Rappaport, F.; de Vitry, C.; Vallon, O.; et al. Nitric Oxide-Triggered 
Remodeling of Chloroplast Bioenergetics and Thylakoid Proteins upon Nitrogen 
Starvation in Chlamydomonas Reinhardtii. Plant Cell 2014, 26 (1), 353–372. 
(54)  Düner, M.; Lambertz, J.; Mügge, C.; Hemschemeier, A. The Soluble Guanylate Cyclase 
CYG12 Is Required for the Acclimation to Hypoxia and Trophic Regimes in 
Chlamydomonas Reinhardtii. Plant J. 2018, 93 (2), 311–337. 
 
97 
 
CHAPTER 5 
 
 
EXPERIMENTS PERTAINING TO CHAPTER 4, SUMMARY, AND FUTURE 
DIRECTIONS 
 
 
Summary 
 
The work presented in this thesis has answered outstanding questions concerning the biochemistry 
of gas receptor proteins and in the process discovered a new class of these receptors. In Chapter 2, 
the full-length structure of Manduca sexta sGC was described and the binding pocket of small 
molecule stimulators was found to be directly between the β H-NOX domain and the two CC 
domains. Chapter 3 presented studies that sought to uncover the role of the second NO binding 
site, which will lead to the outlining of new and potentially impactful experiments needed to 
answer this question. Chapter 4 described a new class of soluble guanylate cyclase proteins that 
are most activated by carbon monoxide. The remainder of this thesis will be devoted to 
experiments performed that were not published previously relating to work done in Chapter 4, as 
well as a treatise concerning future directions of the biochemistry of gas receptor proteins. 
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Introduction 
 
 The unicellular alga Chlamydomonas reinhardtii has been shown to possess six genes that 
encode for proteins with the same domain structure as the mammalian nitric oxide receptor, soluble 
guanylate cyclase (sGC).1 Chapter 4 of this thesis described the biochemistry of one these gene 
products, Cyg11, and showed that this homologue of sGC is more active when carbon monoxide 
(CO) is bound than when nitric oxide (NO) is bound.2 This is the first sGC to be characterized with 
this activation profile, which brings credence to the idea of CO functioning as a signaling molecule 
in a eukaryotic organism. However, there are outstanding questions still to be addressed both 
within this story and within the larger study of gas receptor proteins. 
 
 With six total genes that resemble the mammalian sGCs architecture in the genome of C. 
reinhardtii, yet sequence analysis unable to sort these genes into α-like and β-like genes, there 
exists 21 possibilities of homodimeric and heterodimeric oligomers. Some heterodimeric 
combinations seem more likely than others, such as Cyg11-Cyg12, which exist next to each other 
in the genome. Different combinations of these genes were co-expressed to determine the ligand-
stimulated activity of these different oligomers. 
 
 Despite Cyg11 from C. reinhardtii possessing the lowest KD,CO of any previous 
biochemically characterized sGC at 2.5 µM2, the KD,NO is presumed to be many orders of 
magnitude lower, as is common for ferrous heme proteins.3 This fact is often cited as the reason 
CO is not a good candidate for a signaling gas, and why organisms that possess both NO-specific 
and O2-specific sGCs transcriptionally regulate their expression so they are never expressed 
together in the same tissues4 The evidence presented in Chapter 4 showing that Cyg11 potentially 
is activated by CO in vivo raises the question about how large the the KD,NO for Cyg11 is. 
 
 Additionally, the datasets that showed cyg11 to be increasing in transcription as the iron 
level decreased in the culturing media were taken from large transcriptomics datasets and are worth 
repeating. This chapter outlines the experiments conducted with regards to heterodimers, the NO 
on-rate of Cyg11, and the levels of mRNA present for all six cyg genes. 
 
 
Materials and Methods 
 
Materials 
All chemicals were purchased from commercial vendors and used without further purification 
unless otherwise noted. Primers were obtained from Integrated DNA Technologies (Coralville, 
IA). Gibson Master Mix was purchased from New England Biolabs (Ipswich, MA). PrimeSTAR 
Max DNA polymerase and His60 Ni Superflow resin was purchased from Takara Bio USA 
(Mountain View, CA). DNA purification kits were purchased from Qiagen (Germantown, MD). 
Terrific Broth media powder, ampicillin, and 4-(2-aminoethyl)benzenesulfonyl fluoride 
hydrochloride (AEBSF) were purchased from Research Products International (Mount Prospect, 
IL). Hemin chloride, sodium dithionite (Na2S2O4), DNAse I from bovine pancreas, β-
mercaptoethanol, H2NaPO4, NaCH3CO2, Mg(CH3CO2)2, and guanosine 5′-triphosphate sodium 
salt (GTP) (>95%, HPLC) were purchased from Millipore Sigma (Burlington, MA). Isopropyl β-
D-1-thiogalactopyranoside (IPTG), 4-(2-Hydroxyethyl)piperazine-1-ethanesulfonic acid 
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(HEPES), and Pierce BCA Protein Assay Kit, were purchased from Thermo Fisher Scientific 
(Waltham, MA). Benzamidine, lysozyme from chicken egg white, and sodium chloride (NaCl) 
were purchased from VWR Life Science (Visalia, CA). Dithiothreitol (DTT) was purchased from 
Bachem (Bubendorf, Switzerland). Imidazole was purchased from Oakwood Chemical (West 
Columbia, SC). Vivaspin spin concentrators were purchased from Sartorius (Concord, CA). PD-
10 desalting columns were purchased from GE Healthcare (Pittsburgh, PA). DEA NONOate was 
purchased from Cayman Chemical Company (Ann Arbor, MI). Nitric oxide (NO, >99.5%) gas 
and carbon monoxide (CO, >99%) gas were purchased from Praxair Inc. (Danbury, CT). NO gas 
was bubbled through 10 M NaOH to remove higher oxides prior to use. 
 
Construction of Expression Plasmids 
The Core cDNA library of Chlamydomonas reinhardtii was purchased from the Chlamydomonas 
Resource Center (University of Minnesota). Primers were designed against the 3′ and 5′ UTR of 
cyg11 (transcript name: Cre07.g320700.t1.1) Fwd: 5′-GGATCCATCGATGCTTAGGAGGTC 
GCCATGCAGTTCATTCTTAGT -3′, Rev: 5′-CTGCTCATGTTTGACAGCTTATCATCG 
CGTGTCCGCGAGCAATGGTAA -3′. The underlined regions of the primers anneal to 3′ and 5′ 
UTR of Cyg11. The other C. reinhardtii genes were cloned out of the C. reinhardtii library by 
Jonathan Winger, PhD. The transcript names for cyg12, cyg15, and cyg38 are Cre07.g320750.t1.1, 
Cre07.g321150.t1.1, Cre16.g649050.t2.1, respectively. The purified PCR product was subcloned 
into a linearized pCW vector with Gibson Master Mix, and the product was verified by DNA 
sequencing (UC Berkeley DNA Sequencing Facility). The C. reinhardtii sGC predicted protein 
sequence were aligned to the β-subunit protein sequence of Rattus norvegicus (Rn) sGC (Uniprot: 
Q02153-1) using Clustal Omega (EMBL-EBI). The crystal structure of the Homo sapiens catalytic 
domain (99% identical to Rn, PDB ID: 4NI2) was used to identify the last ordered residue, and 
thus the N-terminal amino acids were subcloned from the full-length C. reinhardtii sGC genes. 
The final homodimer expression plasmids include either a hexahistidine tag or a strep tag at the C-
terminal of the protein, as the N-terminus of H-NOX domains are buried in the heme binding 
pocket and cannot be extended. The six co-expression plasmids were made by cloning the genes 
out of the subcloned plasmids and into a modified pET_duet plasmid. The final expression and co-
expression constructs listed from 5′ to 3′ are pCW_Cyg11615_His6, pCW_Cyg12651_His6, 
pCW_Cyg15600_His6, pCW_Cyg38583_His6, pET_Cyg11615_His6_Cyg12651_ST, 
pET_Cyg11615_His6_Cyg15600_ST, pET_Cyg11615_His6_Cyg38583_ST, 
pET_Cyg15600_His6_Cyg12651_ST, pET_Cyg38583_His6_Cyg12651_ST, and 
pET_Cyg15600_His6_Cyg38583_ST. The full peptide sequences of constructs used in this chapter 
is included in Figure C.1. 
 
Protein Expression and Purification 
Please see the Chapter 4 Materials and Methods section for the protein expression and purification 
of the four homodimeric constructs. The following changes were made for heterodimeric 
constructs. Expression, cell lysis, clarification, and a preliminary purification by IMAC with His60 
was performed as before. The elution was buffer exchanged to remove the imidazole, and then 
applied to a column with Streptactin resin (Qiagen) and eluted off with increasing concentrations 
of desthiobiotin up to 2.5 mM (Millipore Sigma). Western blots were probed for both His tagged 
and strep tagged proteins by applying mouse anti-His6 Ab followed by a goat anti-mouse HRP 
conjugate Ab (Life Technologies) as before. The blots were stripped by the addition of two 5 mL 
washes for five minutes each with Stripping Buffer (200mM Glycine, 1% Tween20, 0.1% SDS). 
100 
 
The blot was re-blocked followed by the application of a strep tag antibody conjugated to HRP 
(BioRad) at a 1:5000 dilution and detected with Classico substrate (Millipore Sigma). 
 
Activity Assays and Quantification 
Steady-state kinetics for Cr sGC were measured by quantifying the amount of cGMP produced in 
duplicate endpoint activity assays, performed in at least biological triplicate. Samples were 
reduced in an anaerobic glove bag with 5 mM Na2S2O4 for 15 minutes, and then desalted with a 
Minitrap column equilibrated with Buffer E (50 mM Hepes, pH 7.5, 150 mM NaCl, 5% (v/v) 
glycerol, degassed. The protein concentration was determined using the protein A280 peak with 
extinction coefficients generated from ExPASy with all cysteines reduced. CO (g) saturated buffer 
(950 μM) was prepared by sparging 3 mL of Buffer E in a Reacti-vial for 15 mL with CO (g). Gas-
bound complexes of the samples were formed by adding DEA NONOate to a final concentration 
of 500 μM or CO (g) saturated buffer to a concentration of 425 μM. Activity assays were conducted 
at 25 °C and pH 7.5 in Buffer E, supplemented with 5 mM DTT and 5 mM MgCl2. Reactions were 
initiated with 2 mM GTP and timepoints from were quenched with 125 mM Zn(CH3CO2)2, 
followed by 125 mM Na2(CO3) to adjust to pH 7. Samples were frozen at –80 °C until 
quantification. Quenched assays were thawed, and the zinc precipitate was spun down for 10 min 
at 23,150 g. The reactions were diluted by one to three orders of magnitude, and the cGMP was 
quantified in duplicate using an extracellular cGMP Enzyme Linked Immunosorbent Assay, 
following the manufacturer’s instructions (Enzo Life Sciences). Concentrations of cGMP were 
determined from a standard curve, generated over 0.16–500 pmol/mL. Initial rates were calculated 
from the linear phase of the time course, where 5–10% of the GTP substrate was consumed. 
 
Gas Binding Kinetics of NO 
NO association rates (kon) were determined for ferrous Cyg11. Samples (approximately 2 μM) 
were transferred in gas-tight syringes into the stopped-flow system that was made anaerobic by 
incubating the sample-handling unit with 10 mM Na2S2O4 for 30 minutes. Dilutions of NO-
saturated buffer were made on the sample handling unit in gas-tight syringes by diluting NO-
saturated buffer with anaerobic Buffer H (50 mM HEPES, pH 7.5, 150 mM NaCl, 0.22 μm filtered) 
via a three-way valve. Reactions were initiated by mixing equal volumes of protein solution and 
NO-saturated buffer at 5 °C for a final protein concentration of 1 μM. 
 
Transient Absorption Spectroscopy 
The Cyg11 homodimer was reduced with 50 mM Na2S2O4 for 15 minutes at room temperature. 
The reduced sample was desalted over a Miditrap G-25 column equilibrated in Buffer I (50 mM 
K2HPO4 pH 8, 200 mM NaCl, 5% glycerol, 0.22 μM filtered, degassed), adjusted to 20 µM, and 
snap frozen in liquid nitrogen. Samples were transported to either Caltech or Lawrence Berkeley 
National Laboratory on dry ice. Buffer I was degassed by pulling vacuum and backfilling with Ar 
(g) 10 times. NO (g) saturated buffer (1.9 mM) was prepared by sparging 3 mL of anaerobic Buffer 
I for 15 minutes in a Reacti-vial. In a glove box, four different samples of Cyg11 with different 
NO (g) concentrations (200 µM, 100 µM, 50 µM, and 25 µM) were prepared. UV-Vis absorption 
spectra were taken prior to and after transient absorption spectroscopy. 
 
Transient absorption spectroscopy was performed with a Nd:YAG laser tuned to the second 
harmonic in order to provide more power (~100 mJ) over timescales out to: 2 µs, 100 µs, 10 ms, 
and 500 ms. Two different probe lights were used for different time scales, a xenon arc lamp was 
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used for timescale shorter than 10 ms and a tungsten lamp was used for timescales longer than 500 
ms. 
 
Strains, Media, and Growth Conditions 
Chlamydomonas reinhardtii WT(+) was received as a gift from the Niyogi lab (UC Berkeley). The 
following stock solutions were prepared and autoclaved, with the stock concentration indicated in 
parenthesis: FBS (80x): 600 mM NH4Cl, 27 mM CaCl2, 32 mM MgSO4; KPO4 (200x): 200 mM 
K2HPO4; Modified Trace Metals solution (200x): 27 mM EDTA, bring to pH 6.5, 3.6 mM FeSO4, 
15 mM ZnSO4, 37 mM H3BO3, 5.2 mM MnCl2, 1.3 mM CuCl2, 1.1 mM H2MoO4, and 1.3 mM 
CoCl2; HSBeji (200x): 1,900 mM NH4Cl, 14 mM CaCl2, 16 mM MgSO4; HSPhos (200x): 2,710 
mM K2HPO4. TAP media was prepared by preparing 20 mM Tris base in 975 mL of Milli Q dH2O 
followed by the addition of 1 mL of glacial acetic acid for a final concentration of 17.5 mM of 
acetate. Next, 12.5 mL of FBS (80x) and 5 mL each of KPO4 (200x) and Modified Trace Metals 
solution (200x) were added under sterile conditions. To prepare TAP-agar, 1.5% (w/v) of Difco 
agar was added at this stage. The TAP media or TAP-agar was autoclaved for 45 minutes at 121 
°C. HS media was prepared by adding 5 mL each of HSBeji (200x), HSPhos (200x), and Modified 
Trace Metals solution (200x) to 985 mL of Milli Q dH2O, and autoclaving for 45 minutes at 121 
°C. 
 
C. reinhardtii was maintained on TAP-agar plates grown with 20-100 μmol m–2 s-1 of photons of 
light and plates were restreaked every 3-4 days. It should be noted that this is considered dim light 
for C. reinhardtii, as typically algae are grown in high light (1,200 μmol m–2 s-1 of photons).5 Cells 
were transferred from plates to suspension culture by scraping a pea-size amount of cells into 50 
mL of the appropriate media and shaking for 48 hours at room temperature for the culture to 
acclimate. Cultures were synchronized with 12 hours in the dark (wrapped in foil), followed by 12 
hours in the light. Three different growth conditions were used: mixotrophic (TAP + light), 
photosynthetic (HS media + light), and dark (TAP + dark). C. reinhardtii cells were counted with 
a Coulter Counter by diluting 50 μL of culture into 10 mL of isoton solution, and adjusting the 
OD750 to the Coulter Counter readings. 
 
RNA extraction, cDNA preparation, and RT-qPCR quantification 
All steps were performed at 4 °C unless otherwise noted. RNA was isolated from mid-log phase 
C reinhardtii cultures. 2 x 107 cells were lysed with 1 mL of Trizol reagent (Thermo Fisher), then 
boiled at 95 °C for 5 min. Debris was pelleted by centrifuging the sample at 12,000 g, 4 °C, for 10 
minutes. Nucleic acids were separated with the addition of 0.2 mL chloroform, the sample was 
vortexed well and then centrifuged at 12,000 g, 4 °C, for 15 minutes. A 500 μL fraction of the 
aqueous layer (top) was added to 0.5 mL ice cold isopropanol, incubated at RT for 10 minutes, 
and then centrifuged at 12,000 g, 4 °C, for 10 minutes. The resulting pellet was washed with 1 mL 
of 75% ethanol and dissolved in 40 μL RNAse-free dH2O. Any remaining DNA was digested with 
a DNase kit following manufacturer’s instructions (Ambion). Prepare cDNA with cDNA synthesis 
kit following manufacturer’s instructions (Invitrogen SuperScript II). Primer efficiency was 
checked by diluted either plasmid or C. reinhardtii gDNA from 3000 pg down to 0.3 pg per well. 
cDNA was quantified with Maxima SYBR Green/Fluorescein qPCR Master Mix following the 
manufacturer’s instructions (Thermo Fisher). Controls included no nucleic acid with all primer 
pairs and RNA without cDNA synthesis for all primer pairs. 
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Results and Discussion 
 
Meta-Analysis of Cr sGC Transcriptomics 
 While Chapter 4 showed that homodimeric Cyg11 is active and stimulated by CO, there is 
the possibility that other heterodimeric sGCs could form in Chlamydomons reinhardtii. These 
heterodimeric species could have different activation profiles than Cyg11. It was hypothesized that 
if heterodimers formed in C. reinhardtii, there should be equivalent upregulation of these two 
genes in response to a stimulus. Thus, a meta-analysis of RNAseq datasets for gene transcription 
was performed using data that has been compiled by JGI Phytozome (Figure 5.1A). Figure 5.1B 
shows a selection of experiments that result in the upregulation of some of the six Cr sGCs, with 
the left panel comparing light and dark growth conditions and the right panel comparing 
mixotrophic (acetate + light) and photosynthetic (no acetate + light) conditions. While cyg12 was 
upregulated in both dark and photosynthetic conditions and cyg38 was upregulated in 
photosynthetic conditions only, the only two sGCs that seemed to be upregulated concomitantly 
were cyg11 and cyg12 in photosynthetic conditions. Additionally, the genes for cyg11 and cyg12 
are found in direct proximity to each other on chromosome 7, lending additional support to the 
hypothesis that the product of these two genes could form a heterodimeric species (Figure 5.1C). 
Therefore, a coexpression vector was designed in order to express both Cyg11 and Cyg12 from 
the same plasmid to test the ligand-stimulated activity for this heterodimer. 
 
Activity Assays of Cr sGC Heterodimers 
The co-expression construct contained Cyg11615 with a His6 tag and Cyg12651 with a Strep 
tag. This design allowed for the separation of any Cyg11 or Cyg12 homodimers from the 
heterodimer by passing lysate first through a Ni2+ IMAC column followed by a streptactin column. 
Figure C.2 shows SDS-PAGE purification gels and Western blots with both anti-His and anti-
Strep antibodies. The presence of both tags in the final elution volume is indicative of the 
successful purification of the heterodimer Cyg11-Cyg12. Next, the ligand-stimulated activity of 
the Cyg11-Cyg12 heterodimer was interrogated with in vitro cGMP assays, followed by cGMP 
quantification with a cGMP-specific ELISA. Figure 5.2 shows the amount of cGMP produced by 
the heterodimeric construct both after the Ni2+ IMAC column and the Strep column compared to 
a Rn sGC WT enzyme control. There is no discernable ligand-stimulated activity for this 
heterodimeric construct. Thus, the other five heterodimeric constructs were cloned but were not 
expressed to determine if they showed the same result. 
 
NO On Rate for Cyg11 
 Cyg11 has the lowest KD,CO for any biochemically characterized sGC, suggesting that CO 
is possibly the physiological ligand. However, NO typically has a very low KD,NO for ferrous heme 
cofactors. For example, the KD,NO for Rn sGC is estimated to be < 1.2 × 10–12 M.3 Chapter 4 
reported the off-rate for NO from Cyg11 was two orders of magnitude faster than the off-rate for 
NO from Rn sGC, however in order to compare dissociation constants both the off-rate and the 
on-rate are required. Similar to what has been done previously, stopped-flow spectroscopy was 
used with varying NO concentrations in attempts to obtain the kon,NO. We would expect to see the 
Soret peak undergo two transitions.3 The first transition begins with the unliganded peak centered 
at 431 nm that converts to a 6-coordinate ferrous nitrosyl peak at 420 nm with the proximal 
histidine still bound. The second transition begins with the 6-coordinate ferrous nitrosyl and 
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converts to a 5-coordinate ferrous nitrosyl peak at 399 nm with the cleavage of the iron histidine 
bond. Figure 5.3A shows the change of the Soret peak at three different  
 
Figure 5.1 – Transcriptomic analysis of C. reinhardtii sGCs. Data in this figure is from JGI Phytozome 
(https://phytozome.jgi.doe.gov/pz/portal.html) A) mRNA transcript level in FPKMs of the six Cr sGCs in over 130 
different experiments. B) Selected experiments that show differential expression in one or more Cr sGCs. C) 
Schematic of Cr chromosome 7 where Cyg11 and Cyg12 are directly adjacent to each other in the genome. The 
transcript number of the genome neighborhood is listed below the genes. 
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Figure 5.2 – Endpoint activity assay of Rn sGC and Cyg11-Cyg12 co-expression. No significant activity was observed 
for the heterodimeric construct of Cyg11-Cyg12. Other heterodimeric constructs were cloned but never expressed and 
purified. 
 
wavelengths over time. Only the transition from 420 nm to 399 nm is observed, indicating that the 
association between NO and Cyg11 is occurring within the dead time of the instrument. Even when 
the NO concentration is decreased to 29 μM, only one transition is observed (Figure 5.3B). These 
transitions at 431 nm can be fit by double exponential decay functions and Figure 5.3C indicates 
that only one of the parameters is concentration dependent. However, without observing the 
transition from 431nm to 420 nm, only a lower limit for kon,NO of 7.43 x 104 M–1 s–1 can be set 
based on the faster transition in Figure 5.3C (kfast). Combining this with the koff,NO measured in 
Chapter 4, an upper limit for KD,NO for Cyg11 is 1.9 μM, which is still lower than the KD,CO for 
Cyg11 (2.5 μM). 
 
 To obtain a NO on-rate for Cyg11 at timescales shorter than milliseconds, we turned to 
transient absorption spectroscopy. Ultra-fast dynamics of NO binding to the Rn sGC heme have 
been reported, albeit on a laser setup made in-house.6 Two different Nd-YAG flash photolysis 
laser setups were used, one at Caltech (Gray lab) and one at Lawrence Berkeley National Lab (Frei 
lab). Experiments began with a sample of Cyg11 with NO bound to the heme. A 532 nm pulse  
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Figure 5.3 – Cyg11 NO on-rates. A) The change in three different wavelengths is plotted over time as unliganded 
Cyg11 homodimer is mixed with NO (0.029 mM). B) The change in absorbance at 431 nm corresponding to the 
maximum peak of the unliganded Soret band is plotted over time and fit to double exponential decay functions, the 
residuals of which are shown on the right. C) The fast biexponential rate constant varied over different concentrations 
of NO while the slow biexponential rate constant was constant over a range of NO concentrations. 
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would rupture the bond between the iron and NO and changes in the Soret band would be observed 
on timescales long enough that we were confident that a bimolecular process was occurring (and 
the NO was not remaining within the protein to rebound back onto the heme). While some 
quenches and absorptions were observed, the many different processes occurring at 431 nm and 
the proportion of protein that was predicted to undergo a bimolecular process (~5%) in addition to 
indications of sample degradation prevented interpretable data from being obtained. 
 
Targeted Transcriptomics of Cr sGCs 
 In order to examine the relevance of gas signaling in cultures of C. reinhardtii, attempts 
were made to examine the properties and activation of natively expressed sGCs. C. reinhardtii 4A 
mt(+) was grown in different conditions to interrogate if any condition increased the expression of 
Cr sGCs. As noted above, C. reinhardtii can either use acetate as a carbon source or use 
photosynthesis to grow on CO2, so three different growth conditions were used: mixotrophic 
(acetate + light), photosynthetic (no acetate + light), and dark (acetate + dark). A growth curve for 
C. reinhardtii in these three different conditions is shown in Figure 5.4. For the mixotrophic and 
photosynthetic conditions, cultures were in fact grown under dim light (20-100 μmol m-2 s-1). 
Figure 5.4 – C. reinhardtii growth curves measured by optical density. Growth curves of C. reinhardtii are plotted in 
from cultures grown in different growth conditions. The optical density at 750 nm was calibrated to cell counts 
measured by a Coulter Counter. 
 
Initial investigations focused on mRNA levels for sGCs in different conditions. Two 
different reference genes were investigated for stable expression over all three conditions, CβLP 
(rack1, receptor of activated protein kinase C) and ubiquitin (UBQ2).7,8 Figure 5.5A shows the 
relative CβLP transcription remained constant in the three different growth conditions, and thus 
CβLP was used to normalize all transcription in future experiments. Only primer pairs for three of 
the six Cr sGCs (cyg12, cyg38, and cyg56) were shown to both be both specific and efficient, and 
the relative transcription of these genes is shown in Figures 5.5B-D. Transcription of both cyg12 
and cyg56 showed significant increases in both the dark and photosynthetic growth conditions, 
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suggesting that gas sensing is potentially more important in times when the preferred carbon source 
is not readily available (keeping in mind that cultures were not given sufficient light in the  
Figure 5.5 – Cr sGC transcriptomics and heme incorporation. A-D) Relative expression of one reference gene CβLP 
and three Cr sGCs was quantified by RT-qPCR and the data are shown. Both cyg12 and cyg56 are upregulated in 
photosynthetic growth conditions. Increases in cyg12 transcription were expected based on data collected from JGI 
Phytozome. Increases in cyg56 transcription were not expected. E) Relative heme incorporation for homodimers of 
Cyg11, Cyg12, Cyg15, and Cyg38. Chapter 4 discussed the heme incorporation for Cyg11 to be one heme per 
homodimer. 
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photosynthetic growth condition). The biochemical data collected for the homodimers of Cyg12 
and Cyg38 revealed that neither homodimer had high levels of heme incorporation (Figure 5.5E), 
and no biochemical data had been collected for Cyg56. The fact that transcriptomics of cyg11 was 
not able to be collected leaves gaps between the biochemical data and the transcriptomic data that 
potentially could be complementary in the future. 
 
 
Conclusion 
 
 Chlamydomonas reinhardtii possesses six genes whose gene products are homologous to 
the mammalian nitric oxide receptor, sGC. One of those gene produces, Cyg11, has been found to 
be the first sGC homologue that is activated more by CO than by NO. However, there are lingering 
questions that work in this chapter sought to address. Despite co-expression analysis that did not 
predict any of these Cr sGCs to be co-expressed, the potential for homodimerization of these genes 
in vivo still exists. Targeted transcriptomic analysis of the complement of these genes in different 
growth conditions is still warranted to understand the transcription patterns and gain insight into 
the signaling pathways the gene products are a part of. Cyg11 must have a lower KD,NO than KD,CO, 
however whether or not the alga produces and/or encounters both of these gases at the same time 
and at what concentration is not known. The results of the experiments presented here do not 
constitute a completed story, and further work is necessary to gain a complete understanding on 
the biochemical gaseous signaling pathways in Chlamydomonas reinhardtii. 
 
 
Cumulative Future Directions 
 
The work presented in this thesis describes the full-length structure of the eukaryotic nitric 
oxide receptor soluble guanylate cyclase, the investigation into cysteine residues as the potential 
second site of nitric oxide binding on sGC, and the discovery of a new class of soluble guanylate 
cyclases that are more activated by CO than by NO. Many new areas of research can now be 
initiated based off of results presented herein. 
 
The full-length structure of sGC presented in this thesis, in combination with a high-
resolution structure of the human sGC that was recently published9, allow for the first time targeted 
mutational analysis of sGC to understand the activation mechanism. All residue numbers in this 
section will refer to the Hs sequence from PDB IDs 6JT0 and 6JT2 unless explicitly stated. 
Analyses of the structures begins with a close examination of the β H-NOX domain in the inactive 
and active states. The distance between the ε2 nitrogen of βH105 and the iron of the heme cofactor 
in the inactive state is 3.6 Å, however that distance only increases 0.3 Å to 3.9 Å in the activated 
structure (Figure 5.6). This is in contrast to bacterial H-NOX domains in different gas-bound states. 
For example, the H-NOX protein from Shewanella oneidensis has a distance between the ε2 
nitrogen of H103 and the iron of 2.2 Å in the unliganded state. However that distance increases to 
10.4 Å in the NO-bound state.10 This implies that there is not the same rotation of the αF helix in 
sGCs that there is in H-NOX domains. However, in both Hs sGC and So H-NOX structures, the 
N-terminal subdomain of the H-NOX rotates ~4° away from the C-terminal subdomain. It is 
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possible this motion is the critical conserved motion of H-NOX domains, as O2 sensing H-NOX 
domains also show this relative motion between N- and C-terminal subdomains.11 
The β H-NOX in the inactive state contains many residues that make polar contacts with 
residues of other domains (Figure 5.7). Specifically, βD106 contacts βR258, both of which are 
strictly conserved (signified by the underline) from the SSN analysis discussed in Chapter 3, and 
βD106 has been shown to be critical for sGC activation.9,12 Additionally, βR258 is nestled within 
a network of many polar contacts, interacting with βR305 (R/K strictly conserved), βK307, βE370, 
and βD374, with more polar residues existing in a second sphere that supports this inner sphere 
surrounding βR258 (βY363, αD411, and αQ418).  
Figure 5.6 – Canonical motions of the H-NOX domain. Comparison of the rotations of the proximal histidine in Hs 
sGC and So H-NOX structures in the unliganded (gray) and NO-bound (blue) state. Electron density shows that the 
proximal histidine is cleaved from the iron in both cases, however in the bacterial H-NOX the αF helix (on which the 
proximal histidine is located) rotates ~90° where a similar rotation is not observed in the Hs sGC structures.  
 
 
There has been some investigation into other residues on the αF helix of the β H-NOX 
domain that are involved in the initiation of signal transduction from the βH-NOX to the catalytic 
domains, namely βD102 and βT110.13,14 The distance of βD102 ε nitrogen to βR258 decreases 
from 10.9 Å in the inactive state to 3.0 Å in the active state.9 These residues, along with βR40, 
βY83, βH105 (proximal histidine), βD106 (D/E strictly conserved) (highlighted in Kang et. al)9, 
βH107, βT110, βY112, βS122, βH260, βR305 (R/K), βK307, βY363, βT366 and βE370 on the β 
subunit along with αD411, αQ418, and αQ422 of the α subunit are implicated in the β H-NOX 
interface with the other domains of sGC in the active state (Figure 5.8). Both conservative 
mutations and radical mutations of these residues, coupled to rescue double mutants along this 
interface are warranted to dissect the activation pathway of sGC. 
 
The coiled coil domains of sGC are now understood to act as a hinge that transduces the 
signal between the gas-sensing and catalytic domains of sGC. In the inactive state, each coiled coil 
domain is broken into two coiled coil regions connected by linkers αA419-αK426 and βL354- 
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βF359. Kang et al. made the radical mutations αD423P and βG356P and showed that introducing 
kinks in the coiled coil domains prevent activation.9 Different types of mutations in this area can 
expand our understanding of the activation pathway in this region. Specifically, the introduction 
of (GSG)n linkers where n=1 or 2 at these sites could uncouple conformational changes in the β 
H-NOX from the catalytic domains. Mutations that more effectively zip up the coiled-coil by 
introducing a leucine zipper into the inactive conformation of sGC might produce sGC that is 
constitutively activated or maximally active with only one equivalent of NO. Examples of such 
mutations could be combinations of α(A420L/Q423L), α(A420L/D434L), β(Q349L/D353L), 
β(Q349L/D353L), and triple mutants that also include αQ423L and βF350L. 
 
 
Figure 5.7  - The inactive state polar contacts between the β H-NOX domain and the β PAS and α CC domain. 
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Figure 5.8  - The active state polar contacts between the β H-NOX domain and the β PAS and α CC domain. 
 
The identification of the putative binding pocket on sGC of YC-1 discussed in Chapter 2 
is also worthy of mutational analysis. Combining crystal structure 6JT2 and the EM map of 
Manduca sexta with NO and YC-1 allows for identification of residues that are within 5 Å of the 
proposed binding site (Figure 5.9). Residues close to this volume include βF4, βV39, βR40, βF77, 
βS81, βY83, βT112, βT366, and βE370 on the β subunit and αQ422, αL425, αR428, and αL429 
on the α subunit. Conservative or radical mutations of these residues on sGC truncations could be 
used to look at the effect of YC-1 on CO binding the YC-1 dissociation constant15,16, or the EC50 
of YC-1 for activation of full-length sGC in the 1-NO state. Radical mutations that do not interrupt 
full activation by excess NO but do interrupt full activation of the 1-NO state by YC-1 would be 
indicative of a disrupted binding pocket. To see if this site is indeed the only site for small molecule 
drug binding to sGC, cryo-EM of sGC in the presence of NO and stimulators from Bayer and 
Cyclerion Therapeutics (formally Ironwood Inc.). If these compounds indeed bind in the same 
pocket, this would lend more confidence to the hypothesis that stabilization of the β H-NOX 
domain against the CC domains is a similar mechanism of activation for all classes of sGC 
stimulators. 
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Figure 5.9 – Proposed YC-1 binding pocket and interacting residues. The proposed YC-1 binding pocket is shown in 
purple. Residues that surround this pocket are colored in blue. 
 
 
There is overlap of some residues that seem to be involved in the interfaces between the β 
H-NOX domain and other domains of sGC and are also close in space to the putative YC-1 binding 
site. Specifically, βR40, βY83, βT112, βT366, and βE370 on the β subunit and αQ422 on the α 
subunit seem to be critical for both the contacts the β H-NOX subunit makes with other domains 
and are close to the YC-1 binding pocket. Great care should be exercised when analyzing activity 
data from variants with these specific residues mutate so as to not conflate β H-NOX interdomain 
interactions for YC-1 activation. One alternate strategy that uses orthogonal methods to investigate 
the YC-1 binding site would be to use Förster Resonance Energy Transfer (FRET) between a site 
on the protein and a modified stimulator. By selecting emission and excitation wavelengths 
accordingly, it should be possible to attach one fluorophore to sGC at known location (e.g. 
substituting the heme with a fluorescent analog, using a fluorescent nucleotide analog, attaching a 
fluorophore to the C-terminus of one of the catalytic domains) and using a sGC stimulator modified 
with an appropriate donor or acceptor, the distance could be calculated. If two of these approaches 
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(or alternate approaches) succeed, the intersection of the diameters of the spheres away from the 
known site should agree with the location of YC-1 in the structure. 
 
 Experiments described in Chapter 2 used SEC-SAXS to observe a partial elongation of 
sGC in the 1-NO state. As new improvements are constantly being made to the system up at LBNL, 
future scattering experiments are warranted. Firstly, changes in the experimental protocol to ensure 
the concentration of NO is maximal in the sample flow cell should be taken, either by increasing 
the amount of NO donors used or through the use of a new flow cell that can add fast-releasing 
donors directly as the protein is passing through the flow cell. The initial impetus for these 
experiments was the promise of time resolved SAXS, which would require the use of photocaged 
NO donors, or perhaps a timed release of NO donor with a new design of flow cell. The ability to 
measure the kinetics of the conformational change upon activation of NO would provide 
conformation of more indirect measurements of this structural rearrangement. 
 
 NO causes striking conformational changes in sGC. Now that we have the endpoints of 
this activation, it is possible to ask questions about the energetics of this motion. There are three 
likely scenarios as to what the free energy landscape looks like in terms of sGC conformational 
state. The first is of a low free energy inactive state and a high free energy active state, similar to 
that of a spring stretched past its point of equilibrium (sGC is being “stretched” by NO). The 
second is of a high free energy inactive state and a low free energy active state, reminiscent of a 
compressed spring that is constrained in that position (with excess NO “unlocking” the restraint). 
The final scenario involves the lowest free energy conformation changing based on NO 
concentration, similar to a spring made of copper wire that can be deformed. At this point, 
scenarios one and three seem the most plausible because it seems necessary for a sufficient driving 
force to be present for sGC to return to the 1-NO state after removal of excess NO. However, it 
would be interesting to examine these three possibilities using single molecule experiments and 
capture the forces of the motion of sGC in the presence of different stimulators.17 To accomplish 
this, sGC would need to be suspended between two objects, either two beads with optical tweezers 
or a cantilever and a piezoelectric scanner for atomic force microscopy. It has been relatively easy 
to add tags onto the C-termini of sGC; sGC is currently purified with a His6 tag added to the end 
of the α catalytic domain. However, attaching molecules to the N-terminus of sGC would be more 
challenging because the N-terminus of the β H-NOX is buried. One possibility could be to use N-
terminal chemistry (e.g. 2-PCA) and screen for conditions where the α H-NOX is modified but the 
β H-NOX is left unmodified.18 Site-specific unnatural amino acid incorporation could also be 
examined, however with the challenges already associated with sGC expression this might not be 
feasible. These experiments would allow for the exploration of both the thermodynamics and 
kinetics of sGC conformational change and would provide additional insight in to the activation 
mechanism of the canonical gas-receptor protein. 
 
As discussed in Chapter 2, work in this thesis and the structure by Kang et al are the first 
two examples of full-length structures in both inactive and active states that contain the regulatory 
domain known as the S-helix.19 (Note: the proteins with known full-length structures described by 
Montfort et al to contain S-helix domains do not possess the typical sequence motif as explained 
by Aravind et al).19,20 Proteins that contain the S-helix motif possess both sensing domains and 
output domains that are connected by the S-helix, which is thought to communicate the presence 
of signaling molecule in one domain to catalytic output in the other. In sGC, the S-helix motif 
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connects the gas-sensing N-terminal regulatory lobe from the C-terminal catalytic domains and is 
contained within the C-terminal portion of the coiled-coil domains (residues αK427-I457 and 
βR360-L394). However, it is not clear whether the bend in the helices that was observed in sGC 
is a feature of all proteins that contain an S-helix or if the general function of the S-helix results in 
the twisting of the coiled-coils. Structural studies of other proteins that contain S-helix domains 
could provide insight into this conserved signaling strategy employed by receptor proteins. For 
example, the cyclic di-GMP phosphodiesterase PA4781 (Uniprot: Q9HV27) from Pseudomonas 
aeruginosa contains an S-helix that connects its REC domain from the HD-GYP domain, but only 
truncations of protein have been solved.21 Another example is the transcriptional regulator NifA 
(Uniprot: O66591) from Aquifex aeolicus (strain VF5) represents a different class of regulator in 
which only truncations of the protein have been solved.22 Similar to sGC, cryo-EM could be used 
in this case to obtain the full-length structure of these receptors in the on and off state. There are 
possibly many more examples of soluble proteins with S-helix domains, however currently there 
are no structures of any individual domains; a large portion of these proteins do have 
transmembrane domains which, while presenting additional challenges, can still be interrogated 
structurally.23 These structures could then be used to compare S-helix domains across two different 
types of signaling proteins to understand the commonalities furnished by the S-helix and which 
aspects are unique to each receptor. 
 
 Pertaining to Chapter 3 and the search for the second NO binding site on sGC, labeling 
sGC with titrations of bioconjugational agents and testing for both average mass shift as well as 
activity could be particularly insightful to see if at a certain average number of amino acids labeled, 
sGC always loses activity. Perhaps this is specific to cysteines, or perhaps with more lysines or 
carboxylic acid residues labeled sGC might always lose the activity with excess NO. If it turns out 
that the same average labeling of sGC with different bioconjugational agents yields different 
activity profiles, using mass spectrometry to sequence peptides in each condition could potentially 
yield a pattern for amino acids modified in conditions that always loose activity or always maintain 
activity. Additionally, other disulfide exchange reagents with varying steric bulk could be tested 
to see if the size of MMTS is critical in its ability to prevent activation by excess NO. For example, 
2-hydroxyethyl disulfide , 3-carboxylethyl disulfide, and 5,5’-dithiobis-(2-nitrobenzoic acid) 
(which would also provide a colorimetric readout for how many cysteines modified) would 
constitute a steric size series to test if smaller disulfide exchange reagents inhibit sGC to a larger 
extent. In a slightly different vein, the double addition type experiments where first IAM is added 
followed by addition of MMTS or another addition of IAM should be followed with high 
resolution mass spectrometry. Any cysteine labeled with IAM would be considered to be not 
critical, but any cysteine seen with a MMTS labeled would be of interest. For these types of mass 
spectrometry experiments, the observation of a non-labeled cysteine does not mean that it was 
never labeled. It is only the observation of a labeled peptide that can be commented on. With the 
full-length structures now published, any proteomic data can then be overlaid on the structures to 
attempt to rationalize these results. 
 
 A different line of research that should be undertaken is the potential modification of 
βC541, the residue in the active site that discriminates between guanylate cyclases and adenylate 
cyclases (Asp in adenylate cyclases). If this residue is modified by MMTS or NEM, this could 
explain the lack of activity of sGC labeled with these molecules. Either a full kinetic analysis 
should be conducted with sGC in the excess NO state with and without MMTS to compare KM 
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values, or some type of biophysical measurement of the KD (equilibrium dialysis, ITC, or 
fluorescence with a substrate analogue) will be an important control to ensure that the binding of 
the nucleotide is not impaired in the labeling of sGC. If βC541 is being modified by cysteine 
alkylating agents, that would greatly complicate the interpretation of the biochemical activity 
assays. 
 
 Work presented in Chapter 2 has shown that conformational changes of sGC can be 
visualized with biophysical methods such as cryo-electron microscopy and small angle X-ray 
scattering. Comparison of electron densities of sGC with excess NO to sGC labeled with MMTS 
with excess NO could help decipher whether or not MMTS is preventing a conformational change. 
Additionally, comparison of SAXS scattering profiles of sGC with excess NO to sGC labeled with 
MMTS with excess NO could yield subtle differences that could indicate whether or not MMTS 
is indeed preventing a conformational change. 
 
 The slight conformational changes in the β H-NOX domain could potentially drive the 
large-scale conformational changes seen in active sGC. Kang et al describe the active β H-NOX 
domain conformation as being incompatible with the rest of the inactive structure.9 One hypothesis 
that is worth exploring is the ability of MMTS to inhibit this small conformational change in the  
in the β H-NOX. If MMTS is labeling cysteines in the β H-NOX domain that prevent the domain 
from adopting its active conformation, perhaps MMTS is not blocking a second site cysteine at all. 
There are two conserved cysteines in the β H-NOX domain, βC78 and βC122. It is possible that 
variants of these cysteines could render sGC tolerant to MMTS labeling. Past work from other labs 
and work in our lab has shown that the sGC variant βC78S does not bind heme, however serine is 
more polar than cysteine.24 Proposed variants of sGC to explore this hypothesis would be the 
double mutant βC78A/V in combination with βC122A/V. If this variant has an activation profile 
similar to WT labeled with MMTS, then different cysteines are involved. However, if this variant 
has an activation profile similar to WT not labeled with MMTS, this could be the mechanism 
behind MMTS inhibition of sGC. 
 
 Research presented in Chapter 4 and this chapter investigated one of the six sGC 
homologues found in the eukaryotic alga Chlamydomonas reinhardtii, however interesting 
questions still remain in this area. To begin, it is not clear why a Cyg11 homodimer with two heme 
binding sites only binds one heme cofactor. The current hypothesis is that Cyg11 adopts some sort 
of asymmetric conformation so as to allow the binding of one heme but not the other. Biophysical 
experiments such as SAXS and cryo-EM could be used to test this hypothesis. Additionally, the 
final two (cyg56 and cyg57) sGCs were challenging to clone, but perhaps the purchase of codon 
optimized vectors would allow for the biochemical investigation of these final homologues. This 
chapter began to investigate targeted transcriptomics of all of C. reinhardtii’s sGCs, however these 
efforts should be repeated. Finally, although C. reinhardtii is not the most genetically tractable 
model organism, there exists a transposon insertional mutant library that potentially have these 
sGCs knocked out.25 In collaboration with the Merchant lab, mutants with insertions in the CDS 
of Cr sGCs should be examined phenotypically and transcriptomically in regular and stress growth 
conditions (including lack of metals, lack of nitrogen, lack of light, etc.). 
 
 Finally, new work has been recently published that describes a new species of 
choanoflagellate that forms disc-shaped colonies which change their convexity based on light or 
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mechanical stimuli.26 This process is proposed to be regulated by a rhodopsin fused to a cGMP-
specific phosphodiesterase, but the upstream signaling of this process is not yet understood. 
Intriguingly, this organism possesses genes homologous to mammalian nitric oxide synthase 
(NOS) proteins and sGCs. Preliminary data indicate that NO donors induce convexity changes, 
strengthening the argument that NOS and sGC play a role in the communication of this 
choanoflagellate colony. NOSs have been successfully expressed in E. coli previously, but if the 
choanoflagellate sGC is responsive to NO and can be expressed in E. coli that would be very 
intriguing. Additionally, it would be interesting to see if this sGC is responsive to NO and has the 
three-state activation model similar to mammalian sGCs. 
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APPENDICES 
 
 
Appendix A 
Figure A.1 – Biochemical characterization of full-length Ms sGC. A) Representative SDS-PAGE gels for purification 
of Ms sGC. B) Deconvoluted intact protein mass spectrum of purified Ms sGC. C) UV–visible absorption spectra of 
Ms sGC used in activity assays. The 1-NO sample was generated by first adding excess NO followed by buffer 
exchange. D) Representative time courses of the cGMP assay for Ms sGC in different ligation states. The cGMP 
product was quantified using an enzyme linked immunosorbent assay. E) Topology diagram of β H-NOX secondary 
structure. Bottom Left: Front view of the β H-NOX displaying helices αA–αF. Bottom Right: Bottom view of the β 
H-NOX displaying helix αG and sheets β1–β4. 
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Figure A.2 – The structure of the benzyl imidazole compound YC-1. 
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Figure A.3 – Cryo-EM of the Ms sGC inactive state and S-helix alignments A) Representative micrograph with inlet 
of corresponding FFT. B) Electron microscopy flowchart for processing of inactive sGC data with three views of the 
final reconstruction shown colored in gray. C) Selected 2D class averages. D) FSC curve from cryosparc2 with gold 
standard 0.143 FSC shown in blue. E) Plot of single particle population based on orientation parameters. F) Inactive 
reconstruction colored by local resolution calculated using cryosaprc2 implementation of blocres. G) Close up view 
of the modeled inactive CAT dimer highlighting unmodeled density near the α CAT C-terminus. H). Overlay of the 
PDB: 4NI2 (grey) and the inactive CAT dimer (colored by α and β). I) The coiled-coil domain of eight sequences 
from four heterodimeric biochemically-verified NO-responsive sGCs and five sequences from atypical sGCs that 
sense O2 are aligned, with conserved residues are highlighted in blue. The approximate domain architecture from the 
inactive state CC domains are shown above the sequences. J) Inactive model of Ms sGC is shown with the bent helix 
in purple and the S-helix in red. 
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Figure A.4 – Cryo-EM of the Ms sGC active state and HDX-MS overlay A) Representative micrograph with inlet of 
corresponding FFT.B) Electron microscopy flowchart for processing of active sGC data.C) Selected 2D class 
averages.D) FSC curve from cryosparc2 with gold standard 0.143 FSC shown in blue.E) Plot of single particle 
population based on orientation parameters.F) Active reconstruction colored by local resolution calculated using 
cryosaprc2 implementation of blocres. G) Differential H/D Exchange values representing change in percent D by 
subtracting the active state from the inactive state. Regions with large changes in percent D overlay with secondary 
structural elements observed in the structures to undergo large conformational changes, including the αF helix of the 
β H-NOX, the bent CC region, and S-helix motif, and certain helices of the CAT domain. The insets show a close up 
view of the H/D exchange patters of the CC domains. 
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Figure A.5 – SAXS of Ms sGC. A) Top: Small angle X-Ray scattering chromatograms with intensity (lines) and Rg 
(symbols) values for each frame merged across the SEC peak. Middle: UV-visible absorbance chromatograms 
showing the normalized absorbance at 280 (line) and 432 nm (dotted-line). Bottom: Multi angle light scattering 
chromatograms with light scattering signal (line) and molecular weight (dots). All chromatograms aligned to the 
MALS peaks which are furthest downstream to compensate for variations in timing and band broadening. B) 
Normalized Kratky plot for the inactive (black) and active state (gray) of sGC. Inset: Guinier plots within the q*Rg < 
1.3. C) Top: Best fit conformations for the inactive state of sGC. Bottom: Extended structure from the best ensemble 
for the activated sGC conformation 
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Table A.1 
Cryo-EM data acquisition, image processing and model refinement 
 
Imaging/Processing Inactive Active  
Microscope Talos Arctica Talos Arctica 
Voltage (kV) 200 200 
Camera K3 K3 
Defocus range (µm) -1.5 to -3.5 -1.5 to -3.5 
Pixel size (Å) 1.137 1.137 
Total electron dose (e-/Å2) 60 60 
Exposure time (s) 6 6 
Number of movies 2,841 9,330 
Number of frames/movie 60 60 
Initial particle number 675,956  
Final particle number 25,828 40,469 
FSC 0.143 (unmasked/masked, Å) 8.3 / 5.1 7.6 / 5.8 
   
Refinement   
Homology Models (PDB) α/β H-NOX (2O0C), α/β PAS (4GJ4), α/β CC (3HLS), α 
CAT (3UVJ), β CAT (2WZ1) 
Cα Residues  1129 953 
Ligands Heme Heme 
   
RMSDs   
Bond lengths (Å) 0.006 0.009 
Bond angles (˚) 1.096 1.229 
   
Ramachandran   
Favored (%) 82.57 76.35 
Allowed (%) 17.25 23.23 
Outlier (%) 0.09 0.42 
All Atom Clash score 1.38 6.92 
Molprobity score 1.57 2.16 
Accession codes   
EMDB EMD-20282 EMD-20283 
PDB PDB - 6PAS PDB – 6PAT 
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Table A.2 
SEC-SAXS-MALS-UV-visible absorption results for the activation of sGC 
 
Measurement Inactive 1-NO 
SAXS Molecular Weight (kDa) ~140 ~131 
MALS Molecular Weight (kDa) 140.7 (±0.008%) 138.4 (±0.014%) 
Ratio 432/280 nm Absorbance 0.765 0.319 
Radius of Gyration, Rg (Å) 43.1 (±0.4) 43.8 (±0.2) 
Maximum Dimension, Dmax (Å) 133 142 
Porod Exponent, Px 4 4 
Inactive Conformation (%) 100 72 
Partially Extended Conformation 
(%) 0 28 
χ2-value of Fit 1.44 1.51 
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Appendix B 
 
Figure B.1 – Cr sGC sequences and sequence alignments. A) The complete protein sequence of Cyg11615_His6 used 
in this study. B) Alignments of the Cr sGC H-NOX domains (top) and CAT domains (bottom) with Rn sGC α and β 
subunits. The critical residues are highlighted in green. Key residues: * – metal binding, Δ – guanine binding, ▲ – 
triphosphate binding, # – ribose binding. 
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Figure B.2 – Transcriptomics of Cr sGCs in variable iron concentrations. The mRNA abundance for each Cr sGC is 
shown for three growth conditions with decreasing amounts of iron: replete, deficient, or limited. Heterotrophic growth 
signifies that C. reinhardtii was grown both in light and with acetate in the growth media as a carbon source, whereas 
photosynthetic growth indicates that C. reinhardtii was growth in light without acetate. Data collected from Phytozome 
(JGI) and the original data was published by Urzica et al.1  
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Figure B.3 – SDS-PAGE analysis of Cyg11 purification. A) SDS-PAGE gel of a typical immobilized metal affinity 
column purification of Cyg11 using His60 beads. S – soluble fraction, FT – flow through, W – wash; numbers indicate 
increasing concentrations of imidazole (in mM). B) SDS-PAGE gel of a representative size-exclusion chromatography 
purification of Cyg11. P – Pre; numbers indicate fractions collected from each of the three peaks present in the 
chromatogram. Boxes indicate fractions that were pooled and carried forward. 
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Figure B.4: – Cyg11 oligomeric state by analytical SEC A) The oligomeric state of Cyg11 was determined by 
analytical SEC, using five standards of known molecular weight: lysozyme (14.3 kDa), deoxyribonuclease I (31 kDa), 
bovine serum albumin (66.5 kDa), alcohol dehydrogenase (150 kDa), and thyroglobulin (500 kDa). The calculated 
molecular weight of Cyg11 using this method was approximately 200 kDa. B) Standard curve generated from the 
standards shown in panel A. 95% confidence curves are shown. 
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Figure B.5 – Intact protein mass spectrum of Cyg11. Purified Cyg11 was analyzed by intact protein mass spectrometry 
to validate the expression construct and support the results form native mass spectrometry analysis. 
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Ligation State Protein Soret Band β α 
Unliganded   
Rn α1β1 
So H-NOX 
Cyg11 
431 
427 
431 
555 
568 
570 
NO  
Rn α1β1 
So H-NOX 
Cyg11 
398 
398 
399 
537 
544 
542 
572 
572 
575 
CO  
Rn α1β1 
So H-NOX 
Cyg11 
423 
424 
424 
541 
541 
537 
567 
566 
569 
 
Table B.1 – UV-visible Spectroscopy Peak Positions of sGCs (in nm). Rn sGC and So H-NOX peak positions obtained 
from the following references: 2,3  
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Figure B.6 – UV-visable spectra of reconstituted Cyg11. The typical ratio of 431 nm/280 nm ratio for Cyg11 is 
~1.2. For this experiment, Cyg11 with a ratio of 0.9 was used. After reconstitution, the ratio of 431 nm/280 nm was 
1.4. The incorporated heme is able to form a stable 5-coordinate ferrous nitrosyl complex, indicating that the heme is 
very likely present in the H-NOX domain. 
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Figure B.7 – UV-visible spectra of Cyg11 Unliganded exposed to oxygen. Anaerobic, reduced Cyg11 unliganded 
was opened to ambient oxygen concentrations, and the UV/Vis absorbance spectra was recorded every hour for eight 
hours. The Soret band is centered at 431 nm (indicated by the dotted line) decreases in absorbance, most likeley due 
to oxidation and heme loss. However, the Soret does not shift to 416 m, as would be expected for a ferrous-oxy 
complex.4 
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Figure B.8 – Effect of reconstitution on Cyg11 activity. Activity assays conducted with Cyg11 (431 nm/280 nm ratio 
= 0.9) were normalized to heme incorporation levels typically observed (431 nm/280 nm ratio = 1.2). This activity is 
comparable to Cyg11 that was reconstituted with hemin (431 nm/280 nm ratio = 1.4). Error bars represent standard 
deviation (n = 2).  
135 
 
 
Figure B.9 – Michaelis–Menten kinetics of Cyg11 in different ligation states. Enzyme assays of Cyg11 with different 
ligation states was performed at 25 °C and pH 7.5 with varying GTP concentrations. Initial rates were calculated from 
each time course for 5–10% of substrate turnover using GraphPad Prism’s nonlinear regression tools. Error bars 
represent standard deviation (n=3). 
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Appendix C 
 
 
Figure C.1 – Sequence alignment of four Cr sGCs . Key residues: ^ – heme binding, * – metal binding, Δ – guanine 
binding, ▲ – triphosphate binding, # – ribose binding. 
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Figure C.2 – Purification gels and western blots of Cyg11-Cyg12 heterodimer. (Left top) SDS-PAGE of different 
fractions post Ni2+ IMAC. An α His western blot (middle) and a α Strep western are shown below. Boxed fractions 
were combined and assayed for activity and carried forward into the next column. (Right top) SDS-PAGE of 
different fractions post streptactin column. An α His western blot (middle) and a α Strep western are shown below. 
Boxed fractions were combined and frozen  as the heterodimeric Cyg11-Cyg12. 
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